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ABSTRACT 
Alzheimer’s Disease (AD) is a significant challenge to both the pharmaceutical world as 
well as the synthetic organic chemistry world.  One of the most important problems in this field 
is the lack of a unified approach to the most biologically active class of natural products for the 
treatment of AD, the lycopodine alkaloids.  Presented herein is an attempt at the total synthesis of 
a novel member of this family.  The synthesis spans three complete generations of retrosynthesis 
and forward progress.  In the ultimate effort, the carbon backbone of the entire lycopodine class 
was successfully synthesized using a 6 step process in 44% overall yield.  Features of this 
synthesis are the formation of an intermediate aldehyde by tandem Horner-Wadsworth-Emmons 
olefination/Baylis-Hillman reaction, quantitative reduction resulting in a monoprotected diol, 
cationic Au(I) O-vinylation, and microwave assisted Claisen rearrangement.  The final step 
towards the backbone was realized using a hydrozirconation/transmetalation sequence with 
addition to the aldehyde to make the penultimate allylic alcohol in 54% yield.  Final studies on 
the elimation of the allylic alcohol to create the desired 1,3-diene functionality show limited 
access to this important precursor.  Simultaneous model system studies have shown that an 
intramolecular, cationic Rh(I)-catalyzed ynamide Diels-Alder reaction is feasible to set the B and 
D rings of the final lycopodine core, although the reaction requires optimization.  Model systems 
for the unique intramolecular allylation proposed in the retrosynthesis also show feasibility, 
however the intramolecular variant has not been fully explored.  Additional studies towards the 
total synthesis (R)-myricanol are also presented as a continuance of efforts towards general 
approaches to AD combative compounds.  Featured are straightforward methods to the two main 
segments of the natural product, including a three-step process to synthesize the southern half.  
Finally, a successful 2-step synthesis of (R)-convolutamydine E is used to showcase an In(0)-
mediated allylation methodology. 
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PREFACE 
 My road to graduation began in a General Chemistry I lecture at 8:00 in the morning, my 
first day of freshman year at Hamline University.  My professor was Dr. Olaf Rundquist, and 
from the first day, I was hooked.  Upon my graduation from Hamline with my Bachelor’s 
degree, Ole wrote something on an e-mail I will never forget. 
 “Always remember that as a philosopher, you can never prove, only disprove. 
 You can never find truth, only search for it. 
 If you cannot get pleasure from searching for truth, then quit now. 
 The philosopher finds the hunt for truth the exciting part. 
 When a problem is ‘solved’ the fun ends and you have to look for a new puzzle.” 
 
Ole was right.  Solving the puzzle is far more rewarding than reaching the endpoint.  So 
here I am, years later, content with the fact that I never saw my project’s completion.  I enjoyed 
the fight, but it is time to explore the world through a new lens.  It is time for a new puzzle. 
 
This dissertation is a foray into the exteremely complicated and often unsuccessful world 
of total synthesis. 
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CHAPTER 1. A REVIEW OF ALZHEIMER’S DISEASE AND THE ROLE OF ALKALOIDS 
FROM THE LYCOPODIUM/HUPERZINE FAMILY OF PHARMACOPHORES 
 
1.1.  Introduction 
 Alzheimer’s Disease (AD) is one of the most common forms of dementia1.  AD has been 
a ravaging neurological disorder in the public eye for over 100 years; ever since it was first 
identified and reported publicly at a convention of psychiatric professionals in 1906 by Dr. Alois 
Alzheimer.  AD is characterized by a loss of memory and cognition leading to physical disability 
and death
2
.  These physiological changes are brought on by synaptic degradation and neuronal 
death.  Traditionally, the extent of AD in dementia patients could only be determined 
posthumously via autopsy.  Noticeable differences in brain appearance between healthy and AD 
patients appear in the frontal and temporal lobes, with a high concentration of deposited proteins 
around the neural clefts
2
.  This leads to a strangulation of the neurons and an overall shrinkage of 
the brain tissues as the neural networks atrophy.  
AD is also characterized by high levels of oxidation (typically indicative of oxidative 
stress)
3
 as well as dyshomeostasis of several key metal ions, most notably calcium, copper, iron, 
and zinc
4
.  Patient genetics also plays a role in AD progression
5
.  There are many competing 
theories of AD initiation and disease progression and for the sake of context, only three main 
theories will be discussed here: the amyloid cascade hypothesis, the tau aggregation hypothesis, 
and the acetylcholesterase hypothesis.  While there are other theories, many of them do not yet 
possess clear therapeutic targets.  It has also been shown that some of the factors which improve 
the likelihood that AD will develop are genetic and thus inheritable
5
. 
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 1.1.1.  The Amyloid Cascade Hypothesis 
 The amyloid cascade hypothesis is one which was developed through the autopsy-
detected protein buildups around the neural networks.  These proteins were found to be 
aggregates of proteins created though cleavage of the Amyloid Precursor Protein (APP), a 
transmembrane protein found in the primary membrane and mitochondrial membrane of neural 
cells
2
.  The plaques were dubbed amyloid-β (Aβ) proteins and the primary thought was that the 
buildup of the plaques was the direct cause of cognitive function.  It was discovered later, 
however, that the plaques were non-toxic.  Mice incapable of forming Aβ plaques developed the 
disease while mice that formed plaques had no greater propensity for the disease
6
.  It was found 
that the plaques were aggregating due to an imbalance in the clearance of the soluble Aβ 
fragments, either by the ApoE clearance chaperones or the 20S proteasome
7
.  Further elucidation 
showed that two fragments were primary constituents: Aβ1-40 and Aβ1-428.  Although 
structurally similar, Aβ1-42 is significantly more neurotoxic due to the additional hydrophobic 
residues
9
, which promote aggregation
10
 as well as favor protein-protein interactions with other 
cellular components
11
.  It was discovered that of the Aβ1-42 aggregates, the oligomeric 
fragments were the most cytotoxic
12
, affecting synaptic transmission by altering the availability 
of synaptic vesicles
13
.  Presumably this is due to the clogging of the vesicle fusion docking site 
(vesicle fusion is a synaptic trigger event). 
 Amyloid protein fragments are generated by a series of secretases located on the outer 
membrane, as well as the intracellular membrane wall.  Initally, β-secretase cleaves APP 
between methionine 670 and aspartic acid 671, releasing a small fragment as well as a larger, 
mostly insoluble fragment (Figure 1.1).   
3 
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-secretase -secretase
1-40 1-42
670 715
membrane-bound
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Figure 1.1: APP cleavage sites 
 
In an attempt to clear the formed insoluble mass, γ-secretase cleaves the mass into a 40 or 
42 amino acid residue fragment, and a more soluble fragment which coils and is cleared by 
intracellular proteases.  Since the action of γ-secretase is dependent on the initial cleavage by β-
secretase, the process is regulated through the expression of the β-site APP-cleaving enzyme 1 
gene (BACE1).  Smith and co-workers have suggested that, due to an increase in BACE1 
expression in AD patients which corresponds to an increase in Aβ1-42 concentration, BACE1 is 
upregulated by Aβ1-4214.  This implies that once the soluble fragments of the APP are produced, 
a cascade effect is initiated whereby additional fragments are produced.  After enough of these 
soluble protein fragments are generated, they begin to aggregate.  The smaller oligomers are 
generally cytotoxic, while the larger oligomers tend to aggregate further and form fibrils
15
, which 
adhere to one another and become the inactive Aβ plaque deposits commonly associated with 
AD.  These plaques are not responsible for the symptoms of AD, but are rather used as 
repositories of soluble oligomers, which promote those symptoms.  This occurs as the oligomers 
are removed from the system (either by bodily clearance or, more likely in AD, by complexation 
to neural proteins) and the plaques begin to release additional oligomers, reestablishing the 
equilibrium
16
. 
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 1.1.2.  The Tau Aggregation Hypothesis 
In addition to the theory that the soluble fragments from APP are responsible for synaptic 
degradation, an alternative theory has been given, where the Aβ1-42 fragment is indirectly 
responsible.  Instead of interfering with synaptic processes, Aβ1-42 is responsible for promoting 
oxidative stress and a marked increase in Ca
2+
 ion concentration in the intracellular matrix.  It 
has been theorized that Aβ1-42 initiates this increase in Ca2+ concentration by creating gateways 
in the cellular membrane (through intercalation of the membrane itself), or by activating Ca
2+
 
pumps
17
.  This sharp increase in internal Ca
2+
 concentration has been linked to a number of 
cellular mechanisms which are activated by the sudden dyshomeostasis of the Ca
2+
 
concentration, including the hyperphosphorylation of the tau protein
18
. 
The tau protein is the primary structural component of neural pathways inside of the 
neurons themselves.  As synaptic activity is stimulated, tau is phosphorylated and 
dephosphorylated in a regulated fashion to allow for controlled microtubule formation, and 
synaptic information to be transmitted
19
.  Hyperphosphorylation leads to destabilized 
microtubules, and thus inefficient and often disconnected transmissions
20
. 
Tau protein behavior and characteristics are regulated by specific genes which can be 
directly modulated to give rise to multiple neurological disorders, implying that these genes can 
be effective targets for AD therapies, or effective screening markers for AD susceptibility
21
. 
 
 1.1.3.  The Acetylcholesterase Hypothesis 
 Another predominant hypothesis in the field of AD preventative research is the 
acetylcholesterase (AChE) hypothesis.  In this pathway, AChE is responsible for maintaining 
synaptic cleft levels of choline and acetylcholine.  Research has shown that AD patients over-
5 
 
express AChE, and thus a buildup of choline occurs
22
.  This affects a large number of neural 
processes downfield from AChE, and it has been implicated not only in AD, but also Parkinson’s 
Disease and common dementia
23
.  Due to the large number of potential disease treatment 
options, acetylcholesterase inhibitors (AChEi) have been the primary target of pharmaceutical 
companies interested in AD treatments. 
 One neural process downfield from AChE which has received a significant amount of 
attention is the evidence which links neurotransmitters in the choline pathway, namely choline 
and acetylcholine, appear to rapidly promote the cleavage and release of soluble N-terminal 
amyloid protein fragments
24
.  This connection between the acetylcholine pathway and the Aβ 
pathway not only provides additional possibilities towards a unified treatment of the disease but 
also showcases how extremely complex AD is, and how interconnected all of the neural 
pathways are. 
 Due to this large interconnectivity, it is unfortunately realized that most compounds 
slated for AD treatment come with severe side-effects. 
 
1.2.  Current Pharmaceutical Treatments For AD 
 The current treatments for AD vary as much as the theories of action which drive their 
development.  As such the compounds can fall into a variety of categories.  For the purpose of 
comparison, these compounds will be classified as β-amyloid targeted, tau targeted, or 
acetylcholesterase inhibitors.  With the exception of the initial class, most of the compounds used 
to treat AD or show efficacy against AD in some way operate using different mechanisms.  Since 
the brain is so complex, each pathway has multiple treatment options.  As such, there is no 
definitive molecular scaffold on which pharmaceutical companies can build upon to increase 
6 
 
drug efficacy and stability.  Due in part to this problem, more pharmaceutical companies have 
been examining the compounds which are derived from natural sources known to be beneficial to 
synaptic health and memory retention
25
.  Large classes of antibodies have also been developed, 
mostly to detect the toxic Aβ1-42 fragment26. 
 By identifying several of the contributing factors for each targeted pathway, researchers 
have developed novel ways to counteract the deleterious effects of AD’s symptoms.  While an 
outright cure for AD seems a long way off, a removal of the symptomatic suffering of AD 
patients is always a welcome goal.  A corollary to all of the prevailing theories of AD 
development is that many AD patients experience high levels of reactive oxygen species (ROS), 
as well as the tell-tale signs of oxidative damage and high oxidative stress levels.  A school of 
thought in this avenue is that AD creates a dyshomeostasis of various metal ions in the central 
nervous system (CNS), mainly Zn
2+
, Cu
2+
, Fe
2+/3+
, and Ca
2+
 in the cytosol and extracellular 
medium
27
.  In this light, a wide range of metal chelating compounds have been screened against 
AD.  The idea is that the chelating agents, in the right amounts and delivered to the correct 
locations, will help restore balance in the CNS, and the body’s own mechanisms will help to 
restore the cognitive function.  Initially, it was observed that the rate of AD was significantly 
lower in Indian populations of elderly patients
28
.  Correlations with consumption of curry led to 
the identification of cucumin (1.01) as a potent Cu
2+
 chelator, which may aid in destabilizing Aβ 
plaque formation (Figure 1.2).  It has been shown that Cu
2+
 can stabilize the aggregation of Aβ1-
42
29
.  Cu
2+
 has also been shown to favorably interact with the aggregate conformers, stabilizing 
specific geometries
30
.  Varying the concentration of NaCl also shifted the dyshomeostasis of 
specific ions, namely Cu
2+
, suggesting that ionic strength of the neural media plays a critical role 
in the onset of AD-promoting conditions
31
. 
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Figure 1.2: Structure of cucumin 
  
 Based on the perceived notion that metal chelators could be used as effective AD 
therapies, many more chelating compounds were isolated (Figure 1.3).  N-acetylcystine (1.02) is 
a membrane-penetrable chelating agent already used to treat cystic fibrosis
32
. Naturally occurring 
α-lipoic acid (1.03) is found in spinach, while epigallocatechin gallate (1.04) is found in green 
tea.  Melatonin (1.05) is a hormone responsible for hippocampus memory formation
33
 and 
galantamine (1.06) is a potent AChEi
34
.   
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Figure 1.3: Structures of some anti-oxidant, metal-chelating natural products 
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A number of novel Fe
2+
 chelators have also been developed around the 8-
hydroxyquinoline core structure, which have shown good potency as chelators as well as 
antioxidants (Figure 1.4)
35
.  These same structures have also been shown to be AChEi active
36
. 
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Figure 1.4: Structures of anti-oxidant, Fe
2+
 chelators based on 8-hydroxyquinoline 
 
 A number of peptides have been found to improve the cognitive function of AD-afflicted 
mice, most notably the discovery of an orally available peptide which improves clearance of Aβ 
fragments
37
.  These operate by interacting with the soluble Aβ fragments and preventing the 
aggregation that produces toxic, soluble oligomers
38
.  This prevention of aggregation is also a 
key target in pharmaceutical development.  By inhibiting the aggregation, the soluble fragments 
exist in solution long enough as independent entities for the natural clearance apolipoproteins to 
chaperone them out of the cerebral media.  In this light, Rangachari and co-workers have 
reported a bimetallic Rh-Pt complex which they have shown to bind to the N-terminus of Aβ1-
42, thus preventing aggregation
39
. 
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 The prevention of acetylcholine breakdown by inhibition of AChE has widespread 
implications, and many compounds have been developed to reach this target.  The choice of 
AChE over any of the secretases is partially due to lack of understanding of all of the roles 
secretases play in neurological health
40
, as well as the ease with which AChE can be reached as a 
target system.   
There are currently three main compounds available for the treatment of dementia 
associated with AD and Parkinson’s disease (Figure 1.5).  These compounds do not prevent 
dementia or restore cognitive ability, but they do prevent the onset of the more severe symptoms 
and are thus administered in early-stage AD and Parkinson’s.  Donepezil (1.10, trade name: 
Aricept, Pfizer), rivastigmine (1.11, trade name: Exelon, Novartis), and galantamine (1.12, trade 
name: Razadyne, Ortho-McNeil-Janssen Pharmaceuticals) are all AChEi which act by preventing 
the over-degradation of acetylcholine, and thus preventing choline-dependent interferences 
downstream
41
.  All of these treatment options involve the transmission of the active compounds 
across the Blood-Brain Barrier (BBB), a feat which until recently was thought to be difficult for 
some of the compounds.  Recent evidence has shown that there is a deterioration of the BBB 
which affects the efficacy of the administered pharmaceuticals
42
.  Any new compound must be 
made with an eye towards this slightly different activity profile. 
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Figure 1.5: Three current pharmaceuticals for treatment of early-stage AD 
 
1.3.  Use of Lycopodium Alkaloids as Treatments of AD 
 Alkaloids from the Lycopodium family of club mosses have long been highly regarded in 
Chinese herbal medicine as promoters of memory and cognitive function
43
.  The most successful 
alkaloid isolated from these mosses and used in human patients is Huperzine A (1.13, Figure 
1.6)
44
. 
NHNH2
O
1.13  
Figure 1.6: Huperzine A 
 
 Huperzine A is a potent and reversible AChEi, with IC50 of 47 nM
45
, currently in use as 
an AChEi in patients with mild AD symptoms.  It is thought that the various alkaloids of the 
lycopodium family bind to AChE on the surface of the protein, rather than in the binding 
pocket
46
.  This causes a conformation change which disables the ability of the enzyme to perform 
11 
 
the hydrolysis of acetylcholine to choline.  While monitoring the 
1
H-NMR relaxation times for 
the binding of 1.13 to AChE, the authors found that other members of the lycopodium alkaloid 
family gave similar results when complexed with the enzyme.  This suggests that all of these 
small molecules interact in similar ways with the surface of the protein.  It is likely that a 
structural characteristic common to all three of the alkaloids is responsible for the binding 
affinities
47
.  Examining the three structures, a common feature is revealed: a bridging 2-
methylpropene unit as well as a basic amine (ranging from 1° to 3°) in the same position (Figure 
1.7).  Kozikowski and co-workers suggested that the unsaturation point on the three-carbon 
bridge was critical for activity, and synthesized a number of analogs to prove this.  It is likely, 
especially considering the activity of other members of the lycopodium alkaloid family which do 
not posses this unsaturation, that what is critical is the geometry around that area of the molecule. 
 
NHNH2
O
Huperzine A, 1.13
NHN
H
O
H
Huperzine B, 1.14
N
OH
O
H
O
Huperzine F, 1.15  
Figure 1.7: Three lycopodium alkaloids and their structural similarities 
 
 The same group reported later an X-ray crystal structure of 1.13 complexed with AChE, 
showing a blockage of the active site’s channel opening by use of non-covalent interactions48.  
The requirement of a basic amine and the sterically encumbered environment surrounding it may 
be to the advantage of complexation with an exposed acidic residue on the surface of the 
enzyme.  Another possibility is that the 2-pyridone moiety in 1.13 and Huperzine B (1.14), as 
12 
 
well as the α-hydroxyketone in Huperzine F (1.15) could be used to chelate a metal ion, 
suggesting a connection between the Huperzine alkaloids and the metal-ion dyshomeostasis 
theory of AD pathology. 
 
 1.3.1.  Core Structure of Lycopodium Alkaloids and Their Relevant Activity 
 While 1.13 and 1.14 reside in the lycodine class of lycopodium alkaloids, all of which 
possess the 2-ketopyridine functionality or similarly aromatic moieties, 1.15 is part of a 
structurally similar family known as the lycopodine class.  This class is based off of lycopodine 
(1.16), a simplified variant of the Huperzine alkaloids which still possess the methylated 3-
carbon bridge required for activity (Figure 1.8).  Examples of this class include Huperzine G 
(1.17), Miyoshianine B (1.18), Selagoline (1.19), and Annotine (1.20). 
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Figure 1.8: Structures of lycopodine and related alkaloids 
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 While Huperzine A is an effective treatment for early AD, many main-stream 
pharmaceutical companies will not market it or its direct analogs due to its original isolation 
information/procedure being in the public domain
44
.  Thus, a strong desire for synthetic 
alternatives to the entire lycopodium family is present in the field of AD thereputics. 
 
1.4.  Conclusions and Implications 
 With the need for new therapeutic compounds for the treatment of AD and the prevalence 
of the lycopodine skeleton in the lycopodium alkaloid family, synthetic efforts which will 
enhance our current ability to fight AD should focus on the synthetically challenging lycopodine 
core.  Many different syntheses of the lycopodium alkaloids have been reported, but all of them 
provide industrially unsuitable processes, or focus mainly on a specific reaction that the research 
group wishes to showcase.  In this light, it has been slow-moving towards a generalized approach 
to the entire family of natural products.  A main goal of the projects to follow is to highlight 
synthetic routes towards this central core of the lycopodium alkaloid family during a total 
synthesis of a new Huperzine alkaloid discovered from the same club moss which has provided 
so much to the AD community already. 
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CHAPTER 2. ATTEMPTED TOTAL SYNTHESIS OF A NOVEL HUPERZINE ALKALOID 
 
2.1.  Introduction 
 As discussed in the previous chapter, the total synthesis of lycopodium alkaloids is a key 
feature in the fight against AD.  The vast majority of the reported syntheses focus on Huperzine 
A, which is the most studied clinically.  Many structural analogs have been reported based 
around the Huperzine A nucleus, but many of them are merely modifying peripheral groups to 
make the compound more potent and selective
1
.  Due to Huperzine A’s classification as a 
lycodine-class alkaloid, those structures have the most well-developed synthetic strategies.  The 
alternative Fawcettimine-class also has a number of well-established protocols for their 
synthesis.  Lycopodine-class alkaloids, however, have not found such a niche in the synthetic 
community. 
 Generally speaking, the lycopodine-class of lycopdoium alkaloids are not as 
metabolically stable, or occasionally do not possess the desired activity
1
.  Many of the Huperzine 
alkaloids are oxidative products of the parent lycopodine (2.01).  As such, their synthesis 
becomes more difficult, as many of the oxidations occur on carbons which bench chemists 
cannot selectively oxidize.  As such, the oxygen-containing functionalities have to be 
incorporated into the synthesis in alternative ways. 
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Figure 2.1: Lycopodine with ring and stereochemical identification 
 
 There have been a number of syntheses focused on this class of alkaloids, and they all 
bring something different to the challenging problem of synthesizing the core quinolizidine 
moiety. 
 
2.2.  Previous Syntheses of Lycopodine-Class Lycopodium Alkaloids 
 2.2.1. Previous Syntheses of Lycopodine 
 One of the major problems faced by synthetic chemists who undertake total synthesis 
projects of these alkaloids is how to incorporate and preserve the 3° amine functionality while 
constructing the rest of the molecule.  Apart from being highly basic, the electronics of many of 
the intermediates suggest an affinity of the nitrogen’s lone pair towards metal chelation.  This 
complicates the ability to form the desired quinolizidine structure.  A method of attenuating this 
electronic hazard is to utilize it directly to drive the reaction progress.  Husson and co-workers 
did just that by using the nitrogen as enamine-enone 2.02 and performing a Diels-Alder reaction 
with acrylonitrile (Scheme 2.1)
2
.  The N-methyl group is present as an artifact from a previous 
reduction of a pyridinium salt. 
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Scheme 2.1: Synthesis of tetrahydroquinoline 2.03 as a lycopodine precursor 
 
 Locking the problematic amine away as an enamine is highly useful, and helps to prevent 
many of the unwanted side-effects of having a basic nitrogen group present during a synthesis.  
Enamines however, are not stable to a number of synthetic transformations, and a majority of the 
syntheses utilize conventional amide or carbamate protecting groups to mask the amine’s 
functionality.  In the context of a Diels-Alder reaction, this makes the corresponding diene or 
dienophile (whichever the amine is incorporated therewithin) more electronically neutral, and 
thus mismatches the electronics of the cyclization.  This is the reasoning behind leaving the 
amine exposed as part of an enamine or similar motif – to drive electronically favorable 
cyclizations to produce the desired 6-membered ring systems. 
 Heathcock and co-workers utilized an intramolecular Mannich reaction to form three of 
the four quinolizidine rings in one step, but the reaction is racemic.  Beginning from diketal acid 
2.04, they first installed the amine through amidation (2.05), followed by reduction of the amide 
to produce the 2° amine 2.06, with a pendant protected alcohol.  Acid-mediated deprotection of 
the two ketal units gave the quinolizidine ring system minus the D ring. (2.07).  Deprotection of 
the alcohol, oxidation under Oppenhauer conditions, and aldolization with the cyclic ketone 
provided the dehydrolycopodine 2.08.  Catalytic hydrogenation gave the racemate of 2.01 in 
18% overall yield from their chosen starting material (Scheme 2.2)
3
. 
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Scheme 2.2: Heathcock synthesis of (±)-lycopodine 
 
 While the Heathcock synthesis is quite nice for the construction of the quinolizidine core, 
it is racemic, and the deprotection/Mannich reaction is extremely slow, providing only 65% yield 
after a full fortnight.  The 2.04 starting material is also semi-tedious to synthesize, involving a 
conjugate addition from which epimerization of the α position is unavoidable.  In this light, the 
Heathcock synthesis lacks the ability to form the central quinolizidine core of the lycopodine-
class in an enantioselective fashion.  The inability of the starting material (2.04) to be produced 
in even a diasteromerically pure fashion highlights the limitations faced by researchers who 
attempt to synthesize the ring systems with any stereocontrol.  It is also possible to optimize the 
final hydrogenation to include much of the robust homogeneous hydrogenation catalysts which 
could impart stereoselectivity.  In this particular case, however, it could only be beneficial if the 
initial ring formations were performed with stereocontrol. 
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 An alternative to closing the D ring was introduced by Kim and co-workers using 
acryloyl chloride to acylate the 2° amine (2.09), already contained in the ABC-ring system 
(2.10).  Catalytic enolization of the B-ring ketone using NaOMe and a dicyclohexyl-18-crown-6 
furnished the Michael adduct 2.11 in 56% yield.  LAH reduction of the amide gave the 
anhydrolycopodine derivative 2.12 (Scheme 2.3)
4
. 
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Scheme 2.3: Kim synthesis of anhydrolycopodine 
 
 The acylamide Michael addition is an attractive methodology, but the yields are 
unimpressive and the subsequent Jones oxidation after LAH over-reduction diminish the yield 
even further.  Nonetheless, it showcases that the D ring is typically the final ring to be 
synthesized in order to make the quinolizidine core structure.  While the Kim synthesis is 
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racemic, it would be difficult to form the D-ring closure stereoselectively without the initial 
material being enantiopure.  If the C-ring is closed enantioselectively, the adjactent carbon 
center’s chirality can directly influence the approach of the enolate to the β position of the 
acrylamide.  In addition to the implications of the C-ring’s stereochemistry, this synthesis is of 
dehydrolycopodine, which possesses a unit of unsaturation higher than the parent lycopodine.  
One of the stereocenters is locked into an sp
2
 C=C bond.  Even the more active Pt hydrogenation 
catalyst could not hydrogenate such a sterically encoubered double bond. 
 Due to the amine’s natural reactivity, the choice to incorporate it in the final steps of the 
synthesis is a natural one.  Grieco and co-workers installed the nitrogenous functionality into the 
all-carbon backbone of their lycopodine skeleton (2.13) through a Beckmann rearrangement, 
followed by a series of reactions culminating in a ring-contracting Stieglitz rearrangement 
(Scheme 2.4)
5
. 
 
O
H
H
H
AcO
H
H
H Me
2.13
1) H
2
NOH
*
HCl
EtOH, NaOAc
2) SOCl
2
dioxane
65%
H
H
AcO
H
H
H Me
N
HO
H
2.14
N O
2.01
steps
 
Scheme 2.4: Grieco synthesis of lycopodine 
 
 The Grieco synthesis of lycopodine illustrates the problems with installing the amine 
group.  By using a Beckmann rearrangement, they obtain a 7-membered lactam, which must be 
converted through a series of oxidations and reductions (including an N-chlorination) to a 
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suitable precursor for the Stieglitz rearrangement.  This lengthens the synthesis and makes it less 
appealing as a general approach towards the synthesis of the quinolizidine core of the 
lycopodium alkaloid’s lycopodine-class of natural products.  It is also apparent that a reasonable 
amount of structural complexity must be lost to make the desired lycopodine. 
 Alternatively, Carter and co-workers developed a novel strategy utilizing the imine-
enamine tautomerization to drive a sulfone rearrangement with a tandem Mannich reaction, 
forming the B and D rings (Scheme 2.5)
6
.  Thus, the advanced azide/sulfone intermediate 2.15 
was reduced with subsequent imine formation using PPh3 to form the A ring in 2.16.  This was 
subjected to their developed methodology using a Lewis acid to mediate the formation of the B 
ring, providing 2.17 in moderate yields.  Alkylation, followed by the previously described 
Oppenhauer oxidation/aldolization reaction provided, after conjugate reduction, 2.01. 
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Scheme 2.5: Carter synthesis of lycopodine 
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 Again, the Carter synthesis utilizes the Oppenhauer oxidation/aldolization reaction to 
form the D ring, while their interesting methodology closes the C ring.  They begin the synthesis 
of 2.15 with forming the B ring first, which is relatively unique to their synthetic strategy.  Using 
a single ring’s established stereochemistry is an effective way of establishing the stereochemistry 
of the other rings.  Unfortunately, even if the stereochemistry was controlled (here it is racemic), 
the final Knovenagel condensation and hydrogenation provides a racemic center at the C-11 
position.  While the Carter synthesis is very enlightening and their Lewis acid chemistry takes 
advantage of an important enamine-imine tautomerization, the Lewis acid must be added in 
stoichiometric amounts.  This severely minimizes the utility of the reaction for larger-scale 
syntheses, as well as increases the potential cost of the reaction. 
 While all of these syntheses are excellent examples of total synthesis, all of them suffer 
from the same few problems.  Firstly, the amine functionality typically hinders the application of 
many reactions in this particular system.  Circumventing this issue by incorporating the nitrogen 
in the final few steps poses alternative challenges such as control of when and where to insert it 
into the typically complex carbon-skeletal intermediate.  It has also been shown that installing 
the nitrogen earlier and using its unique reactivity to assist in reactions is also possible, but the 
yields are somewhat diminished.  Ideally, it would be attractive to install the amine early, to 
avoid the late-stage issues involved with its installation and selectivity, but to mask the amine 
(i.e. protection) until the late stages.  While focusing on these issues, we have decided to embark 
on a total synthesis of a new Huperzine-type alkaloid isolated from the same club moss that has 
spawned so much interest in the lycopodine-class of lycopodium alkaloids. 
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2.2.2.  Novel Huperzine Alkaloid of the Lycopodine-Class 
In 2010, a group of researchers led by Tan isolated a natural product which displayed 
very similar NMR correlations to other known lycopodine-class lycopodium alkaloids.  Isolated 
from the same lycopodium club moss species as many of the same class of alkaloids, this new 
alkaloid possesses some key differences (Figure 2.2)
7
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Figure 2.2: Isolated lycopodine-class lycopodium alkaloid, total synthesis target 
 
 In addition to the standard quinolizidine ring system, there is a fifth ring, created by a 
bridging ether linkage from the already bridging C-ring onto the B-ring at the location of the 
ketone moiety in lycopodine.  The second oxygen functionality is also on the B-ring as a 
hydroxyl group.  This bridging ether linkage creates a “cage”-like structural motif, which makes 
this member of the lycopodine-class a standout.  Officially named, it is 6α-hydroxy-5,15-oxide-
lycopodane, but for simplicity, it will be referred to rom here on as Huperzine X. 
 
2.3.  First-Generation Approach Towards the Total Synthesis of Huperzine X 
 2.3.1.  Retrosynthetic Analysis 
 To begin with, we desired a method to make the quinolizidine core in an efficient 
manner.  If we utilized the B and D-ring’s carbon backbone as a built-in tether for further 
25 
 
reactivity, we could potentially form the A-ring through a similar Michael addition-type of 
reaction.  This Michael addition should be more facile, as nitrogenous nucleophiles are more 
efficient as Michael addition partners.  One of the major hurdles, however, was the construction 
of the bridging ether linkage.  We envisioned first that the action of an oxanion derived from a 
ketone on the C-ring by the addition of a methyl nucleophile could be seen to favor the opening 
of a pendant epoxide on the B-ring (Scheme 2.6). 
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Scheme 2.6: Initial retrosynthetic disconnection to form the bridging ether linkage 
 
 Closer inspection of the steric placement of the bridging ketone in relation to both the 
incoming nucleophile and the reactive epoxide shows that not only is the positioning favorable 
for a nucleophile to approach from the desired face of the ketone, but that the ketone itself is 
blocking the reactive face of the epoxide (Scheme 2.7).  While it is only shown for the ketone-
containing ring (C-ring) to be in the thermodynamically favorable chair conformation, it is also 
possible for it to be in the boat conformation.  If it adopts the boat conformation, the ketone’s 
opposing face will be exposed to nucleophilic attack (i.e. opposite stereoselectivity), as will be 
the electropositive carbons of the epoxide.  It is envisioned that while in the boat conformation, 
the carbonyl will experience unfavorable interactions with the lone pair orbital of the nearby 
nitrogen.  In the shown chair conformation, the orbital of the nitrogen’s lone pair is presumed 
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(due to the chair conformations on all of the rings being lowest in energy and thus adjacent 
atoms are staggered from one another) to be gauche to the α-methylene’s hydrogen atoms of the 
C-ring.  In the boat conformation of the C-ring, the nitrogen’s lone pair orbital could potentially 
encounter the lone pair orbitals of the carbonyl oxygen.  Thus the electron-electron repulsion 
dynamic would increase the energy of the C-ring boat conformation even further, allowing for a 
more favorable chair conformation.  In this light, the proposed mechanistic implications are 
shown for the chair conformation only. 
The oxygenated functionality of 2.19 can be thought of as coming from the parent 
alkenes through oxidative cleavage and epoxidation, respectively, giving 2.20.  Due to the C-
ring’s C=C bond being terminal, it should undergo oxidative cleavage at a much faster rate than 
the internal C=C bond of the B-ring.  This leaves the B-ring’s olefin as the only one left in the 
structure, and being that the molecule possesses a rigid structure due to the bridging nature of the 
C-ring, simple epoxidation agents such as meta-Chloroperoxybenzoic acid (mCPBA) should be 
sufficient in producing the epoxide with the desired stereochemistry.  The bridging methylene 
structure is homoallylic to the nitrogen, suggesting that an allylation of some oxidized form of 
the nitrogen could produce the bridging structure, giving rise to 2.21 as a viable intermediate 
(Scheme 2.8). 
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Scheme 2.7: Potential routes for the addition of Me
-
 to the bridged ketone 2.19 
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Scheme 2.8: Retrosynthesis of 2.19, providing allylation intermediate 2.21 
 
 We envisioned that the allylation could result from the activation of the 2,3-dihydro-
pyridone carbonyl via triflic anhydride (producing the enol triflate) or a general Lewis acid 
(Scheme 2.9).  Activation of the carbonyl would promote electron migration from the nitrogen’s 
lone pair into the imine form of the imine-enamine tautomer, generating an enolate-Lewis acid 
pair (or enol triflate), which could be quenched in situ by the reactive allyl trimethylsilane unit.  
The re-protonation of the enolate can only occur from one direction due to the rigid structure of 
the now completely formed quinolizidine ring system, giving 2.22.  Removal of the ketone is 
expected to be straightforward due to its non-proximity to other reactive functional groups. 
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Scheme 2.9: Application of the intramolecular allylation of the activated iminium of 2.21 
 
 Beginning from the 1,4-cyclohexadiene substructure of 2.21, we foresaw the use of a 
Diels-Alder to set the desired stereochemistry of the allyl unit as well as the junction onto the D-
ring (syn).  In order to preserve the olefin in the pyridone, it was required that we use a ynamide 
precursor.  This did not allow us to have the A ring formed during the Diels-Alder, and we 
decided to form the ring through a series of transformations which greatly resembled the 
previous syntheses applied to the D-ring (Scheme 2.10). 
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Scheme 2.10: Proposed synthesis of the A-ring 
 
 The Diels-Alder between the parent diene and ynamide is intramolecular, which should 
be a favorable process when considering thermal requirements.  However, literature suggests that 
the three reaction sites (diene olefins and ynamide alkyne) can be made to template to a 
transition metal, which brings them into the appropriate orientation.  Rh appears to be uniquely 
poised to accomplish this task, although the only report of this occurring does not control the 
stereoselectivity (Scheme 2.11)
8
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Scheme 2.11: Literature report of Rh(I)
+
-catalyzed intramolecular ynamide Diels-Alder reaction 
 
 Although the literature report uses only ynamides without electron withdrawing groups, 
they were able to perform the reaction using thermal conditions (80°C, benzene, approx. 50%), 
but obtained much better yields with a templating catalyst.  Rh(I) was unable to perform the 
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reaction, but removing the Cl
-
 ligand by using AgSbF6 created a cationic species which 
performed the reaction at RT.  While the thermal reaction gave aromatization as a side product, 
the cationic Rh(I) catalyst did not give any major side products.  The authors suggest that, since 
Rh(I) has been used in previous studies to cyclotrimerize ynamides with other alkynes (both 
intra- as well as intermolecular) by templation, that this reaction behaved much in the same 
way
9
.  The authors also suggest that the reaction occurs because the ynamide nitrogen is electron 
withdrawing due to the tosyl or trifluoroacetate substituent, and thus the ynamide alkyne is 
electron deficient.  In our system the ynamide nitrogen is part of a carbamate, so the alkyne is not 
as electron deficient, but this is offset by the presence of an ester directly conjugated to the 
alkyne.  In theory, our system should work equally as well, since the electronics are similar and 
the templation should be the same.  Thus, 2.24 can come from ynamide 2.25 which in turn can be 
synthesized from diene-carbamate 2.27 (Scheme 2.12).  The diene was chosen to not include the 
trimethylsilyl functionality for fear that during the ynamide coupling, it would be removed.  It 
was decided to use a protected alcohol, which can be transformed into a TMS group through 
displacement of the acetate with hexamethyldisilane and Rh(I)
10
, or displacement of the methyl 
ether with NaTMS
11
.  The ynamide coupling can be done in a number of interesting ways, many 
of which involve Cu catalysis, the most notable and successfully applied being the Danheiser 
method
12
 and the Hsung method
13
.  Unfortunately, we were unable to get the procedure of Stahl, 
et al. to provide any material
14
.  Due to the electron withdrawing nature of the bromoalkyne, the 
Cu-catalysis often promotes dual Michael-type additions of the amide-cuprate to the 
bromoalkyne, and so simple deprotonation (NaH, DMF) can provide a less-reactive, more 
amenable procedure for our purposes
15
.  
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Scheme 2.12: Retrosynthesis of 2.24 to provide carbamate 2.27 and bromoalkyne 2.26 
 
 Carbamate 2.27 was thought to come from the parent alcohol 2.28 through either a 
Mitsunobu reaction with the primary carbamate or a mesylation/displacement with 
azide/reduction/acylation sequence.  We recognized that the 1,3-diene was the logical position to 
break apart for the next stage of the retrosynthesis and we decided that olefination would be an 
acceptable method, since we required both olefins of the diene to possess the trans-geometry.  
Thusly, we envisioned the cleavage occurring between the C7-C8 olefin (numbering from the 
TBS-protected alcohol), giving aldehyde 2.29 and the olefination partner with either a 
phosphonate ester (2.30) or a 2-sulfonylbenzothiazole (2.31).  These would allow for Horner-
Wadsworth-Emmons olefination or Julia olefination, respectively (Scheme 2.13). 
 
NH
MeO2C
OTBS
2.27
OP
OTBS
2.28
OP
O
2.29
+
OTBS
X
2.30: X = P(O)(OEt)2
2.31: X = SO2Btz  
Scheme 2.13: Retrosynthesis of 2.27 resulting from olefination 
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 The aldehyde 2.29 is easily synthesized by monoprotection of the diol followed by 
routine oxidation.  The allylic olefination partner was a more problematic piece to synthesize, 
and we saw it arising from the 1,4-skip diene 2.32 and the simple allylic partner, either 2.33 (X = 
P(O)(OEt)2) or 2.34 (X = SO2Btz).  The two materials could be combined in a cross-metathesis 
reaction, since the skip diene (Type I) and the allylic olefination partner (Type II) are a good 
match for cross-metathesis (Scheme 2.14)
16
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Scheme 2.14: Retrosynthesis of the allylic olefination partners 
 
 Using the Cook Group’s expertise in the field of organoindium chemistry, we envisioned 
an analogous reaction to allylzincation
17
 using allyl indium
18
.  Thus, we decided 2.31 could be 
synthesized from commercially available allyl bromide and TBS-protected propargyl alcohol 
2.35.  The allylic olefination precursors are easily synthesized by Arbuzov reaction of P(OEt)3 
and allyl bromide (2.33) or by the sodium salt of 2-mercaptobenzothiazole and allyl bromide, 
followed by oxidation of the sulfide to the sulfone (2.34). 
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2.3.2.  Forward Synthesis 
Our forward synthesis began with the allylindation of 2.35.  Allylzincation was 
unsuccessful in this case due to excessive heat build-up causing minor explosions during the 
ultrasound-required reaction.  The zinc powder must also be activated by TMSCl and I2, which 
the indium reaction does not require.  The indium reaction also does not require ultrasound, and 
the room temperature reaction provided 2.32 in high yields (Scheme 2.15). 
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Scheme 2.15: Synthesis of 1,4-skip diene 2.32 
 
 With 2.32 in hand, we attempted to synthesize 2.33 and 2.34 using standard methods.  
The Arbuzov reaction was an obvious choice for the installation of the phosphonate.  Using neat 
conditions with triethylphosphite and allyl bromide, we obtained the desired allylic phosphonate 
in near quantitative yield
19
.  The allylic sulfone was synthesized by alkylation of 2-
mercaptobenzothiazole with allyl bromide in EtOH, followed by mCPBA oxidation to the 
sulfone gave 2.34 in good yield (Scheme 2.16)
20
. 
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Scheme 2.16: Synthesis of 2.33 and 2.34. 
 
 Encouraged by such excellent preliminary results, we turned our attention to the cross-
metathesis of the respective olefination precursors and 2.32.  Allylic phosphonate 2.33 was 
efficiently metathesized onto 2.32 in good yields
21
, but the large amount of Ru impurities 
decomposed the product (2.36) rapidly, even at freezing temperatures.  Integrations of the newly 
formed olefin protons showed a 74:26 E:Z ratio, suggesting the reaction favors our desired 
stereoisomer.  The Ru impurities are generally Ru-H species, created by the in situ 
decomposition of the metathesis catalysts during the reaction.  These Ru-H species have been 
recently shown to isomerize dienes under general metathesis conditions
22
.  Yields were 
calculated immediately after column purification, but the material was unuseable in further 
reactions.  This is presumably due to the isomerization (conjugation) of the 1,4-skip diene, which 
moves the internal olefin futher away from the electron withdrawing group (phosphonate or 2-
mercaptobenzothiazole), thus making the α position no longer allylic, increasing its pKa.  This 
increase must be sufficient to either render the proton inert to the tested bases, or lowers the trans 
selectivity of the reaction.  We then attempted to utilize the same protocol by combining 2.34 
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and 2.32.  The yield was significantly lower, but the E:Z ratio remained relatively unchanged.  
Ru impurities also decomposed the product (2.37) rapidly.  We also attempted to cross-
metathesize bis-sulfone 2.38
23
 onto 2.32, harnessing what has been observed for the bis-acetate 
species
24
, but found the reaction to be unsuccessful (Scheme 2.17).  This is presumably due to 
the highly electron poor nature of 2.38.  The use of alternative metathesis catalysts (i.e. 
Hoveyda-Grubbs 2
nd
 generation) did not improve the performance.  All attempts to remove Ru 
impurities by published methods
25
 were successful at removing most color, but whatever residual 
metal impurities remained quickly decomposed even the treated material. 
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Scheme 2.17: Attempts at cross-metathesis of 2.32 with olefination partners 
 
 It became apparent that the direct cross-metathesis of the allylic olefination partners was 
not feasible for a lengthy total synthesis.  We therefore attempted to incorporate the starting 
allylic bromide into 2.32 (Scheme 2.18).  Directly via cross-metathesis required the use of a 
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more robust catalyst due to the electron withdrawing nature of the bromomethyl unit on the 
alkene.  The Hoveyda-Grubbs 2
nd
 generation metathesis catalyst (HG-2) performs well in these 
cases
26
.  While the yield of allyl bromide 2.39 was very good, the E:Z ratio was not, and we 
obtained it as an inseparable 2:3 mixture, favoring the Z isomer (undesired).  Regardless, the 
Arbuzov conditions resulted in decomposition of the starting material, presumably due to the Ru 
residues which very clearly darkened the reagent.  We also attempted to incorporate the allylic 
bromide during the allylindation reaction we had been using.  In this light, we subjected 2.35 to 
the allylindation reaction using bis-allyl bromide 2.40.  Unfortunately we observed no 
conversion, owing likely to the formation of 1,3-butadiene in situ, even with the typically stable 
allyl indium species. 
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Scheme 2.18: Attempts to incorporate the allylic bromide into 2.32 
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 2.3.3.  First-Generation Synthesis Implications 
 While we were unsuccessful at efficiently constructing the backbone of the quinolizidine 
core of Huperzine X, we did develop a significant allylindation procedure which is operationally 
simple and reproducible.  The cross-metatheses were successful, but the products were not stable 
to direct storage.  An attempt was made to perform the olefination using 2.36 immediately after it 
was synthesized, but no reaction was found.  This is presumably due to the impurities in the 
reagent interfering with deprotonation or nucleophilic attack onto the aldehyde. 
 
2.4.  Second-Generation Approach Towards the Total Synthesis of Huperzine X 
 2.4.1.  Retrosynthetic Analysis 
 After our failed attempts at creating the 1,3-diene motif by synthesizing one of the 
olefins, we decided to embark on a route centered around creating the σ-bond linkage of the 1,3-
diene.  Due to the two partners being sp
2
-hybridized, we quickly realized that Pd-mediated cross-
coupling could provide us with such a system.  We envisioned thusly, an identical retrosynthetic 
analysis, but with the key step of forming the carbon skeleton of 2.28 replaced from olefination 
to cross-coupling of vinyl triflate 2.40 with either vinyl zincate 2.41 or vinyl boronate 2.42 
(Scheme 2.19). 
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Scheme 2.19: Retrosynthesis of 2.28 resulting from cross-coupling 
 
 We anticipated that 2.40 could come from the parent aldehyde (2.43) through simple 
enolization/trapping.  The aldehyde was envisioned to come from the mono-protected diol 2.45, 
through the O-vinylated 2.44 intermediate via Claisen rearrangement.  The diol could then be 
seen as coming from the hydroxymethylacrylate 2.47 (Scheme 2.20). 
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Scheme 2.20: Retrosynthesis of vinyl triflate 2.40 
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 The vinyl nucleophile for the cross-coupling was thought to arise from the terminal 
alkyne 2.48, with the heteroatom being attached through transmetalation onto zinc, or by direct 
hydroboration.   The alkyne could thus allow for the early incorporation of the nitrogen, as it 
does not conflict with these reactions (Scheme 2.21). 
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Scheme 2.21: Synthesis of cross-coupling partners 2.41 and 2.42 from a common precursor 
 
2.4.2.  Forward Synthesis 
 Our synthesis first began with an attempt to synthesize the vinyl triflate 2.40.  Treatment 
of triethylphosphonoacetate with aqueous formaldehyde allowed for a very smooth synthesis of 
2.47 through tandem Horner-Wadsworth-Emmons olefination and a Baylis-Hillman reaction 
(Scheme 3.22).  Interestingly enough, if ethyl acrylate (the intermediate product) was directly 
subjected to standard Baylis-Hillman protocol (cat. DABCO, DMF, RT)
27
, only small amounts 
of the desired product were formed.  This is presumably due to the propensity of 2.47 to 
polymerize upon standing, and is likely accelerated by the Baylis-Hillman conditions.  TBS 
protection using standard conditions provided 2.46, which is much more stable to storage.  
Subsequent DIBAL-H reduction provided the mono-protected diol (2.45), which was subjected 
to an O-vinylation protocol using a cationic Au(I) system to effect vinyl transfer from ethyl vinyl 
ether
28
.  Finally, Claisen rearrangement was effected using microwaves to accelerate the 
reaction.  Thermal reaction conditions (toluene, 150°C, sealed tube) provided only approx. 50% 
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yield after 6 days of reaction.  Microwave conditions allowed for nearly quantitative yield in 
only 15 hours.  This supports the known ability of microwaves to accelerate rearrangement 
reactions
29
.  Previous syntheses have utilized Claisen rearrangements to effect this same 
homologation
30
.  The reaction pathway is very efficient, with the precursor aldehyde being 
synthesized in 5 steps with 81% yield and only two required silica-gel plugs for purification. 
 
TBSO
O
2.43
EtO
O
P
OEt
O
OEt
1) paraformaldehyde
1N H
3
PO
4
2) K
2
CO
3(aq.)
93%
OEt
OH O
2.47
TBSCl
imidazole
DCM
93%
OEt
TBSO O
2.46
DIBAL-H
Et
2
O
-78 °C
99%
OTBSOH
2.45
OO
OTBS
2.44
AuCl(PPh
3
) (2 mol%)
AgOAc (2 mol%)
sealed tube, 96%
(first purification)
toluene
150 °C (MW)
99%
 
Scheme 2.22: Synthesis of vinyl triflate precursor 2.43 
 
 In our attempt to transform 2.43 into the required E-vinyl triflate, we utilized a number of 
protocols (Table 2.1).  Although there is much literature evidence to suggest that vinyl triflate 
formation can occur using sterically hindered bases and Comins Reagent [3-chloro-6-(1,1-
bis(trifluoromethylsulfonyl)aminopyridine], we saw no success in applying these procedures
31
. 
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Table 2.1: Attempted synthesis of vinyl triflate 2.40 using standard triflation methodologies 
TBSO
O
2.43
TBSO
OTf
2.40
N
Cl
NTf2
Comins Reagent
Base
Tf
2
O or Comins Reagent
-78 °C, THF
 
Entry Base Triflating Agent Yield (%)
a 
1 Pyridine Comins Reagent or Tf2O 0 
2 2,6-lutidine Comins Reagent or Tf2O 0 
3 2,4,6-collidine Comins Reagent or Tf2O 0 
4 KHDMS Comins Reagent or Tf2O 0 
5 KOtBu Comins Reagent or Tf2O 0 
a
: Refers to yield of desired product as detected by GC-MS 
        
 We were unable to achieve success with the established protocols, so we attempted to 
divine some of our own.  Literature shows that terminal carbonyl compounds tend to be more 
reactive to simple triflic anhydride in the absence of base.  This is due to the initial activation of 
the carbonyl by a triflyl unit, followed by nucleophilic addition of the triflate counteranion, 
generating a bis-triflate species.  This is then acted upon by an added base to provide cis and 
trans isomers of the resultant vinyl triflate (Scheme 2.23)
32
.   
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Scheme 2.23: Observed mechanistic implications in the synthesis of 2.40 
 
By first adding Tf2O to the THF solution of 2.43, a dark solution was obtained after 5 
minutes, that GC-MS showed was the bis-triflate, formed in 100% conversion.  Addition of any 
base (NEt3, DMAP, KHMDS, pyridine, 2,6-lutidine, KOtBu) gave exactly 1:1 mixtures of 
cis:trans vinyl triflate, also formed in 100% conversion from the bis-triflate.  However, we did 
not desire the cis isomer, and it was not possible to separate the isomers from each other.  We 
also investigated the possibility of using a larger base (DBU or similar) to effect the elimination 
with trans-favorability.  We were unsuccessful at all attempts to do so.  It was decided that we 
might be able to separate the currently unseparatable cis:trans mixture after Suzuki cross-
coupling to the expected vinyl boronate or Negishi coupling to the vinyl zincate. 
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 In preparation for this coupling, we investigated the synthesis of vinyl boronate 2.42 from 
4-butyn-1-ol via a series of hydroboration experiements.  Thusly, we subjected 2.48 to standard 
Mitsunobu conditions to install the nitrogen as the bis-protected tosylamide, and subjected the 
produced 2.50 to a large variety of hydroboration experiments (Scheme 2.24).  Direct 
hydroboration using HBpin (Bpin represents the pinacolate ester of the boron species shown) 
was unsuccessful, as were the two main catalytic versions, using Rh(I) and using a catalytic B-H 
species to effect transborylation
33
.  Additional experiments using the Me2S adduct of 
dibromoborane and subsequent trapping of the vinyl dibromoboron species with pinacol were 
also unsuccessful
34
.  Finally, we attempted direct hydroboration using a novel new method 
reported by Snieckus, et al. involving the pre-generation of a dialkylborane and trapping of the 
product with pinacol
35
.  Unfortunately, no products were ever isolated from these reactions.  All 
starting material was consumed, but it is presumably a decomposition pathway that is undergone 
by the unstable terminal vinyl boronate during these reactions.  This is supported by the 
disappearance of the starting alkyne by TLC, NMR, and FTIR.  Although the starting material is 
being consumed, the isolated products do not show many of the desired characteristic peaks in 
their NMR spectra, mostly notably the tosyl peaks as well as the pinacol’s methyl group peak(s). 
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Scheme 2.24: Attempted hydroboration to install the vinyl boronate cross-coupling partner 
 
 In a last-ditch effort to synthesize the required trans-vinyl boronate, we utilized a 
protocol established by Grubbs et al., involving the cross-metathesis of a propenyl boronate onto 
a terminal alkene
36
.  Unfortunately, the analogous amino-alkene 2.52 did not provide the desired 
compound, but rather a large amount of homocoupled material (Scheme 2.25).  Changing the 
concentration, which typically has a large impact on these reactions, did not alter the singularly 
disappointing product distribution.  Undoubtedly this arrises from the terminal olefin being Type 
I and highly reactive to olefin metathesis, while 2.53 is Type II and is thus less reactive.  Type I 
olefins tend to homometathesize under cross-metathesis conditions, and are typically not used for 
this reason. 
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Scheme 2.25: Attempted synthesis of vinyl boronate 2.54 by cross-metathesis 
 
 Our attempts to synthesize the vinyl zinc reagent 2.41 began with an attempt to 
synthesize vinyl iodide 2.55 (Scheme 2.26).  We envisioned that by lithiating the iodide, we 
could effectively transmetallate onto zinc and be provided with a reactive cross-coupling partner 
in one pot.  Unfortunately, all attempts to synthesize the vinyl iodide failed.  The most promising 
pathway required the aldehyde 2.56 to be converted to the vinyl iodide by a Takai olefination
37
.  
The cyclic aminal 2.57 was isolated in all cases, a result of the cyclization/acetalization of 2.56 
in situ. This cyclic aminal was subjected to several iterations of olefination protocols, but 
remained unchanged.  It is not known why 2.57 is so stable to olefination conditions.  It is 
possible that the hydroxyl group directly interacts (most likely through hydrogen-bonding) with 
the carbamate protecting group.  This may increase the stability of the cyclic form, preventing 
the aldehyde functionality from being exposed to participate in the desired reactions. 
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Scheme 2.26: Attempted synthesis of vinyl iodide 2.55 
 
2.4.3.  Second-Generation Synthesis Implications 
 It became apparent that our approach towards the cross-coupling was fruitless.  We were 
able to synthesize aldehyde 2.43 in excellent yields, with minimal purification steps.  We 
therefore wanted to move forward being able to incorporate this molecule into our new synthetic 
strategy.  We also learned that the terminal nucleophile was highly problematic, and that many of 
the precursors (boronates and halides) were highly unstable.  The presence of the nitrogen also 
seemed to make things much more complicated and difficult.  However, performing the reactions 
on a THP-protected alcohol analog did not change the outcomes, suggesting that the product 
moieties are the truly unstable portions. 
 
2.5.  Third-Generation Approach Towards the Total Synthesis of Huperzine X 
 2.5.1.  Retrosynthetic Analysis 
 Similarly to the second-generation synthesis, we maintained focus on the identical steps 
to completion of the natural product.  Since we had invested a significant amount of time and 
effort to synthesize 2.43, we decided the best pathway would be to add a vinyl nucleophile 
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directly to the aldehyde.  As described in the previous section, we had experience difficulties in 
creating a vinyl nucleophile such as a vinyl zinc reagent from direct transmetalation onto the 
vinyl lithiate.  However, we decided that we might be able to make the vinyl zinc compound if 
we transmetallated from a more stable transition metal.  If we could accomplish this, we could 
still utilize our aldehyde synthesis as well as our terminal alkyne starting material (Scheme 2.27). 
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Scheme 2.27: Third-generation retrosynthesis involving addition onto aldehyde 2.43 
 
2.5.2.  Forward Synthesis 
 Our synthesis of the vinyl zinc reagent 2.41 began with firstly protecting 4-pentyn-1-ol as 
its tetrahydropyranyl acetal.  Using Amberlyst-15 ion exchange resin as a source of catalytic 
protons, we were able to isolate the protected alcohol 2.58 in quantitative yield.  We next turned 
to the literature to provide us with alternatives to lithiation of a vinyl iodide, so that we could 
transmetallate directly from a metallated vinylic species created from the terminal alkyne.  There 
are many reports in the literature to accomplish this task.  Most notably among them are 
hydroalumination and hydrozirconation.  In both cases it has been reported that amides 
containing acidic protons or tosyl groups are generally incompatible with these reactions types.  
We therefore attempted to synthesize the hydroaluminated material as well as the 
hydrozirconated material, and found the hydrozirconation to be successful. 
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 Hydrozirconation studies were conducted using the numerous reported literature 
protocols (Table 2.2), and it was found that 1.1 equivalent of Schwartz Reagent in DCM was an 
applicable method for providing the hydrozirconated intermediate. 
 
Table 2.2: Hydrozirconation trials using 2.58 as an alkyne starting material 
OTHP
2.58
OTHP
Zr(Cl)Cp2
Cp
2
Zr(H)Cl
solvent
temperature
time
 
Entry Schwartz Reagent (eq.) Solvent Temperature (°C) Time  conversion
a
 
1 2.2 toluene reflux 5 hrs decomp.
b
 
2 2.2 THF RT  reflux 16 hrs none 
3 1.5 DCM 0°C  RT 25 min complete 
4 1.1 DCM 0°C  RT 10 min complete 
a
: conversion monitored by TLC using p-anisaldehyde as a stain.  Hydrozirconated product appears as red while 
starting alkyne is blue.  
b
: Decomposition confirmed by crude 1H-NMR analysis 
 
Thus, using the optimized protocol, we subjected alkyne 2.58 to hydrozirconation in 
DCM and followed with transmetalation (Scheme 2.28).  Of note is the lack of formation of any 
cis isomers during the hydrozirconation.  This is typical of hydrometalations (hydrozirconation, 
hydrostannation, and hydroalumination being most common), as the metal-hydride is added to 
the alkyne in a syn addition, resulting in the alkyl group and the metal being trans to one another 
in the resultant product.  Regioselectivity is also not a problem for this particular reaction due to 
the alkyne being terminal, and thus the steric bulk of the zirconium species favors the least 
hindered carbon of the alkyne, giving rise to the only observed regioisomer. 
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Scheme 2.28: Hydrozirconation/transmetalation sequence for constructing 2.59 
 
 Initially ZnCl2 was used as a solution in THF for the reaction, but it resulted in no 
conversion to product.  The main products were the reduced alkyne (reduced to alkene, result of 
protonation of the C-Zr bond) and the recovered aldehyde (2.43).  This is presumably due to our 
inability to exclude all water from the ZnCl2 solution.  As an alternative, we attempted to use 
ZnMe2 (as a commercially available solution in toluene) and found that the reaction was 
successful, giving 54% yield of the allylic alcohol.  We also attempted a reported protocol where, 
using a silver salt (AgClO4 or AgOTf), the vinyl zirconium reagent would be ionized to the 
cation and act as a vinyl transfer agent to the aldehyde
38
.  While the mechanistic details located 
in the original paper are convincing, we did not obtain any product even after 24 hours under 
their reported conditions.  The use of a dialkyl zinc reagent is required because the initial stage of 
the transmetalation process is the methylation of the zirconium, forming a transient, hypervalent 
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zirconium complex.  This is much more reactive to transmetalation, and reacts with the present 
ZnMe2.  The released Cp2Zr(Cl)Me is a proficient Lewis acid, and actually accelerates the 
addition of the vinyl zinc reagent to the aldehyde.  When using chiral ligands to effect a 
stereoselective addition to aldehydes, it is common to have to use a larger excess of ligand in 
order for the zinc Lewis acid to effectively compete with the in situ generated zirconecene Lewis 
acid
39
. 
 With the structurally significant carbon backbone 2.59 in hand, we turned our attention to 
the required elimination of the allylic alcohol to make the desired 1,3-diene motif.  Using 
standard conditions (MsCl, NEt3, DCM, then DBU, THF, reflux) resulted in a 1:1 mixture of 
cis:trans isomers for the newly formed olefin.  An alternative procedure using Hünig’s base and 
HMPA
40
 at 160°C resulted also in 1:1 isomeric ratios, but with the added issue of significant 
decomposition of the starting mesylate due to the high temperatures.  The generation of the HCl 
salt of Hünig’s base also promotes the deprotection of the THP ether, which is not found in the 
crude mixture NMR analysis.  It was also explored to initially oxidize the allylic alcohol (MnO2, 
DCM, RT, 24 hrs, 95%), then subject the enone to enolization and trapping with Tf2O.  
Reduction of this 1,3-diene-2-triflate with Pd(0) catalysis proved ineffective at producing the 
deoxygenated compound.  Although we worked diligently to produce the desired 1,3-diene 
structure, we were unable to achieve the transformation.  Due to this limitation, the synthesis was 
halted due to lack of forward progress.  We turned our attention to a proof-of-concept set of 
model system experiments designed to illustrate our vision of the future key reactions in this 
synthesis. 
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2.5.3. Synthetic Approaches to Model Systems 
 With many of our synthetic options exhausted, we turned our attention to creating model 
systems in order to illustrate the potential that the incomplete synthetic steps possess.  Our initial 
approach was to create two distinct models, one dealing with the intramolecular ynamide Diels-
Alder reaction and another dealing with the intramolecular allylation reaction.  Since these two 
reactions are crucial for the success of our entire synthetic strategy, it was imperative that the 
model systems be as similar as possible, while still allowing us access to readily available 
materials for synthetic optimization. 
 
 2.5.3.1. Intramolecular Diels-Alder Model System 
 In preparing our ynamide Diels-Alder model system, we realized that although the two 
appendages to the resultant cyclohexadiene ring would be syn to one another, control of such a 
sterically encumbered system may be detrimental to our optimization of the reaction conditions.  
In this light, we designed a potential system (2.60) which could facilitate our understanding of 
the reaction, its conditions, and the potential for chiral ligand introduction (Figure 2.3). 
 
N
CO2Et
Boc
2.60  
Figure 2.3: Model compound for ynamide Diels-Alder studies and optimization 
 
 Our attempts to synthesize this compound were mainly unsuccessful, due in large part to 
the inability of previously described procedures to provide usable product.  This is mainly due to 
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the instability of the resultant ynamide-ester as well as the high reactivity of the standard Cu-
amide reaction intermediates with bromoalkyne 2.26.  Unfortunately, the C7 backbone, due 
almost certainly to the odd number of carbons, is not commercially available, so the terminal 
carbon must be included with the nitrogen as a cyanide addition.  Thusly, simple esterification of 
sorbic acid gave methyl sorbate (2.61)
41
, which was subjected to base-induced olefin 
isomerization
42
, giving the 1,3-diene as a terminal moiety in 2.62.  Reduction with LAH gave the 
alcohol 2.63, which was tosylated to give 2.64.  Cyanide displacement and subsequent LAH 
reduction gave the free amine
43
, which was directly protected as the Boc carbamate 2.65 in 71% 
yield over two steps.  With the amine in hand, we attempted the previously described ynamide 
formation procedure using the “push-pull” bromoalkyne14.  Unfortunately, the product was not 
stable to chromatography and it was unable to be isolated.  The starting carbamate was recovered 
in a 10% yield.  The corresponding amount of bromoalkyne was also recovered (Scheme 2.29). 
These results point to the electron withdrawing nature of the ester group being a primary culprit 
in the instability of the resultant ynamide.  It is possible that the desired Diels-Alder 
cycloaddition is occurring due to the high electronic instability of the ynamide-ester, however 
there was no indication of this material passing through the column used to purify the ynamide. 
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Scheme 2.29: Attempted synthesis of Diels-Alder model compound 2.60 
 
 Due to the unstable nature of the ynamide product, we sought an alternative ynamide 
formation procedure which would give us a stable precursor to test the Diels-Alder reaction 
upon.  In this light, we identified the ynamide synthesis described by Witulski and co-workers
7,8
.  
Using the hypervalent iodine TMS-alkyne, we subjected 2.65-2.67 to the KHMDS-mediated 
coupling of hypervalent iodine reagent 2.68 (Scheme 2.30).  This reaction functions by the initial 
anionic amide nitrogen attacking the β carbon of the iodonium alkyne, forming an intermediate 
iodoylide, which decomposes to iodobenzene and a vinylidene carbene
44
.  This carbene can 
undergo the desired 1,2-migration of the TMS group to provide the ynamide in low yields.  The 
carbene can also undergo rapid 1,5-insertion to form a 2,3-dihydropyrrole-type of product, which 
may undergo further reactions.  Lastly, the carbene can be envisioned to participate in [2+1] 
cycloaddtions with the pendant olefins present in the model system.  One way to remove this 
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reactivity is to conjugate the vinylidene carbene to a phenyl group, which removes the electron 
density around the carbene center and allows for more time to facilitate the 1,2-migration
45
.  In 
the case of 2.71, the ultimate goal is to functionalize the position onto which the TMS group 
migrates.  If the TMS group is maintained, it becomes vinylic, which allows for the ipso 
substitution by a reactive acid chloride; something a larger, potentially more stable group cannot 
do.  In this light, the possible permutations of replacement groups for TMS is severely limited to 
1,2-migratory aptitude. 
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2.70, Pg = COCF3, 0%
2.71, Pg = Ts, 34%
KHMDS
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Scheme 2.30: Ynamide formation using iodonium alkyne 2.68 
 
 All protecting groups gave acceptable yields for our model system studies with the 
exception of 2.66, which did not allow us to purify either the starting amide or the resultant 
ynamide, as the trifluoroacetyl group was too unstable to chromatographic separations, which are 
required after the aforementioned reaction.  The Boc and Tosyl protected compounds (2.65 and 
2.67, respectively) gave acceptable yields with pure products after chromatography.  Due to 
limitations in the scale of these reactions and the length of time to synthesize additional material, 
we elected to perform the studies on the Diels-Alder cyclizations in situ using NMR studies.  
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Thus we subjected 2.71 as a model compound to the reaction conditions described in Witulski et 
al (Scheme 2.31)
7
. 
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Scheme 2.31: Intramolecular Diels-Alder reaction of model compound 2.71 
 
 Our results were promising: we obtained 2.72 after column chromatography (neutral 
Al2O3) in a 20% yield (isolated, 
1
H-NMR indicated only a 75% purity of the isolated material 
even after chromatography).  These results indicate that the intramolecular ynamide Diels-Alder 
system does indeed work for our system.  While the yield discrepencies with the original paper 
are unfortunate, it does indicate that there is promise in the Diels-Alder system.  The reason for 
the difference is most likely due to the reported protocol providing 5,6-fused ring systems, 
whereas the approach towards 2.72 produces 6,6-fused ring systems, which are kinetically less 
stable, and the reaction is under kinetic control. 
 
2.5.3.2. Intramolecular Allylation Model System 
 The intramolecular allylation is made more complicated by the presence of the D-ring in 
the backbone of the molecule.  While the stereochemistry of the allyl appendage would direct the 
stereochemistry of the allylation, our inability to synthesize the backbone makes it essential that 
we establish the correct set of conditions in order to not waste precious material.  We therefore 
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set out to create a model system which would mimic the electronic complexity of the 2,3-hydro-
4-pyridone structural motif without the aliphatic side chain.  This resulted in our decision to 
attempt the intermolecular allylation using allyltrimethylsilane on 2,3-dihydro-4-pyridone 2.73 
as well as the intramolecular variant using the tethered pyridone-allyl silane 2.74 (Figure 2.4). 
 
N
Ph
O
2.73
N
Ph
O
TMS
2.74  
Figure 2.4: Substrates for the study and optimization of the pyridone allylation model system 
 
 The 2,3-dihydro-4-pyridone 2.73 is synthesized by Hg(OAc)2-mediated dehydrogenation 
from the readily available 4-piperidone
46
, while 2.74 can be envisioned as coming from the α-
iodo analog of 2.73 (2.75) by way of a Cu-catalyzed conjugate addition of the metallated 
Grignard followed by a Wittig olefination from 2.76 (Scheme 2.32). 
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Scheme 2.32: Retrosynthesis of the inter- and intra-molecular allylation model systems 
 
 We initially synthesized 2.73 from the saturated piperidone using the Hg(OAc)2-
catalyzed reaction.  While the original publication reports high yields, the transformation was 
only able to reproducibly give average yields of 50%.  Nonetheless, 2.73 was taken forward to 
install the iodine at the α position using standard DMAP-catalyzed halogenation47, providing 
2.75 in high yield (Scheme 2.33).  Using 2.73, it was attempted to utilize a number of different 
Lewis acids, as well as triflic anhydride to promote the addition of allyl trimethylsilane (Table 
2.3).  Unfortunately, none of our efforts were successful.  Even the use of TBAF to force the 
silicon-carbon bond cleavage resulted in no yield (Table 2.3, Entry 7).   
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Table 2.3: Attempts to add allyl trimethylsilane to 2.73 using various Lewis acids 
N
O
Ph
2.73
TMS
additive
THF
N
O
Ph
 
Entry Activating Agent (mol %) Result
a 
1 InCl3 (10%) NR 
2 InBr3 (10%) NR 
3 BiCl3 (10%) NR 
4 BiBr3 (10%) NR 
5 In(OTf)3 (10%) NR 
6 Tf2O (110%) NR 
7 TBAF (110%) NR 
a
: NR = No Reaction (no 2.73 consumption);   
AllylTMS reagent consumed in all cases. 
 
It occurred to us that the β position of the enone/enamine 2.73 was too electron rich, since 
the nitrogen’s lone pair is in direct conjugation with the system.  This would prevent additional 
electron density from being introduced by the nucleophile.  A compensation to this would be to 
replace the benzyl protecting group with a more electron withdrawing group, such as a tosyl.  
Doing this would also make the model system more analogous to our Diels-Alder model system. 
In preparation for the synthesis of the intramolecular allylation model system, the α-
iodoenaminone 2.75 was metalated using iso-propylmagnesium chloride in the manner described 
by Luzung and co-workers for aryl iodides
48
.  After transmetalating onto CuI (-30°C), the 
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prepared reagent was combined with methyl vinyl ketone to produce the desilylated analog of 
2.76 (35% yield).  It was attempted to take this material to 2.76 through many different 
transformations, including direct α-silylation, α-hydroxylation (to be converted to the TMS 
compound), and enolization/triflation followed by Kumada coupling with TMSCH2MgCl.  None 
of these procedures were successful.  The current hypothesis is that the electron rich nitrogen is 
interfering with the reactions, particularily the triflation and Kumada coupling route. 
 
2.6. Conclusions and Implications of Model Systems 
 Our experiments into the generation of model systems for our lycopodine-class alkaloid 
synthesis have shown us a great deal about our synthetic strategy and our future directions with 
this project.  While our main synthesis does not seem overly feasible from its current standpoint, 
we have been able to demonstrate that the intramolecular Diels-Alder reaction is a feasible 
forward step.  Something to note is that the DA reaction in question does not result in 
aromatization of the final compound, and thus we are able to obtain the 1,4-cyclohexadiene core 
required for our future endeavors.  With the allylation system, we have shown that the nitrogen 
requires a highly electron withdrawing protecting group in order to activate the β position for 
nucleophilic attack from an allyl silane.  Reports of this kind are already known
49
, and thus our 
choice of a tosylate is a good decision, as it will make the nitrogen electron poor enough to 
undergo the Diels-Alder while also being effective for the allylation step. 
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2.7. Experimental Section 
2.7.1.  General Reaction Considerations 
All reactions were conducted in oven-dried (100°C) glassware, and were run under an 
atmosphere of argon, unless otherwise stated.  DCM and THF were dried by passing the 
degassed solvent through a column of activated Cu/alumina under N2 immediately before use.  
Toluene was dried over activated 3Å molecular sieves.  EtOH used as absolute.  Acetone was 
used as HPLC-grade.  NBS was recrystallized from hot H2O and dried in a dessicator.  Allyl 
bromide was purified by washing with sat. aq. NaHCO3 followed by distilled H2O, drying over 
CaCl2, and distilling under reduced pressure.  Chromatography was performed on EMD silica gel 
(40-60 microns) using air pressure, unless otherwise specified. All other solvents and reagents 
were purchased at the highest level of purity and were used as received. 
NMR spectra were obtained on a Varian INOVA NMR instrument, at the indicated field 
strength in the indicated deuterated solvent.  NMR spectra are referenced to internal 
tetramethylsilane.  HRMS were collected on a Bruker BIOTOF III instrument with a positive 
ESI mode and are referenced to appropriate PEG or NaTFA standards.  FTIR spectra were 
collected on a Bruker Dalton FTIR instrument.  Melting points were collected on a Fisher-Johns 
apparatus and are uncorrected. 
 
2.7.2.  Experimental Details 
Ethyl 3-bromopropiolate (2.26)
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A 25-mL round bottom flask equipped with a magnetic stir bar was charged 
with ethyl propiolate (0.78 mL, 7.66 mmol) and acetone (16 mL).  AgNO3 
(0.13 g, 0.77 mmol) was added in one portion and the reaction was wrapped in foil to protect it 
EtO2C Br
2.26
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against light.  After stirring at RT for 10 min., freshly recrystallized and dried N-
bromosuccinimide (NBS, 1.50 g, 8.43 mmol) was added in one portion and the reaction was 
stirred at RT for 2 hrs.  The reaction mixture was filtered through Celite, with the filter cake 
being washed with acetone (50 mL), and the filtrate was concentrated.  The residue was purified 
by FCC (15% Et2O in pentane) to give 2.26 as a slightly yellow oil which solidifies into a 
colorless solid upon standing (1.19 g, 88%).  CAUTION: The compound is a severe 
lachrymator!  
1
H-NMR (400 MHz, CDCl3) δ  4.24 (q, J=6.8 Hz, 2H), 1.32 (t, J=6 Hz, 3H); 
13
C-
NMR (100 MHz, CDCl3) δ  152.7, 77.0, 62.7, 52.5, 14.2; FTIR (thin film) ῡ (max) 3001, 2983, 
2191, 1688, 1271 cm
-1
. 
 
4-(Tetrahydropyranyl)oxobutyraldehyde (2.29)
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A 500-mL round bottom flask equipped with a magnetic stir bar was 
charged with 1,4-butanediol (22.6 mL, 255 mmol) and DCM (250 mL).  
(+)-camphorsulfonic acid (CSA, 5.92 g, 25.5 mmol) was added in one 
portion to the RT, stirred solution, and the reaction was charged with 3,4-dihydro-2H-pyran 
(23.3 mL, 255 mmol).  After stirring for 4 hrs at RT, the reaction mixture was washed with sat. 
aq. NaHCO3 (3 x 150 mL) and H2O (3 x 150 mL).  The organic phase was dried over MgSO4, 
filtered, and concentrated to give 4-(tetrahydropyranyl)oxo-1-butanol as a colorless oil (32.6 g, 
74%).  
1
H-NMR (400 MHz, CDCl3) δ  4.46 (m, 1H), 3.72 (m, 1H), 3.62 (m, 1H), 3.51 (m, 1H), 
3.37 (m, 1H), 3.31 (m, 1H), 2.85 (bs, 1H), 1.68 (m, 1H), 1.59 (m, 4H), 1.40 (m, 5H); 
13
C-NMR 
(100 MHz, CDCl3) δ  98.9, 67.6, 53.8, 30.8, 30.0, 26.7, 25.6, 19.7 
 
O O
H
O
2.29
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A 50-mL round bottom flask equipped with a stir bar was charged with the alcohol from 
the previous step (2.00 g, 11.48 mmol) and DCM (16.4 mL).  The reaction was stirred at RT and 
TEMPO (0.18 g, 1.15 mmol) was added, followed by a portion-wise addition of PhI(OAc)2 (4.07 
g, 12.63 mmol).  The reaction stirred at RT overnight, then was quenched by addition of 1:1 sat. 
aq. Na2S2O3:sat. aq. NaHCO3 (20 mL).  The phases were separated and the organic phase was 
washed with brine (10 mL), dried over MgSO4, filtered, and concentrated.  FCC of the residue 
(1:1 pet. ether:Et2O) gave 2.29 as a slightly yellow oil (1.05 g, 50%).  
1
H-NMR (400 MHz, 
CDCl3) δ  9.74 (t, J=1.6 Hz, 1H), 4.54 (dt, J=8.4 Hz, 4 Hz, 1H), 3.74 (m, 2H), 3.35 (m, 2H), 2.50 
(tt, J=2 Hz, 6.8 Hz, 1H), 2.43 (td, J=2 Hz, 7.6 Hz, 1H), 1.76-1.45 (m, 9H); 
13
C-NMR (100 MHz, 
CDCl3) δ  202.6, 98.9, 62.4, 41.2, 30.9, 26.7, 25.7, 22.8, 19.7; FTIR (thin film) ῡ (max) 2946, 
2874, 1723 cm
-1
. 
 
1-(tert-Butyldimethylsilyl)propargyl alcohol (2.35)
52
 
A 250-mL round bottom flask equipped with a magnetic stir bar was charged 
with tert-butyldimethylsilyl chloride (TBSCl, 7.12 g, 47.27 mmol) and DMF 
(75 mL).  Imidazole (3.22 g, 47.27 mmol) was added to this solution at RT.  
Propargyl alcohol (2.59 mL, 44.59 mmol) was added dropwise at RT, with a slight exotherm 
being observed upon addition.  After addition was complete, the reaction ran at RT overnight, 
then was poured into a seperatory funnel containing 125 mL H2O.  The product was extracted 
with Et2O (2 x 100 mL) and the combined organic phases were washed with H2O (200 mL), 
brine (150 mL), dried over MgSO4, filtered, and concentrated.  The crude product was purified 
by passage through a plug of silica gel using 20% EtOAc in hexanes as eluent, providing 2.35 as 
a colorless oil (7.59 g, quant.).  
1
H-NMR (400 MHz, CDCl3) δ  4.31 (d, J=2.4 Hz, 2H), 2.39 (t, 
O Si
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J=2.4 Hz, 1H), 0.91 (s, 9H), 0.13 (s, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  73.0, 51.7, 25.8, 25.7, 
18.5, -5.0. 
 
2-(tert-Butyldimethylsilyloxy)methyl-1,4-pentadiene (2.32)
53
 
A 10-mL reaction vial equipped with a magnetic stir bar was charged with 2.35 
(0.341 g, 2.00 mmol) and THF (2.00 mL).  Freshly distilled allyl bromide (1.38 
mL, 16.00 mmol) was added and the reaction stirred at RT as In powder (0.344 
g, 3.00 mmol) was added.  The reaction was capped without concern for air or 
moisture and left to stir overnight.  The reaction mixture was concentrated and the residue was 
suspended in 3:2 EtOAc:hexane and passed through a plug of silica gel, using the same eluent.  
The filtrate was concentrated and the residue was purified by FCC (2% EtOAc in hexane) to give 
2.32 as a colorless oil (0.425 g, quant.).  
1
H-NMR (400 MHz, CDCl3) δ  5.82 (m, 1H), 5.06 (m, 
3H), 4.84 (m, 1H), 4.07 (s, 2H), 2.76 (dd, J=0.8 Hz, 6.8 Hz, 2H), 0.92 (s, 9H), 0.07 (s, 6H); 
13
C-
NMR (100 MHz, CDCl3) δ  147.1, 136.2, 116.4, 109.8, 65.8, 37.5, 26.1, 18.6, -5.2; FTIR (thin 
film) ῡ (max) 2956, 2928, 2856, 1472, 1463, 1257 cm-1. 
 
Diethyl allylphosphonate (2.33)
54
 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged with 
triethylphosphite (20.0 mL, 116.6 mmol) and freshly distilled allyl bromide (11.0 
mL, 127.1 mmol).  The reaction mixture was heated to reflux (ca. 125°C) for 4 hrs 
then cooled to RT.  The excess allyl bromide was removed in vacuo and the resultant yellow oil 
was purified by FCC (100% EtOAc) giving 2.33 as a colorless, odiferous liquid with a minor 
(<5%) presence of triethylphosphite (20.4 g, 98%).  Material is sufficiently pure for all desired 
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uses.  Continued chromatography (40% EtOAc in hexane) provides analytically pure material.  
1
H-NMR (400 MHz, CDCl3) δ  5.64 (m, 1H), 5.04 (m, 2H), 3.95 (m, 4H), 2.46 (dd, J=7.2 Hz, 
22Hz), 1.18 (m, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  127.7, 119.8, 61.9, 60.3, 16.4; FTIR (thin 
film) ῡ (max) 2984. 2939, 2907, 2240, 1733, 1249, 1030 cm-1. 
 
2-Allylsulfonyl-benzothiazole (2.34)
55
 
A 50-mL round bottom flask equipped with a magnetic stir bar was 
charged with 2-mercaptobenzothiazole (0.836 g, 5.00 mmol), NaOH (0.31 
g, 7.75 mmol), and EtOH (25 mL).  With stirring at RT, freshly distilled 
allyl bromide (0.498 mL, 5.75 mmol) was added dropwise, and the reaction mixture was stirred 
at RT for 20 hrs.  The slurried reaction was then diluted with EtOAc (50 mL) and quenched with 
H2O (25 mL).  The phases were separated and the aq. phase was extracted with EtOAc (25 mL).  
The combined organic phases were washed with H2O (25 mL), brine (25 mL), dried over 
MgSO4, filtered, and concentrated.  The crude allyl sulfide was used directly in the next step 
(1.04 g, quant.) 
 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged with the 
crude allyl sulfide (0.34 g, 1.64 mmol) and DCM (20 mL).  The reaction mixture was cooled to 
0°C and stirred as mCPBA (77%, 0.742 g, 3.31 mmol) was added in portions over 5 min.  After 
10 additional min. the reaction was allowed to warm to RT and stirred there for 18 hrs.  The 
reaction was concentrated and the residue was suspended in EtOAc (20 mL) and washed with 
sat. aq. NaHCO3 (20 mL).  The aq. phase was re-extracted with EtOAc (20 mL), and the 
combined organic phases were washed with sat. aq. NaHCO3 (25 mL), H2O (25 mL), brine (25 
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mL), dried over MgSO4, filtered and concentrated.  FCC of the residue (15% Et2O in pentane) 
gave 2.34 as a white solid (0.294 g, 75%).  mp 59-60°C; 
1
H-NMR (400 MHz, CDCl3) δ  8.23 
(dd, J=0.8 Hz, 7.2 Hz, 1H), 8.01 (dd, J=0.8 Hz, 7.2 Hz, 1H), 7.62 (m, 2H), 5.89 (m, 1H), 5.37 
(dd, J=10.4 Hz, 11.6 Hz, 2H), 4.25 (d, J=7.2 Hz); 
13
C-NMR (100 MHz, CDCl3) δ  128.3, 127.9, 
126.4, 125.7, 123.3, 122.5, 59.3; FTIR (thin film) ῡ (max) 2919, 1471, 1328, 1144 cm-1. 
 
α-Hydroxymethylethyl acrylate (2.47)56 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged with 
paraformaldehyde (6.05 g, 201.4 mmol) and H2O (15 mL).  The slurry was then 
charged with 1 N H3PO4 (0.575 mL) and set to stir at reflux until the reaction 
became a clear, homogeneous solution (approx. 30 min. – 1 hour).  The reaction was then cooled 
to RT and triethylphosphonoacetate (10.00 mL, 50.40 mmol) was added in one portion.  The 
reaction was warmed to 40°C and stirred while a solution of K2CO3 (7.66 g, 55.44 mmol) in H2O 
(8.15 mL) was added dropwise.  The reaction ran at 40°C for 10 min., then was placed directly in 
an ice bath and quickly diluted with Et2O and brine (15 mL each).  The phases were separated 
and the aq. phase was extracted with Et2O (3 x 15 mL).  The combined organic phases were 
washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated to give 2.47 (6.54 g, 
99%) as a colorless oil.  
1
H-NMR (400 MHz, CDCl3) δ  6.26 (d, J=1.2 Hz, 1H), 5.85 (d, J=1.2 
Hz, 1H), 4.33 (s, 2H), 4.24, (q, J=7.2 Hz, 2H), 2.12 (bs, 1H), 1.32 (t, J=7.2 Hz, 3H); 
13
C-NMR 
(100 MHz, CDCl3) δ  166.6, 139.8, 125.6, 62.4, 61.0, 14.3; FTIR (thin film) ῡ (max) 3447, 2926, 
1716, 1456 cm
-1
; HRMS:  material polymerizes rapidly upon exposure to ESI. 
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α-(tert-Butyldimethylsilyl)hydroxymethylethyl acrylate (2.46)56 
A 250-mL round bottom flask equipped with a magnetic stir bar was charged 
with 2.47 (6.00 g, 46.10 mmol) and DCM (150 mL).  With stirring, imidazole 
(7.85 g, 115.26 mmol) was added in one portion, followed by TBSCl (8.69 g, 
57.63) in portions over 5 min.  The cloudy solution was stirred at RT for 
2.5hrs, then was quenched by the addition of sat. aq. NH4Cl, and the phases were separated.  The 
aq. phase was extracted with DCM (3 x 50 mL), and the combined organic phases were dried 
over Na2SO4, filtered, and concentrated to give a light yellow oil.  Further reactions did not 
require additional purification, however, analytically pure material was obtained by FCC (Si gel, 
100% hexane  5% EtOAc in hexane), providing 2.46 (11.16 g, 99%) as a colorless oil.  1H-
NMR (400 MHz, CDCl3) δ  6.23 (apparent q, J=1.6 Hz, 2.0 Hz, 1H), 5.88 (apparent q, J=2.0 Hz, 
2.4 Hz, 1H), 4.35 (apparent t, J=2.4 Hz, 2H), 4.18 (q, J=7.2 Hz, 2H), 1.27 (t, J=7.2 Hz, 3H), 0.91 
(s, 9H), 0.07 (s, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  166.0, 140.1, 123.6, 61.6, 60.6, 25.9, 14.2, 
-3.5, -5.4; FTIR (thin film) ῡ (max) 2956, 2858, 1716, 1472 cm-1; HRMS (ESI), m/z: 267.1394 
(M+Na
+
), calc. for C12H24O3SiNa: 267.1387. 
 
2-Methylidene-3-(tert-butyldimethylsiloxy)-1-propanol (2.45)
56 
A 1-L round bottom flask equipped with a magnetic stir bar and an addition 
funnel was charged with 2.46 (9.65 g, 39.48 mmol) and Et2O (340 mL).  The 
reaction was cooled to -78°C and the addition funnel was charged via cannula 
with DIBAL-H (1.0 M solution in hexane, 118.45 mL).  The DIBAL-H solution 
was added dropwise over 2 hrs., and the reaction ran an additional 30 min. at -78°C.  The 
reaction was then diluted with EtOAc (200 mL) and quenched with sat. aq. Rochelle’s Salt (200 
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mL).  The solution was allowed to warm to RT and stirred vigorously overnight.  The phases 
were then separated and the aq. phase was extracted with EtOAc (3 x 100 mL).  The combined 
organic phases were dried over Na2SO4, filtered, and concentrated to give 2.45 (7.91, 99%) as a 
colorless oil.
  1
H-NMR (400 MHz, CDCl3) δ  5.09 (m, 2H), 4.23 (s, 2H), 4.14 (s, 2H), 2.71 (bs, 
1H), 0.91 (s, 9H), 0.07 (s, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  147.7, 110.9, 65.0, 64.4, 26.0, -
3.5, -5.3; FTIR (thin film) ῡ (max) 3389, 2955, 2858, 1472 cm-1; HRMS (ESI), m/z: 225.1283 
(M+Na
+
), calc. for C10H22O2SiNa: 225.1281. 
 
1-(Ethylidene)-2-methylidene-3-(tert-butyldimethylsiloxy)-1-propanol (2.44) 
A 35-mL pressure tube equipped with a magnetic stir bar was charged with 
2.45 (2.00 g, 9.88 mmol), [(PPh3)AuCl] (0.098 g, 0.198 mmol), AgOAc 
(0.049 g, 0.296 mmol), and ethyl vinyl ether (9.46 mL, 72.11 mmol) and was 
sealed without exclusion of air and heated to 60°C for 18 hrs.  The black 
reaction mixture was directly transferred to a Si-gel column pre-treated with 1:1 hexane:EtOAc 
with 0.1% (v/v) NEt3, and eluted with the same eluent to provide 2.44 (2.19 g, 97%) as a 
colorless oil.  
1
H-NMR (400 MHz, CDCl3) δ  6.37 (dd, J=6.8 Hz, 14 Hz, 1H), 5.15 (m, 1H), 5.05 
(m, 1H), 5.01 (m, 1H), 4.18 (m, 3H), 4.11 (s, 2H), 0.91 (s, 9H), 0.07 (s, 6H); 
13
C-NMR (100 
MHz, CDCl3) δ  151.6, 144.3, 112.5, 111.2, 69.1, 64.0, 26.0, -3.4, -5.3; FTIR (thin film) ῡ (max) 
2953, 2929, 2857, 1471, 1463 cm
-1
; HRMS (ESI), compound de-vinylates upon exposure to ESI 
field. 
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4-(tert-Butyldimethylsilyl)hydroxymethyl-4-pentenaldehyde (2.43) 
A 30-mL Biotage microwave vial equipped with a magnetic stir bar was 
charged with 2.44 (2.30 g, 10.07 mmol) and toluene (15 mL) and heated in 
a 150W microwave reactor for 15hrs at 150°C.  The reaction mixture was 
cooled to RT and transferred to a Si-gel column and eluted with 100% 
hexanes until the toluene was flushed through.  The eluent was then changed to 1:1 
hexane:EtOAc and the product was eluted, providing 2.43 as a light yellow oil (2.29 g, 99%).  
1
H-NMR (400 MHz, CDCl3) δ  9.77 (t, J=1.6 Hz, 1H), 5.07 (s, 1H), 4.82 (s, 1H), 4.09 (s, 2H), 
2.62 (dt, J=7.6 Hz, 1.6 Hz, 2H), 2.37 (t, J=7.2 Hz, 2H), 0.91 (s, 9H), 0.09 (s, 6H); 
13
C-NMR (100 
MHz, CDCl3) δ  202.3, 147.0, 130.0, 66.2, 60.6, 42.0, 26.1, -3.4, -5.2; FTIR (thin film) ῡ (max) 
2954, 2928, 2856, 1733, 1472 cm
-1
; HRMS (ESI), m/z: 251.1446 (M+Na
+
), calc. for 
C12H24O2SiNa: 251.1438. 
 
tert-Butoxycarbonyl-p-toluenesulfonamide (2.49)
57
 
A 250-mL round bottom flask equipped with a magnetic stir bar was charged with p-
toluenesulfonamide (4.00 g, 23.36 mmol), DMAP (0.29 g, 2.34 mmol), and DCM 
(50 mL).  NEt3 (3.58 mL, 25.70 mmol) was added to this solution at RT.  A solution 
of Boc2O (6.17 mL, 26.86 mmol) in DCM (80 mL) was added to the solution over 10 minutes.  
The reaction was stirred at RT for 30 minutes, then concentrated.  The residue was dissolved in 
EtOAc (240 mL) and washed with 1N HCl (150 mL), H2O (150 mL), brine (150 mL), and dried 
over MgSO4.  Filtration and concentration gave 2.49 as a white powder (6.24 g, 98%).  Product 
was further purified by recrystallization: Dissolve the product in hot Et2O (50 mL), cool to RT, 
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layer the solution with hexane (175 mL) and allowing to diffuse overnight.  Thusly, pure 2.49 
was obtained as large, colorless hexagonal rods (5.22 g).  An additional crop (0.76 g) was 
obtained by cooling the filtrate from isolation in a freezer over 3 days.  This second crop is 
isolated as small, colorless needles.  mp 124-125°C; 
1
H-NMR (400 MHz, CDCl3) δ  7.91 (d, J= 
8.4 Hz, 2H), 7.55 (bs, 1H), 7.34 (d, J= 8.4 Hz, 2H), 2.45 (s, 3H), 1.39 (s, 9H); 
13
C-NMR (100 
MHz, CDCl3) δ  149.5, 144.9, 136.2, 129.7, 128.4, 84.3, 28.1, 21.9; FTIR (thin film) ῡ (max) 
3250, 2981, 2934, 1745, 1348, 1147, 1089 cm
-1
; HRMS (ESI), m/z: 294.0769 (M+Na
+
), calc. for 
C12H17SNO4Na: 294.0770. 
 
tert-Butoxycarbonyl-p-toluenesulfonamide (2.50) 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged 
with 4-pentyn-1-ol (0.17 mL, 1.84 mmol) and THF (18.4 mL).  The 
solution was stirred at RT as 2.49 (0.50 g, 1.84 mmol) was added, followed by PPh3 (0.48 g, 1.84 
mmol).  Diisopropylazodicarboxylate (DIAD, 0.36 mL, 1.84 mmol) was added dropwise and the 
reaction ran at RT overnight.  The reaction was then concentrated and the residue was dissolved 
in 4:1 hexane:EtOAc (10 mL) and stored, capped, in a freezer over 2 days.  The crystallized 
diisopropylhydrazinedicarboxylate (white needles) was cold-filtered, and the filtrate was 
concentrated.  The residue was purified by FCC (4:1 hexane:EtOAc) to give 2.50 as a light 
yellow oil (0.32 g, 51%).  
1
H-NMR (400 MHz, CDCl3) δ  7.78 (d, J= 8.4 Hz, 2H), .729 (d, J= 8 
Hz, 2H), 3.79 (t, J= 7.6 Hz, 2H), 2.43 (s, 3H), 2.04 (s, 1H), 1.78 (q, J= 7.2 Hz, 2H), 1.33 (s, 9H), 
0.96 (apparent t, J=7.2 Hz, 2H); 
13
C-NMR (100 MHz, CDCl3) δ  151.2, 144.1, 137.8, 129.4, 
128.0, 103.9, 84.1, 60.5, 48.8, 28.0, 23.6, 21.7, 11.2; FTIR (thin film) ῡ (max) 2971, 2936, 2877, 
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1728, 1356, 1155 cm
-1
; HRMS (ESI), m/z: 360.1234 (M+Na
+
), calc. for C17H23SNO4Na: 
360.1240. 
 
E/Z-1-(4,4,5,5-Tetramethyl-1,3,2-dioxaboro)propene (2.53)
36 
A 200-mL 2-neck round bottom flask equipped with a magnetic stir bar, addition 
funnel, and reflux condenser was charged with Mg turnings (1.22 g, 50.00 mmol) 
and THF (20 mL).  This slurry was warmed to approx. 60°C, and a crystal of I2 
was added.  A solution of E/Z-1-bromopropene (approx. 1:1 cis:trans, 6.00 mL, 
70.00 mmol) in THF (80 mL) was added at moderate rate, over approx. 30 minutes.  A light 
yellow color begins to develop after ~50% addition.  After addition had completed, the reaction 
was heated to reflux until all of the Mg had reacted, about 3 hours. 
 A second, 500-mL round bottom flask equipped with a magnetic stir bar and an addition 
funnel was charged with trimethylborate (4.46 mL, 40.00 mmol) and Et2O (10 mL).  This 
solution was cooled to -78°C, and the warm (40-50°C) Grignard solution was transferred via 
cannula to the addition funnel.  The solution was added warm (to prevent precipitation and 
clogging of the addition funnel neck), dropwise over 30 minutes.  The reaction ran at -78°C for 1 
hour, then was warmed to 0°C.  Hydrolysis was initiated by addition of 30% HCl (70 mL) and 
the reaction ran for 30 minutes at 0°C, then was allowed to warm to RT.  The reaction mixture 
was extracted with Et2O (3 x 100 mL) and the combined organic phases were dried over Na2SO4, 
filtered, and concentrated (bath temp ≤ 30°C) to give the crude boronic acid as a brown-yellow 
oil. 
 A 100-mL round bottom flask equipped a magnetic stir bar was charged with 4Å MS 
(5.00 g) and the sieves were flame-activated.  After cooling to RT, Et2O (50 mL) was added and 
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the reaction was charged with the crude boronic acid from the previous preparation (using some 
Et2O to aid in transfer).  The reaction stirred at RT while pinacol (7.09 g, 60.00 mmol) was 
added.  The reaction ran overnight at RT, then was filtered through Celite and the filtrate was 
concentrated (bath temp ≤ 30°C).  The orange residue was purified by FCC (9:1 pentane:Et2O) to 
give 2.53 as a yellow oil (2:1 mixture of cis:trans, 2.93 g, 44%).  
1
H-NMR (400 MHz, CDCl3) δ  
cis: 6.52 (m, 1H), 5.34 (dt, J= 13.6 Hz, 3.2 Hz, 1H), 1.97 (dd, J= 7.2 Hz, 1.6 Hz, 3H), 1.26 (s, 
12H, mixed with trans peak); trans: 6.65 (m, 1H), 5.45 (dt, J= 17.6 Hz, 1.6 Hz, 1H), 1.84 (dd, J= 
6.4 Hz, 2 Hz, 3H), 1.26 (s, 12H, mixed with cis peak); 
13
C-NMR (100 MHz, CDCl3) δ  149.8, 
83.1, 25.0, 21.8, 18.7; FTIR (thin film) ῡ (max) 2978, 2926, 2855, 1635, 1145 cm-1. 
 
4-Pentyn-1-(tetrahydropyranyl)-ol (2.58)
58
 
A 200-mL round bottom flask equipped with a magnetic stir bar was 
charged with 4-pentyn-1-ol (5.53 mL, 59.44 mmol) and DCM (77.5 mL).  
The reaction was stirred at RT and Amberlyst-15 (0.305 g) was added in 
one portion.  The reaction was heated to reflux and 2,3-dihydropyran (5.69 mL, 62.41 mmol) 
was added dropwise.  The reaction stirred at reflux for 30 min, and then cooled to RT and 
filtered.  The catalyst was washed with DCM (10 mL) and the filtrate was concentrated to give a 
yellow oil which was purified by FCC (9:1 hexane:Et2O) gave 2.58 (9.915 g, 99%) as a colorless 
liquid.  
1
H-NMR (400 MHz, CDCl3) δ  4.60 (t, J=4 Hz, 1H), 3.83 (m, 2H), 3.49 (m, 2H), 2.32 
(m, 2H), 1.95 (t, J=2.4 Hz, 1H), 1.82 (m, 3H), 1.71 (m, 1H), 1.54 (m, 4H); 
13
C-NMR (100 MHz, 
CDCl3) δ  99.0, 84.2, 68.6, 66.0, 62.4, 30.8, 28.9, 25.7, 19.7, 15.5; FTIR (thin film) ῡ (max) 
2941, 2870, 2119 cm
-1
; HRMS (ESI), m/z: 191.1051 (M+Na
+
), calc. for C10H16O2Na: 191.1043. 
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9-[(tert-Butyldimethylsilyl)hydroxymethyl]-1-(tetrahydropyranyloxy)dec-4,9-dien-6-ol 
(2.59) 
A 25-mL Schlenk flask equipped with a magnetic stir bar was charged 
with 2.58 (0.307 g, 1.825 mmol) and DCM (6.1 mL) and the reaction was 
purged with N2.  With stirring, the reaction was cooled to 0°C and 
Schwartz Reagent ([Cp2Zr(H)Cl], 0.517 g, 2.008 mmol) was added in 5 
portions over 20 minutes under a positive N2 flow.  The cloudy suspension 
was then warmed to RT and stirred until homogeneous (approx. 30 min.  Reaction progression 
was checked by TLC using 4:1 hexane:EtOAc and p-anisaldehyde stain.  The hydrozirconated 
product appears as a blue spot whereas the alkyne starting material appears as a red spot).  The 
reaction was then cooled to -78°C and Me2Zn (1.2 M in toluene, 1.76 mL) was added dropwise 
via syringe pump over 1 hr.  The reaction was stirred at -78°C for an additional 30 min. then was 
warmed to 0°C and a solution of 2.43 (0.500 g, 2.19 mmol) in DCM (1.0 mL) was added via 
syringe pump over 1hr.  The reaction was stirred at 0°C for 6 hrs., then quenched with 5% aq. 
NaHCO3 and extracted with Et2O (3 x 10 mL, using solid NaCl to break up Zn aggregates when 
observed).  The combined organic phases were washed with brine (10 mL), dried over Na2SO4, 
filtered, and concentrated.  The crude product was purified by FCC (4:1 hexane:EtOAc, Rf = 
0.25) to give 2.59 as a faintly yellow oil (0.298 g, 41%).  
1
H-NMR (400 MHz, CDCl3) δ  5.67 
(dt, J=6.4 Hz, 15.6 Hz, 1H), 5.50 (dd, J=7.2 Hz, 15.6 Hz, 1H), 5.05 (s, 1H), 4.84 (s, 1H), 4.57 (t, 
J=2.4 Hz, 1H), 4.08 (s, 2H), 3.86 (m, 1H), 3.74 (m, 1H), 3.47 (m, 1H), 3.39 (m, 1H), 2.12 (m, 
2H), 1.85 (m, 1H), 1.56 (m, 16H), 0.95 (s, 9H), 0.07 (s, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  
148.4, 133.4, 131.7, 109.0, 99.1, 72.9, 67.0, 66.2, 62.5, 60.6, 34.7, 31.8, 29.1, 28.7, 26.1, 22.8, 
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21.2, 19.9, 18.6, 14.4, 0.16, -5.2; FTIR (thin film) ῡ (max) 3452, 2924, 2856, 1464, 1456 cm-1; 
HRMS (ESI), m/z: 421.2750 (M+Na
+
), calc. for C22H42O4SiNa: 421.2745. 
 
Methyl sorbate (2.61)
 38
 
A 500-mL round bottom flask equipped with a magnetic stir bar was charged with 
sorbic acid (10.00 g, 89.18 mmol) and MeOH (200 mL).  The reaction was cooled to 
0°C and SOCl2 (14.31 mL, 196.20 mmol) was added dropwise.  The reaction was 
allowed to warm to RT and then was heated to reflux for 3.5 hours.  The reaction was 
concentrated, giving a dark red liquid which was purified by FCC (2% EtOAc in hexane) to give 
2.61 as a yellow oil (9.12 g, 81%).  Spectral data is consistent with the literature
38
. 
 
Methyl 3,5-hexadieneoate (2.62)
59
 
A 250-mL round bottom flask equipped with a magnetic stir bar was charged with 
diisopropylamine (6.67 mL, 47.56 mmol) and THF (80 mL).  The reaction was 
cooled to -78°C and nBuLi (2.5M in hexane, 19.02 mL, 47.56 mmol) was added 
slowly.  HMPA (8.96 mL, 51.52 mmol) was added dropwise via addition funnel, 
at -78°C.  The reaction ran for 30 minutes after addition, then 2.61 (5.00 g, 39.63 mmol) was 
added dropwise over 2 hours.  The reaction ran at -78°C for an additional 1 hour, then was 
transferred slowly via cannula (as close to dropwise as possible) into a cooled (0°C) solution of 
AcOH (6.81 mL) in H2O (150 mL).  The yellow solution was extracted with pentane (3 x 50 mL) 
and the combined organic phases were washed with sat. aq. NaHCO3 (50 mL), H2O (50 mL), 
dried over MgSO4, filtered, and concentrated.  Vacuum distillation (145°C bath temp, 110°C 
head temp) gave 2.62 as a yellow oil (2.28 g, 46%).  
1
H-NMR (400 MHz, CDCl3) δ  6.33 (dt, 
OMeO
2.61
2.62
OMe
O
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J=6.8 Hz, 17.2 Hz, 1H), 6.16 (m, 1H), 5.79 (m, 1H), 5.17 (dd, J=1.6 Hz, 16 Hz, 1H), 5.07 (dd, 
J=0.4 Hz, 10.4 Hz, 1H), 3.69 (s, 3H), 3.13 (d, J=7.2 Hz, 2H), 1.85 (d, J=5.6 Hz, 2H); 
13
C-NMR 
(100 MHz, CDCl3) δ  172.0, 136.5, 134.6, 125.7,117.1, 52.0, 37.9, 18.8; FTIR (thin film) ῡ 
(max) 2952, 2927, 2855, 1740 cm
-1
; HRMS (ESI), m/z: 127.1754 (M+H
+
), calc. for C7H11O2: 
127.0754. 
 
3,5-Hexadiene-1-ol (2.63)
59 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged with 
Et2O (30.00 mL).  The flask was cooled to 0°C and LiAlH4 (0.527 g, 13.89 mmol) 
was added portionwise to the flask.  The reaction was then charged with a solution 
of 2.62 (2.19 g, 17.36 mmol) in Et2O (6.00 mL) dropwise.  After 1 hour at 0°C, the reaction was 
quenched with 2:1 THF:H2O (30 mL) followed by 1N HCl (30 mL).  The product was extracted 
with EtOAc (2 x 10 mL) and the combined organic phases were washed with brine (15 mL), 
dried over MgSO4, filtered, and concentrated to give 2.63 as a yellow oil (1.70 g, quant.).  
1
H-
NMR (400 MHz, CDCl3) δ  6.34 (dt, J=10 Hz, 17.2 Hz, 1H), 6.18 (m, 1H), 5.73 (m, 1H), 5.16 
(dd, J=1.6 Hz, 16.8 Hz, 1H), 5.04 (dd, J=2 Hz, 10.4 Hz, 1H), 4.17 (d, J=6 Hz, 1H), 3.70 (t, J=6 
Hz, 2H), 2.38 (q, J=6.8 Hz, 2H); 
13
C-NMR (100 MHz, CDCl3) δ  136.8, 133.7, 130.6, 115.9, 
61.9, 35.9; FTIR (thin film) ῡ (max) 3345, 2931, 2878 cm-1; HRMS (ESI), m/z: 219.1352 
(2M+Na
+
), calc. for C12H20O2Na: 219.1356. 
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3,5-Hexadien-1-(p-toluenesulfonyl)-ol (2.64) 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged with 
2.63 (1.70 g, 17.32 mmol), DCM (30 mL), NEt3 (3.62 mL, 25.98 mmol), and 
DMAP (0.216 g, 1.732 mmol).  The solution was cooled to 0°C and TsCl (3.63 g, 
19.05 mmol) was added in portions over 10 minutes.  The yellow solution was allowed to warm 
to RT and stir for 3 hours.  The reaction was quenched by pouring into H2O (50 mL) and the 
phases were separated.  The organic phase was washed with sat. aq. NH4Cl (30 mL), sat. aq. 
Na2CO3 (30 mL), dried over MgSO4, filtered, and concentrated to give 2.64 as a brown oil (4.18 
g, 96%).  The material was used directly in the next step without further purification. 
 
3,5-Hexadien-1-(tert-butoxycarbonyl)-amine (2.65) 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged 
with crude 2.64 (4.18 g, 16.57 mmol) and DMSO (50 mL).  With stirring, NaCN 
(1.22 g, 24.86 mmol) was added in one portion, with a rapid color change of 
orange to brown occurring.  The reaction stirred at RT for 24 hours, then was diluted with H2O 
(25 mL, EXOTHERMIC) and extracted with Et2O (3 x 10 mL).  The combined organic layers 
were washed with H2O (60 mL), brine (60 mL), dried over Na2SO4, filtered, and concentrated to 
give the nitrile as a light orange oil (1.01 g, 57%).  The material was taken forward without 
further purification. 
 A 50-mL round bottom flask equipped with a magnetic stir bar was charged with Et2O 
(12.5 mL) and cooled to 0°C.  LiAlH4 (0.267 g, 6.99 mmol) was added in portions to the cooled 
solvent.  The reaction was then charged with the crude nitrile from the previous preparation (1.01 
g, 9.33 mmol) dropwise.  The reaction ran at 0°C for 2 hours, then was quenched by the addition 
2.64
OTs
2.65
NHBoc
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of H2O (1.5 mL), 15% aq. NaOH (1.5 mL), and H2O (4.5 mL).  The reaction was warmed to RT 
and MgSO4 was added.  The slurry was filtered and washed with Et2O.  The filtrate was 
concentrated to give the crude amine as a yellow oil which was taken forward without further 
purification. 
 A 200-mL round bottom flask equipped with a magnetic stir bar was charged with Boc2O 
(2.36 mL, 10.26 mmol) and DCM (30 mL).  The reaction was cooled to 0°C and NEt3 (2.86 mL, 
20.53 mmol) was added slowly.  A solution of the crude amine from the previous preparation in 
DCM (30 mL) was added slowly, and the reaction was allowed to warm to RT.  The reaction ran 
for 18 hours, then was quenched with 0.1M aq. citric acid (50 mL) and the phases were 
separated.  The aq. phase was extracted with DCM (2 x 20 mL).  The combined organic phases 
were washed with sat. aq. NaHCO3 (30 mL), brine (30 mL), dried over MgSO4, filtered, and 
concentrated.  The orange residue was purified by FCC (4:1 hexane:EtOAc) to give 2.65 as a 
yellow liquid (1.40 g, 71% over two steps).  
1
H-NMR (400 MHz, CDCl3) δ  6.29 (dt, J= 10.4 Hz, 
16.8 Hz, 1H), 6.05 (dd, J= 10.4 Hz, 15.2 Hz, 1H), 5.68 (dt, J= 6.8 Hz, 15.2 Hz, 1H), 5.08 (d, 
J=16.8 Hz, 1H), 4.96 (d, J= 10.4 Hz, 1H), 4.72 (bs, 1H), 3.12 (broad q, J= 6.8 Hz, 2H), 2.12 
(apparent q, J= 6.8 Hz, 2H), 1.59 (m, 2H), 1.44 (s, 9H); 
13
C-NMR (100 MHz, CDCl3) δ  146.9, 
137.2, 134.1, 131.7, 115.2, 85.2, 60.4, 27.5, 21.1, 14.3; FTIR (thin film) ῡ (max) 3420, 2982, 
2936, 1811, 1758, 1716 cm
-1
; HRMS (ESI), m/z: 234.1473 (M+Na
+
), calc. for C12H21O2NNa: 
234.1465. 
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3,5-Hexadien-1-(para-toluenesulfonyl)-amine (2.67) 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged 
with crude 2.64 (4.63 g, 18.34 mmol) and DMSO (62 mL).  With stirring, NaCN 
(1.35 g, 27.51 mmol) was added in one portion, with a rapid color change of 
orange to brown occurring.  The reaction stirred at RT for 24 hours, then was diluted with H2O 
(25 mL, EXOTHERMIC) and extracted with Et2O (3 x 20 mL).  The combined organic layers 
were washed with H2O (60 mL), brine (60 mL), dried over Na2SO4, filtered, and concentrated to 
give the nitrile as a light orange oil (1.12 g, 57%).  The material was taken forward without 
further purification. 
 A 50-mL round bottom flask equipped with a magnetic stir bar was charged with Et2O 
(16 mL) and cooled to 0°C.  LiAlH4 (0.297 g, 7.84 mmol) was added in portions to the cooled 
solvent.  The reaction was then charged with the crude nitrile from the previous preparation (1.12 
g, 10.45 mmol) in Et2O (5 mL) dropwise.  The reaction ran at 0°C for 2 hours, then was 
quenched by the addition of H2O (4.5 mL), 15% aq. NaOH (4.5 mL), and H2O (4.5 mL).  The 
reaction was warmed to RT and MgSO4 was added.  The slurry was filtered and washed with 
Et2O.  The filtrate was concentrated to give the crude amine as a yellow oil which was taken 
forward without further purification. 
 A 100-mL round bottom flask equipped with a magnetic stir bar was charged with the 
crude amine from the previous step and DCM (20 mL).  Pyridine (2.54 mL, 31.35 mmol) was 
added and the solution was cooled to 0°C.  TsCl (2.19 g, 11.50 mmol) was added slowly, with 
the orange solution turning deep red upon addition.  After 24 hrs, the reaction was quenched with 
H2O (20 mL) and extracted with Et2O (3 x 20 mL).  The combined organic phases were washed 
with brine (20 mL), dried over MgSO4, filtered, and concentrated.  The orange residue was 
2.67
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purified by FCC (10% EtOAc in hexanes  15% EtOAc in hexanes) to give 2.67 as an orange 
oil (0.53 g, 19% over two steps).  
1
H-NMR (400 MHz, CDCl3) δ  7.72 (d, J=7.2 Hz, 2H), 7.26 
(d, J=8 Hz, 2H), 6.21 (dt, J=16.8 Hz, 10.4 Hz, 1H), 5.94 (ddd, J=15.2 Hz, 10.4 Hz, 0.4 Hz, 1H), 
5.23 (dt, J=14.4 Hz, 6.8 Hz, 1H), 5.03 (d, J=16.8 Hz, 1H), 4.92 (d, J=10.4 Hz, 1H), 4.90 (bs, 
1H), 2.90 (q, J=6.8 Hz, 2H), 2.39 (s, 3H), 2.03 (q, J=7.2 Hz, 2H), 1.53 (p, J=7.2 Hz, 2H); 
13
C-
NMR (100 MHz, CDCl3) δ  143.5, 137.2, 137.1, 133.5, 132.1, 129.9, 127.3, 115.6, 42.8, 29.6, 
29.2, 21.7; FTIR (thin film) ῡ (max) 3284, 2931, 1326, 1159 cm-1; HRMS (ESI), m/z: 288.1028 
(M+Na
+
), calc. for C14H19O2NSNa: 288.1029. 
 
(2-Trimethylsilylethylyn)iodosobenzene trilfate (2.68)
60
 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged 
with PhI(OAc)2 (8.05 g, 25.0 mmol) and DCM (25 mL).  The reaction mixture 
was cooled to 0°C and set to stir, under N2.  Triflic anhydride (2.10 mL, 12.5 
mmol) was added dropwise, resulting in a yellow slurry.  The reaction was stirred for 30 min, 
then bis(trimethylsilyl)acetylene (5.66 mL, 25.0 mmol) was added dropwise, resulting in a 
homogeneous solution.  After 2 hrs at 0°C, the reaction mixture was concentrated to a white 
paste and triturated with Et2O.  The white crystalline solid thus obtained was filtered and dried in 
vacuo to give 2.68 as white crystals (8.01 g, 71%).  All melting point and spectral data are 
consistent with the literature. 
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3,5-Hexadien-1-(tert-butoxycarbonyl)-1-(2-trimethylsilylethylyn)-amine (2.69) 
A 25-mL round bottom flask equipped with a magnetic stir bar was charged with 
2.65 (0.20 g, 0.947 mmol) and toluene (9.23 mL).  The reaction was cooled to 
0°C and KHMDS (0.91 M in THF, 1.26 mL, 1.14 mmol) was added dropwise, 
resulting in an orange solution.  The reaction was stirred for 30 min, then 2.68 
(0.256 g, 0.568 mmol) was added in small portions over 5 minutes.  The reaction was allowed to 
warm to RT and stirred for 24 hrs.  The reaction was then filtered through a plug of Si-gel using 
1:1 Petroleum Ether:Et2O as eluent.  The filtrate was concentrated and the residue was purified 
by FCC (9:1 Petroleum Ether:Et2O) to give 2.69 as an orange oil (0.060 g, 34%).  
1
H-NMR (400 
MHz, CDCl3) δ  6.27 (dt, J=16.8 Hz, 10.4 Hz, 1H), 6.04 (ddd, J=14.4 Hz, 10.4 Hz, 0.8 Hz, 1H), 
5.67 (dt, J=14.4 Hz, 6.8 Hz, 1H), 5.06 (d, J=16.4 Hz, 1H), 4.94 (d, J=10 Hz, 1H), 3.54 (t, J=7.6 
Hz, 2H), 2.07 (q, J=7.2 Hz, 2H), 1.65 (t, J=2 Hz, 2H), 1.47 (s, 9H), 0.16 (s, 9H); 
13
C-NMR (100 
MHz, CDCl3) δ  152.8, 137.7, 134.3, 130.4, 127.6, 115.3, 82.3, 58.1, 46.3, 30.0, 28.6, 28.3, -0.3; 
FTIR (thin film) ῡ (max) 2968, 2068, 1747, 1696, 1367, 1251, 1135, 884 cm-1; HRMS (ESI), 
m/z: 330.1247 (M+Na
+
), calc. for C17H29O2NSiNa: 330.1238. 
 
3,5-Hexadien-1-(para-toluenesulfonyl)-1-(2-trimethylsilylethylyn)-amine (2.71) 
The title compound was prepared as described for 2.69, using 2.67 (0.20 g, 0.754 
mmol), toluene (9.23 mL), KHMDS (0.91M in THF, 0.994 mL, 0.904 mmol), and 
2.68 (0.204 g, 0.452 mmol).  FCC (9:1 Petroleum Ether:Et2O) gave 2.71 as an 
orange oil (0.056 g, 34%).  
1
H-NMR (400 MHz, CDCl3) δ  7.73 (d, J=8.4 Hz, 2H), 
7.31 (d, J=8 Hz, 2H), 6.27 (dt, J=20.4 Hz, 10 Hz, 1H), 6.03 (ddd, J=15.2 Hz, 10.4 Hz, 0.8 Hz, 
1H), 5.61 (dt, J=14.4 Hz, 6.8 Hz, 1H), 5.07 (d, J=16.8 Hz, 1H), 4.96 (d, J=10 Hz, 1H), 3.28 (t, 
2.69
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J=7.2 Hz, 2H), 2.43 (s, 3H), 2.09 (apparent q, J=6.4 Hz, 2H), 1.71 (apparent p, J=7.2 Hz, 2H), 
0.13 (s, 9H); 
13
C-NMR (100 MHz, CDCl3) δ  205.0, 144.8, 137.7, 137.2, 133.4, 132.2, 130.4, 
129.8, 128.0, 115.6, 50.9, 29.3, 27.6, 21.8, 0.3; FTIR (thin film) ῡ (max) 2955, 2162, 1368, 1171, 
844 cm
-1
; HRMS (ESI), m/z: 384.1435 (M+Na
+
), calc. for C19H27O2NSSiNa: 384.1424. 
 
1-Benzyl-2,3-dihydro-4-pyridone (2.73)
46
 
A 250-mL round bottom flask equipped with a magnetic stir bar was charged with 1-
benzyl-4-piperidone (1.00 mL, 5.39 mmol) and H2O:EtOH (2:1, 120 mL).  With 
stirring at RT, Hg(OAc)2 (1.80 g, 5.66 mmol) was added in one portion and the 
solution became yellow and opaque immediately.  EDTA (1.65 g, 5.66 mmol) was 
added in one portion and the reaction was heated to 80°C for 3 hours.  The reaction was then 
cooled and the metallic Hg generated was filtered through Celite, washing with 2:1 H2O:EtOH.  
The filtrate was diluted with sat. aq. NH4Cl (50 mL) and extracted with DCM (3 x 30 mL).  The 
combined organic phases were washed with H2O (50 mL), brine (50 mL), dried over Na2SO4, 
filtered, and concentrated to give 2.73 as an orange oil (0.50 g, 50%).  
1
H-NMR (400 MHz, 
CDCl3) δ  7.36 (m, 3H), 7.26 (m, 2H), 7.16 (d, J= 7.2 Hz, 1H), 4.99 (d, J= 7.2 Hz, 1H), 4.35 (s, 
2H), 3.37 (t, J= 7.6 Hz, 2H), 2.45 (t, J= 8 Hz, 2H); 
13
C-NMR (100 MHz, CDCl3) δ  191.7, 154.5, 
135.9, 129.2, 128.6, 127.8, 98.6, 60.0, 46.9, 35.7; FTIR (thin film) ῡ (max) 3029, 2960, 1631, 
1591 cm
-1
; HRMS (ESI), m/z: 188.1071 (M+H
+
), calc. for C12H14ON: 188.1070. 
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1-Benzyl-3-iodo-5,6-dihydro-4-pyridone (2.75)
47
 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged with 
2.73 (0.10 g, 0.53 mmol), DMAP (0.13 g, 1.06 mmol), and DCM (12 mL).  The 
reaction was wrapped in foil and set to stir at RT.  A slurry of I2 (0.16 g, 0.64 mmol) 
in DCM (5 mL) was added to the reaction, using additional DCM to ensure all I2 
crystals were transferred.  The reaction was stirred for 18 hours, then was quenched by the 
addition of H2O (10 mL).  The phases were separated and the aq. phase was extracted with DCM 
(2 x 10 mL).  The combined organic phases were washed with sat. aq. NH4Cl (10 mL), H2O (10 
mL), sat. aq. Na2S2O3 (10 mL), brine (10 mL), dried over Na2SO4, filtered, and concentrated.  
The residue was purified by FCC (1% NEt3 in EtOAc) using a column pre-treated with the same 
eluent to give 2.75 as a yellow oil (0.15 g, 91%).  
1
H-NMR (400 MHz, CDCl3) δ  7.67 (s, 1H), 
7.39 (m, 3H), 7.27 (m, 2H), 4.43 (s, 2H), 3.50 (t, J= 7.6 Hz, 2H), 2.66 (t, J= 7.6 Hz, 2H); 
13
C-
NMR (100 MHz, CDCl3) δ  185.3, 158.8, 135.2, 129.4, 128.9, 127.9, 60.1, 47.0, 34.7; FTIR (thin 
film) ῡ (max) 3030, 2910, 1628, 1570 cm-1; HRMS (ESI), m/z: 335.9861 (M+Na+), calc. for 
C12H12ONINa: 335.9856. 
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CHAPTER 3. ATTEMPTED TOTAL SYNTHESIS OF (+)-(R)-MYRICANOL 
 
3.1.  Introduction 
 In the pathology of AD, one of the hallmarks is the inability of neurotransmitters to 
migrate from one neuron to another.  The facilitation of this movement is made possible by 
microtubules formed through tau protein-stabilized architecture.  Tau protein binds to the various 
proteins involved in microtubule formation, and allows for the system to be structurally sound
1
.  
In AD, tau protein tends to favor self-aggregation, very much like Aß1-42.  When aggregated, 
tau protein is unable to stabilize these neurological microtubules, and the transmission of 
neurologically active molecules shuts down, leading to lapses in various functions of the brain, 
including memory, movement, and involuntary muscle control. 
 As previously discussed, AD and other neurological disorders are difficult to combat due 
to lack of fundamental understanding of mechanistic pathways with which pharmaceuticals can 
be attenuated.  The tau protein aggregation pathway presents an alternative therapeutic target to 
the more traditional BACE-1 inhibitors or the direct Aβ aggregation diffusers.  In addition to 
compounds which could feasibly prevent tau protein from aggregating, it may also be possible to 
“tag” advanced tau intermediates for clearance by proteases.  This would not only enable direct 
targeting of tau intermediates which have not been shown to be beneficial at all, but would also 
allow for the body’s own defenses to naturally clear problematic protein tangles.  Presumably, 
this would lead to lower compound toxicity, as the compound is essentially a suicide molecule 
used to label the destructive tau aggregate. 
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3.2.  Tau Protein Aggregation Inhibitors 
 The tau protein contains a binding domain near the C-terminus for binding to the 
microtubule proteins.  This binding domain is exposed in biologically active tau due to 
conformational configurations based around a repeat series of Ser/Thr, which are generally 
located next to a Pro residue
2
.  Nitrogen-dependant kinases phosphorylate these residues, 
causeing conformational changes which expose alternative binding sites which favor 
homoprotein interactions over tau/microtubule interactions.  It is thought that tau 
hyperphosphorylation is responsible for this, but that normal, regulated phosphorylation is 
necessary for functionality of the tau protein.  Thus, it is difficult to find the “right balance” in 
the blocking of phosphorylation either by kinase inhibition or phosphatase activation. 
 
3.3.  (+)-R-Myricanol 
 Recently, researchers have found that extracts from the Bayberry root-bark promote tau 
aggregate clearance in biological assays
3
.  Known compounds which were found in Bayberry 
that had tau clearance properties did not match to the observed levels, and it was eventually 
found that a diarylheptanoid, (+)-aR,11S-myricanol (Figure 3.1) was responsible for the activity.  
Interestingly enough, although the authors confirmed the structure by NMR comparisons, the 
optical rotation of the compound is opposite to the published value, suggesting that the 
enantiomer of the previously reported compound may be responsible. 
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(R)
(S)
OH
MeO
MeO
OH OH
(aR,S)-3.01  
Figure 3.1: Structure of the diarylheptanoid (+)-aR,11S-myricanol 
 
 This natural product has many interesting features aside from its beneficial biological 
activity.  It is a diarylheptanoid, meaning that is possesses axial chirality, which is not seen as 
often in the pharmaceutical industry (the most notable exception being vancomycin).  In 
addition, it possesses a chiral 2° alcohol on the carbocyclic side chain.  The highly oxygenated 
ring structure of 3.01 also shares many similarities with compounds used as antioxidants.  
Reactive Oxygen Species (ROS), as described earlier, are implicated in many neurodegenerative 
disorders.  Due to all of these interesting structural and biological features, we decided to 
undertake the total synthesis of 3.01, keeping in touch with our goal of studying the synthetic 
approaches to anti-AD compounds.  
 
3.4.  Previous Approaches Towards Myricanol-Like Molecules 
 Reviewing the literature surrounding the diarylheptanoid family of myricanol, it was 
found that there are a number of potential methods for developing a racemic synthesis.  Whiting 
and Wood developed a diasteroselective synthesis based on a Ni(0)-mediated oxidative coupling 
procedure of the electron rich aromatic rings of 3.02 (Scheme 3.1)
4
. 
 
88 
 
OBn
MeO
MeO
H
OAc
BnO
I
I
Ni(PPh
3
)
2
Cl
2
PPh
3
, Zn powder
DMF, 65 °C
72 hrs, 7.3%
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H
OAcBnO
3.03  
Scheme 3.1: Oxidative coupling of bisiodide 3.02 giving protected (±)-myricanol 3.03 
 
 Although this procedure is quite low yielding, it shows that coupling protocols are 
approachable avenues for construction of the biaryl moiety.  In fact, 3.03 is only the protected 
form of the racemic natural product.  The initial isolation paper stated that the natural samples 
are generally racemic (only approx. 3% ee), but the active sample was scalemic (approx 86% ee).  
Generally speaking, this indicates a need for enantiocontrol over the formation of the biaryl 
functionality, as rotation about the joining bond would undermine resultant ee values, and thus 
erode the biological activity. 
 
3.5.  Retrosynthetic Analysis 
 Our approach to the retrosynthesis of (R)-myricanol (3.01) was to synthesize the 
carbocyclic, 13-membered ring lastly, using the now commonplace RCM reaction, giving 3.04.  
The cis vs trans issue sometimes encountered by these reactions would be of little concern, as we 
would simply hydrogenate the product to get the saturated ring system.  The southern metathesis 
partner could come from an asymmetric allylation of the parent aldehyde (3.05).  It is our 
thought that the distance between the axially chiral biaryl moiety and the more mobile, freely 
rotating aldehyde would be too great to impart a great deal of stereochemical information.  
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However, using the biaryl group as a potential alignment tool for an asymmetric ligand (through 
π-stacking, most likely), may allow us to use the In(0)-mediated allylation that the Cook group 
has focused much of their research efforts.  As a corollary to that promising idea, we would have 
to screen different ligands, because it is possible that the PhPyBOX ligand system we have 
developed (see Chapter 4) will not be as effective for the more flexible aliphatic aldehyde as it 
was for the more rigid isatin nucleus.  It has been shown that simple amino alcohols can provide 
effective ligand control for these types of reactions
5
. 
 From the relatively less complex 3.05 we can envision an asymmetric Suzuki coupling, 
which has been shown to be effective for the synthesis of biaryl systems
6
.  This provides aryl 
boronate 3.06 and aryl bromide 3.07.  The borylation can be made from the bromide, and the 
bromide may be installed from the bis-protected triphenol 3.08.  Installation of the allyl group to 
the ortho position must be accomplished prior to the installation of the bromine, otherwise there 
will be selectivity issues between ortho and para bromination, both of which are highly 
favorable due to the high electron density of the ring.  Thankfully, this is easily accomplished 
through a Claisen rearrangement from the O-allyl ether.  Triphenol 3.08 can be synthesized from 
2,3-dihydroxybenzaldehyde, using a Bayer-Villiger oxidation followed by hydrolysis of the 
formate ester.  Aryl bromide 3.07 can be synthesized from the aliphatic ester through 
electrophilic bromination and DIBAL-H reduction, giving 3.09, which can easily be synthesized 
from 4-iodophenol though a Heck reaction/hydrogenation sequence (Scheme 3.2). 
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Scheme 3.2: Retrosynthetic analysis of myricanol 
 
3.6.  Forward Synthesis 
 Our convergent synthetic approach began with our attempt to synthesize aryl boronate 
3.06.  We initially subjected 2,3-dihydroxybenzaldehyde to dimethylation using various 
protocols (Table 3.1).  Our attempt was to optimize the first step to give us the most reliable 
yield and purity for the subsequent oxidation step. 
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Table 3.1: Optimization of dimethylation reaction 
OH
OH
HO
MeI
base
solvent
reflux
MeO
MeO
HO
3.10  
Entry Solvent Base Yield (%)
a
 
1 DMF K2CO3 64 
2 DMF Cs2CO3 59 
3 Acetone K2CO3 25 
4 Acetone Cs2CO3 0 
a
: isolated yield, reactions run for 24 hrs. 
 
 Using K2CO3 in DMF
7
, we were able to isolate the product as a white crystalline solid 
reproducibly.  Acetone proved to be an inferior solvent under all circumstances for this reaction.  
This is most likely due to limited solubility of the base during the reaction.  Bayer-Villiger 
oxidation of 3.10 with mCPBA and hydrolysis of the formate ester using NaOH in MeOH/H2O 
gave the bis-protected triphenol 3.08
8
.  Alternatively, hydrolysis using more conventional LiOH 
produces similar results, but reproducibility varied based on the initial moisture content of the 
LiOH used.  NaOH was far more consistent, even when an old bottle was used.  Alkylation using 
allyl bromide as an electrophile proceeded smoothly using K2CO3/acetone to provide the allyl 
phenyl ether 3.11 (Scheme 3.3). 
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Scheme 3.3: Synthesis of allyl phenyl ether 3.11 
 
 We then turned our attention to the Claisen rearrangement of 3.11 to ortho-allyl phenol 
3.12.  We attempted both a thermal and a microwave series of reactions, utilizing different 
solvents, as well as various additives (Table 3.2)
9
.  Unfortunately, none of the reactions gave us 
any appreciable (>5%) yield.  We suspect that the aromatic ring is too electron rich to participate 
in the rearrangement, since the small methoxy groups should not be sterically significant enough 
to interfere.  We also never observed para rearrangement, which is sometimes possible if the 
ortho position is blocked
10
.  There is little literature evidence to suggest possible reasons for the 
inability of 3.11 to undergo the Claisen rearrangement as written.  A variety of solvents were 
screened, all showing no product formation, and in most cases no loss of starting material.  
Microwaves have been used to accelerate these reactions
11
, and an application of this 
methodology did not provide any change to the initial results (Table 3.2, Entries 4 and 7).  Lewis 
acid catalysts may also accelerate the Claisen rearrangement in certain cases
12
, and efforts to use 
these also produced none of the desired product (Table 3.2, Entries 8 and 9).  Finally, water is 
also a potential accelerant due to its ability to form hydrogen-bond networks with the substrate, 
encouraging conformations which promote rearrangement.  However, even water (Table 3.2, 
Entry 7) could not produce the desired results. 
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Table 3.2: Attempted [3,3]-sigmatropic rearrangement of 3.11 
O
MeO
MeO
3.11
OH
MeO
MeO
3.12
conditions
solvent
 
Entry Conditions
a
 Solvent (temp) Additive 
1 A toluene (80 °C) none 
2 A toluene (reflux) none 
3 B toluene (150 °C) none 
4 C toluene (175°C) none 
5 A N,N-diethylaniline (reflux) none 
6 B N,N-diethylaniline (250 °C) none 
7 C toluene (175 °C) H2O (3 eq.) 
8 A toluene (reflux) BiCl3 (1.5 eq.) 
9 A N,N-diethylaniline (reflux) BiCl3 (1.5 eq.) 
Note: All reactions yielded no product, and were run for 24 hrs (thermal) or 6 hrs (μW) 
a: (A) thermal, traditional glassware; (B) thermal, sealed tube; (C) 150W μW 
 
 Since the Claisen rearrangement was unsuccessful, we next attempted to use an installed 
carbamate (3.13) to utilize Directed ortho Metalation (DoM)
13
.  Unfortunately, the electron-rich 
nature of the substrate proved too much to overcome, and the metalation never occurred.  
Quantitiative recovery of the starting carbamate was observed in all cases (Scheme 3.4).  The 
large increase in electron density of the ortho position due to the deprotonation event leads to an 
increase in overall electron density of the ring current, which is already increased by the 
prescence of the three phenolic groups.  Additional electron density cannot therefore be accepted 
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into the ring current, and metalation does not occur.  Modification of the initial DoM protocols 
using tBuLi did not produce any metalation either.  Quenching of the reaction mixture with D2O 
did not produce an ortho deuterium, supporting the observation that metalation is not occurring.  
In addition to these efforts, the series of butyl lithium reagents (nBuLi, sBuLi, tBuLi) were all 
screened in conjunction with TMEDA, N,N,N’,N’-tetramethylpropyldiamine, and 12-crown-4 for 
deaggregation of the lithium species.  None of these additives had any effect on the outcome of 
the reaction. 
 
OH
MeO
MeO
3.08
NaH
THF
73%
NEt2
O
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O
MeO
MeO
O
NEt2
3.13
sBuLi
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THF
-78 °C, then
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O
MeO
MeO
O
NEt2
3.14
 
Scheme 3.4: Attempted DoM to install the C-6 allyl group 
 
With the initial attempts to synthesize the allyl group having failed, we turned to a set of 
procedures using tBuLi to metalate the ortho bromine of 3.16.  Unfortunately, quenching with 
allyl bromide or the previously reported boron reagent failed to give useable product (Scheme 
3.5)
14
.  This suggested that even the more facile metal-halogen exchange was being blocked by 
the highly electron rich nature of the arene ring.  This observation was supported by the presence 
of the bromine atom in all recovered starting material.  Again, quenching of the reaction mixture 
with D2O did not produce deuteration of the ortho position, but rather the starting material was 
recovered with the bromine intact, supporting that the initial metalation did not occur.  Screening 
of the previously mentioned chelating agents also did not affect the reaction outcome. 
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Scheme 3.5: Attempted synthesis of the allyl group though metalation of 3.16 
 
With the synthesis of 3.06 stalled, we turned our attention to the synthesis of the southern 
portion 3.07.  Beginning with 4-iodophenol, we subjected it directly to basic Heck reaction 
conditions, providing 3.18 in excellent yield.  Simple hydrogenation using H2 gas over Pd/C 
solid support gave no product, but an alternative protocol using triethylsilane and Pd/C gave very 
high yields.  This selective reactivity is attributed to the surface interactions of the silyl species 
generated during hydrogen abstraction by the Pd surface.  This species, whose nature is unclear 
but is presumably of the form Pd-SiEt3, operates to attract the chalcone to the surface, where the 
traditional Pd-H reduction takes place.  Without this attracting agent, 3.18 does not interact with 
the surface of the Pd for long enough exposure times to affect the reduction.  The main 
byproduct is Si2Et6, formed from either the recombination of two SiEt3 radicals or the 
nucleophilic attack of an SiEt3 anion to an SiEt3 cation.  Either of these scenarios could produce 
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activating agents for the chalcone’s carbonyl.  Reproducibility of this reaction was found to be 
affected by the vendor of the triethylsilane.  Yields with reagent purchased from the Acros 
Chemical company gave very high (≥ 90%) yields, while reagent purchased from Sigma Aldrich 
chemical company gave consistently low (≤ 30%) yields.  The hydrogenated 3.19 was then 
subjected to bromination, giving 3.20 in moderate yield (Scheme 3.6). 
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Scheme 3.6: Synthesis of 3.20 
 
Protection of the phenol as the MOM ether provided 3.21.  It is our belief that the MOM 
group will serve as adequate steric bulk to promote atropisomerism in the subsequent Suzuki 
cross coupling, while also acting as a directing group for the Pd in the aforementioned coupling 
reaction.  Any attempts to introduce the boron moiety to 3.21 (or the benzoylated analog) gave 
only deprotection of the phenol (Scheme 3.7).  We decided that our synthetic strategy would 
only be successful if the boron was included in the cross coupling partner 3.06.  The issue of 
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deprotection was also apparent if alternative protecting groups were used, such as benzoyl and 
benzyl.  The proximity of the protected phenol seems to make the resultant boronate unstable.  
This is evidenced by the observation that if the conditions are changed to lithiation and 
quenching of the lithiate with a boron compound, similar results are observed, even though 
lithiation was confirmed through D2O quenching. 
 
OH
CO2Et
Br
3.20
MOMO
CO2Et
Br
3.21
MOMO
CO2Et
Bpin
3.22
MOMCl
DIPEA
DCM
64%
borolation
conditions
not observed, only deprotection 
Scheme 3.7: Final synthesis of 3.21 
 In several experiments, we found that reduction of the ester to an aldehyde as desired 
(3.07) gave poor yields.  DIBAL-H reductions are difficult to control completely, and a complete 
reduction is most likely the more efficient pathway, with a reoxidation occurring to enable 
allylation of the resulting aldehyde.  We decided to perform the final reduction after the cross 
coupling was performed.  We renewed our efforts to synthesize the allyl group onto the C-6 
position of 3.08, but all of our efforts were unsuccessful.  It is possible that our mistake was 
oxidizing the original aldehyde to the phenol.  Perhaps the electron withdrawing nature of the 
aldehyde would provide us with acceptable electronics for subsequent reactions.  We regretted 
the choice to discontinue the project due to lack of forward progress and lack of personelle to 
perform the reactions.   
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3.7.  Implications and Conclusions of the Synthesis 
 While our synthetic efforts did not yield the natural product, we are confident that our 
synthetic strategy is viable, provided 3.06 could be synthesized.  We have no reason to believe 
that the cross coupling will not work as described, and we believe our ortho position groups 
(MOM protected phenol in 3.21 and methoxy in 3.06) would give us enough steric crowding to 
promote atropisomerism with the addition of a known chiral ligand
15
.  We performed a simple 
experiment using hydrocinnamaldehyde and our allyl indium protocol (see Chapter 4) and found 
that our PhPyBOX ligand system is ineffective at providing a chiral alcohol as in 3.04.  The yield 
is quantitative, but there is no ee.  This issue would require either a large screening of other types 
of ligands, or the use of other allylation methods such as Brown allylation. 
 
3.8.  Experimental Section 
3.8.1.  General Reaction Considerations 
All reactions were conducted in oven-dried (100°C) glassware, and were run under an 
atmosphere of argon, unless otherwise stated.  DCM was dried by passing the degassed solvent 
through a column of activated Cu/alumina under N2 immediately before use.  MeOH was 
distilled from Mg turnings and stored over 3Å MS.  Acetone was used as HPLC-grade.  Allyl 
bromide was purified by washing with sat. aq. NaHCO3 followed by distilled H2O, drying over 
CaCl2, and distilling under reduced pressure.  Chromatography was performed on EMD silica gel 
(40-60 microns) using air pressure, unless otherwise specified. All other solvents and reagents 
were purchased at the highest level of purity and were used as received. 
NMR spectra were obtained on a Varian INOVA NMR instrument, at the indicated field 
strength in the indicated deuterated solvent.  NMR spectra are referenced to internal 
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tetramethylsilane.  HRMS were collected on a Bruker BIOTOF III instrument with a positive 
ESI mode and are referenced to appropriate PEG or NaTFA standards.  FTIR spectra were 
collected on a Bruker Dalton FTIR instrument.  Melting points were collected on a Fisher-Johns 
apparatus and are uncorrected. 
 
3.7.2.  Experimental Details 
2,3-Dimethoxybenzaldehyde (3.10)
16
 
A 3-neck, 250-mL round bottom flask equipped with a mechanical stirrer, stopper, 
and condenser was charged with 2,3-dihydroxybenzaldehyde (5.00 g, 36.2 mmol) 
and DMF (40 mL).  The reaction was stirred as methyl iodide (5.41 mL, 86.7 
mmol) was added, followed by solid K2CO3 (20.00 g, 144.9 mmol) in portions as to not impede 
the stirring by addition.  The reaction slurry was heated to reflux for 24 hours, then cooled to RT, 
diluted with H2O (250 mL), and extracted with EtOAc (3 x 100 mL).  The combined organic 
phases were washed with H2O (200 mL), brine (150 mL), dried over MgSO4, filtered, and 
concentrated.  The residue was purified by FCC (3:2 hexane:EtOAc) to give 3.10 as white 
crystals (3.85 g, 64%).  
1
H-NMR (400 MHz, CDCl3) δ  10.40 (s, 1H), 7.38 (dd, J= 2.8 Hz, 6.8 
Hz, 1H), 7.08-7.14 (m, 2H), 3.96 (s, 3H), 3.88 (s, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  190.3, 
153.2, 152.9, 130.0, 124.3, 119.4, 118.3, 62.5, 56.2; FTIR (thin film) ῡ (max) 2964, 2873, 2749, 
1688 cm
-1
; HRMS (ESI), m/z: 189.0529 (M+Na
+
), calc. for C9H10O3Na: 189.0522. 
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2,3-Dimethoxyphenol (3.08)
8 
A 100-mL round bottom flask equipped with a magnetic stir bar was charged with 
3.10 (1.25 g, 7.52 mmol) and DCM (25 mL).  mCPBA (approx. 50% wt/wt, 5.20 
g, 15.04 mmol) was added in one portion and the reaction ran at RT for 18 hours.  
The resultant slurry was filtered and the filter cake (m-chlorobenzoic acid) was washed with 
DCM.  The filtrate was concentrated and the residue was dissolved in MeOH (25 mL).  A 
solution of NaOH (0.65 g, 16.40 mmol) in H2O (0.88 mL) was added dropwise and the reaction 
ran at RT for 2.5 hours.  The mixture was concentrated and the residue was suspended in 1:1 sat. 
aq. NH4Cl:brine and extracted with EtOAc (2 x 50 mL).  The combined organic layers were 
dried over MgSO4, filtered, and concentrated.  The residue was purified by FCC (1% MeOH in 
DCM) to give 3.08 as a brown oil (0.68 g, 59%).  
1
H-NMR (400 MHz, CDCl3) δ  10.40 (s, 1H), 
6.90 (t, J= 8.4 Hz, 1H), 6.58 (d, J= 8.4 Hz, 1H), 6.45 (d, J= 8.4 Hz, 1H), 5.88 (bs, 1H), 3.87 (s, 
3H), 3.84 (s, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  152.9, 149.9, 136.1, 124.2, 108.6, 104.3, 61.0, 
55.9; FTIR (thin film) ῡ (max) 3528, 2944, 2840 cm-1; HRMS (ESI), m/z: 267.1394 (M+Na+), 
calc. for C12H24O3SiNa: 267.1387. 
 
1-Allyloxy-2,3-dimethoxybenzene (3.11) 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged 
with 3.08 (2.20 g, 14.27 mmol), K2CO3 (2.96 g, 21.41 mmol), and acetone (25 
mL).  Allyl bromide (1.36 mL, 15.70 mmol) was then added and the reaction 
was heated to reflux for 18 hrs.  The reaction mixture was then cooled to RT and filtered through 
Celite, rinsing with acetone.  The filtrate was concentrated and the resiude purified by FCC (4:1 
Hexane:EtOAc) to give 3.11 as a colorless oil (2.22 g, 80%).  
1
H-NMR (400 MHz, CDCl3) δ  
OH
MeO
MeO
3.08
O
MeO
MeO
3.11
101 
 
6.89 (dt, J=8.4 Hz, 1.2 Hz, 1H), 6.52 (dd, J=8.4 Hz, 1.2 Hz, 2H), 6.01 (m, 1H), 5.36 (dq, J=17.2 
Hz, 0.8 Hz, 1H), 5.21 (dt, J=10.8 Hz, 1.6 Hz, 1H), 4.54 (m, 2H), 3.82 (s, 3H), 3.79 (s, 3H); 
13
C-
NMR (100 MHz, CDCl3) δ  153.9, 152.7, 138.9, 133.7, 123.7, 117.5, 107.4, 105.7, 70.0, 60.9, 
56.2; FTIR (thin film) ῡ (max) 2937, 2836, 1596, 1495, 1476 cm-1 
 
2,3-Dimethoxy-1-N,N-diethylcarbamoylphenol (3.13) 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged 
with NaH (60% in oil, 88 mg, 2.2 mmol) and THF (2 mL).  The reaction was 
cooled to 0°C and stirred for 10 min.  A solution of 3.08 (300 mg, 2.0 mmol) 
in THF (2 mL) was then added dropwise.  After 1 hr, N.N-diethylcarbamoyl 
chloride (0.30 mL, 2.2 mmol) was added in one portion and the reaction mixture was allowed to 
warm to RT and stirred overnight.  The reaction was quenched with sat. aq. NH4Cl and the 
phases were separated.  The aqueous phase was extracted with EtOAc (3 x 5 mL).  The 
combined organic phases were washed with brine (10 mL) and dried (Na2SO4).  Filtration and 
concentration gave a brown residue which was purified by FCC (1% MeOH in DCM) to give 
3.13 as an orange oil (370 mg, 73%).  
1
H-NMR (400 MHz, CDCl3) δ  6.90 (t, J=8.4 Hz, 1H), 
6.67 (m, 2H), 3.76 (s, 6H), 3.34 (m, 4H), 1.14 (m, 6H); 
13
C-NMR (100 MHz, CDCl3) δ  171.1, 
153.9, 145.3, 141.7, 123.3, 115.9, 109.8, 60.7, 60.5, 56.2, 42.3, 14.2, 13.5; FTIR (thin film) ῡ 
(max) 2974, 2938, 2837, 1720, 1599, 1494, 1471 cm
-1
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6-Bromo-2,3-dimethoxyphenol (3.15)
14 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged 
with 3.08 (0.57 g, 3.7 mmol) and THF (15 mL).  The reaction was cooled to -
78°C and NBS (recrystallized, 0.66 g, 3.7 mmol) was added in one portion.  
The reaction stirred at -78°C for 4 hrs, then was allowed to warm to RT overnight.  The reaction 
was then concentrated and the residue was dissolved in DCM (20 mL) and washed with H2O (20 
mL) and brine (20 mL).  The organic phase was dried (MgSO4), filtered, and concentrated.  The 
residue was purified by FCC (19:1 Petroleum Ether:Et2O) to give 3.15 as a thick, orange oil 
(0.60 g, 70%).  
1
H-NMR (400 MHz, CDCl3) δ  7.13 (d, J=8.8 Hz, 1H), 6.39 (d, J=8.8 Hz, 1H), 
5.98 (bs, 1H), 3.89 (s, 3H), 3.83 (s, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  152.2, 147.0, 136.6, 
127.0, 105.4, 100.5, 61.3, 56.3; FTIR (thin film) ῡ (max) 3515, 2942, 2837, 1494, 1466, 908, 733 
cm
-1
. 
 
1-Benzyloxy-6-bromo-2,3-dimethoxybenzene (3.16)
14 
A 50-mL round bottom flask equipped with a magnetic stir bar was charged 
with 3.15 (583 mg, 2.50 mmol), K2CO3 (519 mg, 3.75 mmol), and acetone (25 
mL).  The reaction was stirred as benzyl bromide (0.47 mL, 2.75 mmol) was 
added, and the reaction was set to stir at reflux for 4 hrs.  The reaction was cooled to RT and 
concentrated.  The paste-residue was suspended in DCM (20 mL) and washed with H2O (15 
mL), brine (15 mL), dried (MgSO4), filtered, and concentrated.  The residue was purified by 
FCC (19:1 Petroleum Ether:Et2O) to give 3.16 as a colorless solid (768 mg, 95%).  m.p. 71-
73°C; 
1
H-NMR (400 MHz, CDCl3) δ  7.55 (dd, J=7.6 Hz, 1.2 Hz, 2H), 7.36 (m, 3H), 7.21 (d, 
J=8.8 Hz, 1H), 6.59 (d, J=9.2 Hz, 1H), 5.06 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H); 
13
C-NMR (100 
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MHz, CDCl3) δ  153.6, 150.1, 144.0, 137.3, 128.8, 128.6, 128.4, 127.1, 109.1, 75.6, 61.4, 56.4; 
FTIR (thin film) ῡ (max) 2936, 2836, 1574, 1478, 1092, 1009 cm-1; HRMS (ESI), m/z: 345.0085, 
347.0070 (M+Na
+
), calc. for C15H15O3BrNa: 345.0097, 347.0078. 
 
Ethyl 4-hydroxy-trans-cinnamaic acid (3.18)
17
 
A 250-mL round bottom flask equipped with a magnetic stir bar was 
charged with 4-iodophenol (2.00 g, 9.08 mmol), Pd(OAc)2 (10.2 mg, 
0.045 mmol, 0.5 mol%), and PPh3 (23.8 mg, 0.091 mmol, 0.8 mol%).  
The flask was sealed under argon and charged with DMF (28 mL), NEt3 (3.80 mL, 27.60 mmol), 
and ethyl acrylate (4.00 mL, 36.8 mmol).  The reaction mixture was set to stir at 100°C for 24 
hrs.  The reaction was then cooled to RT and diluted with 2:1 EtOAc:Et2O (75 mL).  The 
solution was washed with 1N HCl (50 mL), brine (50 mL), dried (Na2SO4), filtered, and 
concentrated.  Purification of the residue by FCC (4:1 hexane:EtOAc) gave 3.18 as yellow 
crystals (1.76 g, 99%).  m.p. 69-72°C; 
1
H-NMR (400 MHz, CDCl3) δ  7.61 (d, J=16 Hz, 1H), 
7.39 (d, J=8.4 Hz, 2H), 6.85 (dd, J=10 Hz, 8.4 Hz, 2H), 6.27 (d, J=16 Hz, 1H), 4.25 (q, J=7.2 
Hz, 2H), 1.32 (t, J=7.2 Hz, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  168.7, 158.8, 145.4, 130.3, 
126.8, 116.2, 115.1, 61.0, 14.5; FTIR (thin film) ῡ (max) 3335, 2981, 1684, 1604, 1515 cm-1; 
HRMS (ESI), m/z: 215.0646 (M+Na
+
), calc. for C11H12O3Na: 215.0679. 
 
Ethyl 4-hydroxy-hydrocinnamaic acid (3.19)
18
 
A 100-mL round bottom flask equipped with a magnetic stir bar was 
charged with 3.18 (2.20 g, 11.40 mmol), Pd/C (0.18 g, 15 wt%), and 
MeOH (21 mL).  The reaction was sealed under argon and a bubbling 
OH
CO2Et
3.18
OH
CO2Et
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outlet was affixed.  Triethylsilane (18.10 mL, 116.50 mmol) was added dropwise, with vigorous 
hydrogen gas evolution occurring upon addition.  The reaction was allowed to stir at RT for 72 
hrs before filtering through Celite, rinsing with MeOH.  The filtrate was concentrated and the 
residue was purified by FCC (4:1 hexane:EtOAc) to give 3.19 as a yellow oil, which on occasion 
has solidified to give pale yellow crystals (2.08 g, 94%).  
1
H-NMR (400 MHz, CDCl3) δ  7.01 (d, 
J=8.8 Hz, 2H), 6.85 (bs, 1H), 6.75 (d, J=8.4 Hz, 2H), 4.11 (q, J=7.2 Hz, 2H), 2.85 (t, J=7.6 Hz, 
2H), 2.58 (t, J=8.4 Hz, 2H), 1.21 (t, J=7.2 Hz, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  174.3, 
154.7, 132.2, 129.6, 115.6, 61.0, 36.6, 30.4, 14.3; FTIR (thin film) ῡ (max) 3393, 2982, 2936, 
1707, 1597 cm
-1
. 
 
Ethyl 3-bromo-4-hydroxy-hydrocinnamaic acid (3.20) 
A 50-mL round bottom flask equipped with a magnetic stir bar was 
charged with 3.19 (0.70 g, 5.12 mmol) and CHCl3 (7 mL).  The 
reaction was cooled to 0°C and Br2 (neat, 0.15 mL, 2.92 mmol) was 
added dropwise over 5 min.  The reaction was allowed to warm to RT and stirred for 4 hrs.  The 
reaction mixture was directly washed with 1N HCl (5 mL), brine (5 mL), dried (Na2SO4), 
filtered, and concentrated.  The residue was purified by FCC (4:1 hexane:EtOAc) to give 3.20 as 
a yellow oil (0.40 g, 41%).  
1
H-NMR (400 MHz, CDCl3) δ  7.26 (m, 1H), 6.99 (dd, J=8.4 Hz, 2 
Hz, 1H), 6.88 (d, J=8.4 Hz, 1H), 5.73 (bs, 1H), 4.09 (q, J=11.6 Hz, 2H), 2.82 (t, J=7.6 Hz, 2H), 
2.54 (t, J=8 Hz, 2H), 1.20 (t, J=6.8 Hz, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  173.1, 151.0, 
134.3, 132.1, 131.9, 129.2, 60.8, 36.2, 30.0, 14.3; FTIR (thin film) ῡ (max) 3406, 2982, 2936, 
1727, 1497, 1184, 1041 cm
-1
; HRMS (ESI), m/z: 295.0002, 296.9992 (M+Na
+
), calc. for 
C11H13O3BrNa: 294.9940, 296.9921. 
OH
CO2Et
Br
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Ethyl 3-bromo-4-(methoxymethyloxy)-hydrocinnamaic acid (3.21) 
A 50-mL round bottom flask equipped with a magnetic stir bar was 
charged with 3.20 (0.30 g, 1.09 mmol) and DCM (7.5 mL).  With 
stirring at RT, N,N-diisopropylethylamine (DIPEA, 0.28 mL, 1.65 
mmol) was added, followed by chloromethyl methyl ether (MOMCl, 0.12 mL, 1.65 mmol) 
resulting in a white gas formation.  The reaction was allowed to stir for 18 hrs at RT, then was 
diluted with Et2O (10 mL) and washed with H2O (10 mL), brine (10 mL), dried (Na2SO4), 
filtered, and concentrated.  The residue was purified by FCC (4:1 hexane:EtOAc) to provide 3.21 
as a colorless oil (0.22 g, 64%).  
1
H-NMR (400 MHz, CDCl3) δ  7.34 (s, 1H), 7.03 (m, 2H), 5.18 
(s, 2H), 4.09 (q, J=7.2 Hz, 2H), 3.48 (s, 3H), 2.84 (t, J=7.6 Hz, 2H), 2.54 (t, J=8 Hz, 2H), 1.20 (t, 
J=6.8 Hz, 3H); 
13
C-NMR (100 MHz, CDCl3) δ  172.8, 152.4, 135.9, 133.3, 128.5, 116.5, 113.0, 
95.4, 60.7, 56.5, 36.0, 30.0, 14.4; FTIR (thin film) ῡ (max) 2984, 2906, 1727, 1495, 1244, 1044 
cm
-1
; HRMS (ESI), m/z: 339.0193, 341.0181 (M+Na
+
), calc. for C13H17O4BrNa: 339.0202, 
341.0183. 
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CHAPTER 4. TOTAL SYNTHESIS OF (+)-CONVOLUTAMYDINE E AND ATTEMPTED 
TOTAL SYNTHESES OF RELATED 3-HYDROXYINDOLIN-2-ONE NATURAL 
PRODUCTS 
 
4.1.  Introduction 
 The total synthesis of natural products has been a highly useful tool for organic chemists 
to showcase their methodologies, identify new candidates for pharmaceutical development, and 
expand the capabilities of modern chemistry.  A wide range of natural products exist, with a 
diverse range of functional groups and biological activities as well as complex structural 
scaffolds.  This is exemplified in the total synthesis of vancomycin (Figure 4.1) by the Nicolaou 
group
1
.  The total syntheses of these types of molecules have opened up a wide array of synthetic 
tools for the modern organic chemist in the form of established chemical reactions. 
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Figure 4.1: Vancomycin 
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4.1.1.  Allyl Groups as Functional Handles for Organic Synthesis 
Allylation is a key synthetic strategy in organic synthesis.  The allyl group can be used as 
a transformative synthon for a wide number of other functional groups (Figure 4.2). 
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Figure 4.2: Synthetic utility of the allyl group 
 
 A large number of synthetic strategies centered on the allyl group have been developed.  
The allyl group, being a 3-carbon unit, provides access to [2,3] and [3,3]-sigmatropic 
rearrangements such as the [2,3]-Wittig rearrangement and Claisen rearrangement.  By 
incorporating the allyl group as a side chain of Boc-protected benzyl amine 4.01, Anderson, et 
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al. were able to deprotonate the benzylic position and facilitate the thermal [2,3]-Wittig 
rearrangement to 4.02
2
 (Scheme 4.1). 
 
N
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Scheme 4.1: Example of a [2,3]-Wittig rearrangement 
 
Claisen rearrangements are also highly useful reactions where allyl groups play an 
integral role.  Buchwald and co-workers have developed an O-vinylation using Cu-catalyzed 
cross coupling of allylic alcohol 4.03 and vinyl iodide 4.04, resulting in the cross coupled 
product 4.05.  The allyl vinyl ether, under the thermal reaction conditions, undergoes [3,3]-
sigmatropic rearrangement to give the homallylic aldehyde 4.06
3
 (Scheme 4.2). 
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Scheme 4.2: Example of [3,3]-sigmatropic rearrangement (Claisen rearrangement) of an allyl 
vinyl ether 
 
Allyl groups can also be isomerized into internal alkenes through transition metal 
catalyzed C-H bond functionalization.  By isomerizing the allyl group, it can then be subjected to 
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numerous other reactions where the internal substitutions can be utilized.  For example, a Rh-
catalyzed alkene isomerization using the Grubb’s 2nd generation catalyst readily isomerizes allyl 
groups to the internal alkenes, which can allow for compounds such as N-allyl indole 4.07 to be 
converted into the enamine 4.08, which can then be easily deprotected (Scheme 4.3)
4
. 
 
N
Cl
CHO
4.07
N
Cl
CHO
4.08
Grubbs' II (10 mol%)
MeOH, 60 °C
12hr, 69%, 4:1 E:Z
 
Scheme 4.3: Example of an allyl group isomerization catalyzed by Rh 
 
Allyl groups can also be subjected to Ring-Closing Metathesis (RCM) or Cross-
Metathesis (CM) via the same catalyst (Grubbs’ II), but in a different solvent (CH2Cl2).  Using 
this catalyst system, bis allyl ether 4.09 is subjected to RCM, providing dihydropyran 4.10 in a 
very good yield (Scheme 4.4)
5
. 
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Scheme 4.4: Example of allyl groups participating in RCM 
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The allyl group also has been utilized recently in the explosion of C-H bond activation 
chemistry.  Using the allyl’s alkene pi system as a “docking handle” for transition metals, the 
allylic C-H bonds become readily accessible for functionalization.  In work pioneered separately 
by M. Christina White and J. DuBois, Pd or Rh can be used to similar effect to functionalize the 
C-H bonds of the allylic carbon.  As an example, from the White group, homoallylic carbamate  
4.11 can be ring closed onto the allylic C-H position by Pd-catalyzed C-H activation, providing 
cyclic carbamate 4.12 in good yields and with moderate diastereoselectivity (Scheme 4.5)
6
. 
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Scheme 4.5: Example of allylic C-H bond functionalization using Pd catalysis 
 
Allylation has become one of the premier tools in the organic chemist’s toolbox, not only 
for its ease of incorporation into molecular structures, but for its robust reactivity profile.  All of 
the aforementioned reactions can be applied to virtually any terminal olefin, and the allyl group 
provides that, but also provides access to synthetically powerful rearrangements which require a 
three-carbon unit. 
 
4.1.2.  Allylation and the Cook Group Methodologies 
A rapidly developing caveat of organic chemistry is the need to be environmentally 
friendly with our choices of reagents, solvents, and reaction conditions
7
.  In this light, our 
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research group has sought to bring new chemistry to the forefront, based around Indium and 
Bismuth as organometallic precursors.  We have shown that In(0) can be an efficient metal for 
Barbier-type allylations using convenient allyl iodides and bromides
8
. 
The reactions were first utilized on chiral hydrazones, using allyl iodide and the 
stereocontrol was achieved through an adjacent chiral center on the hydrazone’s oxazolidinone 
auxiliary.  Thus, hydrazone 4.13 was allylated using allyl iodide and In(0) in THF to produce 
allylated hydrazine 4.14 in near quantitative yield and diastereomeric ratio (Scheme 4.6)
9
. 
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Scheme 4.6: Cook Group methodology for diastereoselective allylation of hydrazones 
 
The allylation can also be achieved with ligand control by utilizing an atrop-chiral 
BINOL-derived ligand and the addition of 4Å molecular sieves (MS).  The analogous hydrazone 
4.15 can be effectively allylated using these conditions, giving the allylated product 4.16 in good 
yield with moderate-to-good enantioselectivities (Scheme 4.7)
10
. 
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Scheme 4.7: Cook group ligand control of enantioselective hydrazone allylation 
 
Changing the ligand to have a more electron withdrawing nature allowed the allyl iodide 
to be replaced with the easier to use and less reactive allyl bromide
11
.  The reactions give higher 
yields (around 85%) and much better enantioselectivities (90-97% ee).  This allowed for more 
applicability towards different reactions, as allyl bromides are relatively easier to synthesize or 
are commercially available.  One of the ways in which the methodology was applied was 
towards the intramolecular allylation of hydrazones, most notably in the formation of 
aminochromanes.  In this case, a Boc-protected glycinol was used as a ligand, and the substrate 
controlled the diastereoselectivity.  The hydrazone/allyl bromide 4.17 was cyclized via and In(0)-
mediated allylation to give the aminochromane 4.18 in a good yield with excellent 
diastereoselectivity (Scheme 4.8)
12
. 
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Scheme 4.8: Highly diastereoselective intramolecular allylation of hydrazones leading to 
aminochromanes 
 
4.1.3.  Current Cook Group Allylation Methodologies 
 Due to our interest in the allylation of hydrazones and other imine-type substrates, our 
group has expanded its methodologies to include ketone bodies.  The model substrate for these 
investigations has been isatin, 4.19 (Figure 4.3). 
 
N
H
O
O
4.19  
Figure 4.3: Isatin 
 
 Isatin is unique in that the reactive ketone is completely planar, meaning that any 
asymmetric reactions would have to be controlled exclusively from the reagent.  Also, the unique 
placement of the ketone and the amide carbonyl allows for very efficient binding to Lewis acids, 
forming the thermodynamically preferred five-membered ring chelate.  In research already 
established in the Cook group, isatin has been allylated using similar conditions to the hydrazone 
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series.  Thus, isatin (4.19) has been allylated using allyl iodide and Bi(0), using (S)-PhPyBOX as 
a ligand.  In this case a Lewis acid is needed to coordinate to both the chiral ligand and the isatin 
substrate, and so BiCl3 was chosen, providing 3-allyl-3-hydroxyindolin-2-one 4.20 in good 
yields with moderate enantioselectivities (Scheme 4.9)
13
.  Most notably, this reaction is 
operationally simple, with little purification necessary to isolate the product from the reaction 
mixture. 
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Scheme 4.9: Allylation of isatin using Bi(0)/BiCl3 conditions 
 
This methodology lead to the experimentation of the allylation conditions directly from 
the hydrazone chemistry, using In(0) as the Barbier-type metal.  Interestingly, the generated allyl 
indium species was Lewis acidic enough to eliminate the need for an additional Lewis acid 
additive.  Using the ligand optimized for the earlier bismuth allylation chemistry, the 
methodology was developed in earnest until an optimized protocol was achieved.  Isatin was 
allylated using In(0) in methanol using allyl bromide and (S)-PhPyBOX to give the allylated 
product in high yield and good enantioselectivities (Scheme 4.10)
14
. 
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Scheme 4.10: Allylation of isatin using In(0)-mediated conditions 
 
 While this methodology is very robust and highly effective, there was little support for its 
incorporation into a larger synthesis.  In this light, it was decided to pursue a project of total 
synthesis devoted to specific natural products with the 3-hydroxyindolin-2-one core. 
 
4.2.  Selection of Natrual Products for Total Synthesis 
 There are many natural products which contain the desired 3-hydroxyindolin-2-one 
structural motif, but many were deemed too complicated for simple transformations from the 
allyl group.  It was envisioned that the results of the allylation efforts towards 4.19 would allow 
us to utilize the chemically diversifiable allyl group to complete these syntheses.  In this light, 
several natural products were identified as possible targets for a total synthesis project (Figure 
4.4)
15
. 
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Figure 4.4: Possible synthetic targets for total synthesis in support of the Cook group allylation 
methodology 
  
 Firstly considered was Maremycin B (4.21), which was attractive because of the C-10 
methyl group, which we envisioned could come from a crotyl addition to 4.19, as opposed to an 
allylation (i.e. C-10 would be CH2).  However, this was eliminated as a possible choice due to 
the inconsistencies of the crotylation methodologies, as well as the highly complex 2,5-
piperazinedione moiety, which could not be retrosynthesized in an efficient way from the 
crotyl’s terminal double bond.  Secondly, we considered Convolutamydine A (4.22) and 
Convolutamydine E (4.23), both of which can be synthesized easily from the terminal olefin of 
the allyl group.  The only problem we envisioned was the presence of the 4,6-dibromoindolin-2-
one core, which posseses bromines on positions not typically found to be substituted in this class 
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of natural products.  We also examined Arundaphine (4.24) as a possible target.  It possesses a 
potentially atrop-isomeric N-aryl bond, which was not defined in the literature, as well as 
methylamino and N,N-dimethylseratonin moieties.  Early experimentation showed the difficulty 
in creating the N-aryl bond through established methodologies
16
.  Finally, we considered the 
tricyclic CPC-1 (4.25), which could be generated by cyclization of a pendant N-methylamine 
(derived from the allyl group’s olefin) onto the isatin core’s amide carbonyl.  This molecule was 
dropped from consideration due to time limitations during the syntheses of some of the other 
compounds. 
 
4.3.  Previous Syntheses of (R)-Convolutamydines A and E 
 4.3.1.  (R)-Convolutamydine A 
 The compound (R)-convolutamydine A was isolated from the Floridian marine bryozoans 
Amathia convolute in 1995.  It is a potent inhibitor of HL-60 human leukemia cell lines, with an 
active concentration of 0.1-25 μg.  It specifically inhibits adhesiveness to the culture plate, 
arrests growth, and induces phagocytosis of latex particles
17
.  Structurally, it possesses two 
bromine atoms, a methyl ketone, and a fully substituted chiral carbon at C-3 in addition to the 
indolin-2-one core. 
Since the appendage of convolutamydine A (4.22) is a methyl ketone, and the chiral 
carbon is generally derived from the starting ketone (4,6-dibromoisatin 4.26), it is 
understandable that many people have used this molecule as a total synthesis target to showcase 
asymmetric Aldol reactions.  Generally, these are organocatalytic, as strong bases usually 
associated with traditional Aldol reactions would decompose the indolin-2-one ring.  Specific 
119 
 
examples use acetone as a nucleophile and some derivative of L-Proline as an organocatalyst 
(Scheme 4.11)
18
. 
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Scheme 4.11: General organocatalytic approach to the total synthesis of (R)-convolutamydine A 
 
 In addition to these syntheses, many people have tried to focus their synthetic attention 
on the synthesis of 4.26, which is relatively more complicated to synthesize.  Mainly, the 
syntheses of 4.26 begin with 3,5-dibromoaniline (4.27), which can be made from p-nitroaniline 
(4.28) through a simple sequence of electrophilic bromination, diazotization/reduction, and 
reduction of the remaining nitro group (Scheme 4.12)
19
.  Bromination of 4.28 gives the doubly 
directed dibromination product 4.29.  Diazotization under strongly acidic conditions allows for 
the ipso-protonation of the diazonium salt, giving the bis-meta brominated nitrobenzene 4.30.  
Reduction using Raney Ni, and trapping of the aniline as its HCl salt gives 4.27.  A 
multicomponent reaction involving chloral and hydroxylamine under acidic conditions gives the 
isonitrosoanilide 4.31, which is cyclized under fairly hard acidic/thermal conditions to give 4.26.  
The synthesis is carried forward to the natural product by the previously described routes. 
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Scheme 4.12: Previous total synthesis of (R)-convolutamydine A 
 
 Another synthetic strategy, which is related to the previous strategy, is to brominate an 
isatin core directly.  In order to achieve this, protection of the isatin ketone must be enacted, and 
an electrophilic aromatic substitution directing group must be present at C-5.  The Deshpande 
group, which successfully applied microwaves to the synthesis in the previously mentioned 
strategy, has achieved this synthesis from 5-nitroisatin (4.32).  Protection of the 3-keto moiety as 
its 2,2-dimethylpropane-1,3-diol ketal provides 4.33, which is reduced to the 5-aminoisatin 
derivative 4.34.  electrophilic bromination is achieved under neutral conditions, with the amino 
group being diazotized off, akin to the previous syntheses, giving the deaminated, protected 
dibromoisatin 4.35.  Deprotection and Aldol reaction with acetone completes the natural product 
(Scheme 4.13)
20
. 
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Scheme 4.13: Total synthesis of (R)-convolutamydine A without forming the isatin directly 
 
 Interestingly enough, there are few examples where the methyl ketone of 4.22 is not 
synthesized from an Aldol reaction.  Cravotto, et al synthesized 4.22 from a 
dibromophenylglyoxyalic acid derivative (4.36) and, using the menthol ester, added allyl 
bromide by way of the allyl indium species to generate the diastereomeric allylated compound 
4.37.  Deprotection of the Boc-aniline allowed for amidation of the menthol ester, closing the 
indolin-2-one ring and forming the 3-allyl-3-hydroxy isatin derivative 4.38 (Scheme 4.14)
21
. 
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Scheme 4.14: Total synthesis of (R)-convolutamydine A using In-mediated diastereoselective 
allylation 
 
 4.3.2.  Previous Syntheses of (R)-Convolutamydine E 
 (R)-convolutamydine E (4.23) has been less studied as a target of total synthesis, most 
likely due to its lack of significant biological activity as compared with some of the other 
members of the convolutamydine family.  It was isolated from the same bryozoa as the other 
members of the convolutamydine family, and possesses a one-carbon shorter side chain than 
convolutamydine A, with a terminal hydroxyl group
22
. 
 Synthetically, the few efforts towards 4.23 have been centered around the Aldol reaction.  
Hayashi and co-workers have used a 3-hydroxy-L-prolinol organocatalyst to facilitate the Aldol 
reaction between N-protected 4,6-dibromoisatin 4.38 and acetaldehyde.  The resultant aldehyde 
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was then reduced to the natural product.  Unfortunately, this methodology provided only the 
enantiomer of the naturally occurring molecule (Scheme 4.15)
23
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Scheme 4.15: Organocatalytic total synthesis of (R)-convolutamydine E 
 
 The Kobayashi group has also reported a total synthesis which involves a vinylogous 
Mukaiyama Aldol reaction, where silyl enol ether 4.39 is reacted with 4.26 under Lewis acidic 
conditions to give an allylated-type of product, 4.40.  This is oxidatively cleaved to provide the 
aldehyde, which is reduced to the primary alcohol giving 4.23 (Scheme 4.16)
24
.  
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Scheme 4.16: Vinylogous Mukaiyama Aldol reaction leading to (R)-convolutamydine E 
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4.4.  Retrosynthetic Analysis for Convolutamydines A and E 
 In planning a retrosynthetic analysis of 4.22 and 4.23, the common precursor that was 
envisioned was the 3-allyl-3-hydroxy-dibromoisatin, 4.41.  Wacker oxidation of the allyl group 
would provide 4.22 and oxidative cleavage with a reductive work-up would provide 4.23.  The 
allylated material would come from 4.26 via the Cook group’s established In(0)-mediated 
allylation of isatins.  The starting material, 4.26, would come from the known method starting 
from 4.28 (Scheme 4.17). 
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Scheme 4.17: Proposed retrosynthetic analysis of convolutamydines A and E 
 
4.5.  Attempted Synthesis of (R)-Convolutamydine A 
 The synthesis began with the bromination of 4.28 using the established condtions (Br2 in 
AcOH)
25
, giving the dibrominated 4.29 in quantitative yield.  It was also attempted to use direct 
bromination methods of nitrobenzene
26
.  These methods were all unsuccessful due to the highly 
deactivating nature of the nitro group on the aromatic ring.  The literature reports good yields 
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and simple protocols, but all reagents were recovered unchanged in our hands.  Diazotization of 
4.29 under acidic conditions provided 4.30 (Scheme 4.18)
27
.   
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Scheme 4.18: Synthesis of 3,5-dibromonitrobenzene (4.30) 
 
Reduction of the nitro group proved to be more difficult than originally anticipated.  The 
literature showed several options, but all failed to give useful amounts of product when 
attempted.  Only SnCl2 (Table 4.1-Entry 5) acted as an acceptable reduction agent, which 
provided the HCl salt 4.27 in good yields (Table 4.1)
28
.  The protocol involving Raney-Ni was 
unsuccessful in our hands.  The electronic nature of 4.30 requires that a precise matching of the 
reduction potential of the reducing metal be achieved. 
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Table 4.1: Trials for the reduction of 4.30 to 4.27 
NO2
Br Br
4.30
reductant
solvent
temperature NH3Cl
Br Br
4.27  
Entry Reducing Agent Solvent Temperature (°C) Additive % Yield (isolated)
a 
1 Fe(0) AcOH 25 - 15 
2 Fe(0) AcOH 25 Ac2O 10
b 
3 Fe(0) AcOH 80 H2O 2 
4 Sn/HCl H2O 80 - 0 
5 SnCl2 EtOH 95 - 87 
a
: Yields are an average of two trials  
b
: Product was isolated as the acetyl-protected aniline 
 
 To synthesize the require isonitrosoanilide (4.31), the literature utilizes chloral, which is a 
regulated substance according to the Drug Enforcement Agency (DEA).  Due to the lack of DEA 
approval for purchasing chloral, two alternatives were explored.  The isonitrosoanilide could be 
prepared from α,α-bis(acetoxy)acetyl chloride in a midly basic solution along with 
hydroxylamine
29
.  Attempts to synthesize the acetyl chloride lead to low yields of an impure 
product which could not be readily purified by distillation.  Analysis of the literature yielded 
1,1,1-trichloro-2-ethoxyethanol, a convienient chloral surrogate for use in the preparation of 
isonitrosoanilides.  Reaction of 4.27 with 1,1,1-trichloro-2-ethoxyethanol and hydroxylamine in 
an acidic, aqueous environment provided the isonitrosoanilide 4.31.  Interestingly, the addition of 
Na2SO4 (as referenced in the original procedures) was found to be a detriment to product 
isolation.  During the final filtration, the product was adherent to the solid sulfate, and could not 
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be isolated directly.  Upon removal of the sulfate, the reaction proceeded as previously, but the 
material was able to be identified by 
1
H-NMR.  Compound 4.31 was cyclized using the acidic 
conditions described in the precedent syntheses to give 4,6-dibromoisatin 4.26 (Scheme 4.19).  
The cyclization reaction is extremely sensitive to both temperature and concentration of the acid.  
Precise control of both allowed for a good yield of 4.26 to be isolated (Table 4.2-Entry 6). 
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Scheme 4.19: Synthesis of 4,6-dibromoisatin 4.26. 
 
Table 4.2: Cyclization of 4.31 to 4.26 – acid concentration and reaction time experiments 
Entry H2SO4 conc. (%)
a 
Rxn Temp (°C)
b 
Rxn Time (min)
b 
% Yield (isolated) 
1 98 75 10 0 
2 98 75 20 7 
3 98 85 10 0 
4 98 85 20 0 
5 98 80 10 25 
6 80 80 10 85 
a
: % H2SO4 refers to wt/wt % in H2O. 
b
: The substrate was added in portions to the acid at 55°C in all cases.   
The reaction was then warmed to the indicated temperature and stirred for the indicated time. 
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 After synthesizing 4.26, it was subjected to the In(0) mediated allylation conditions 
eastablished by the Cook group.  It was found that an additional equivalent of allyl bromide 
(bringing the total equivalency to 3) was necessary for complete conversion.  Thus, treating 4.26 
with 3 eq. allyl bromide and 1.5 eq. In(0) using 20 mol% (S)-PhPyBOX as a ligand in MeOH 
provided the allylated 4.41 in near quantitative yield with 86% ee (Scheme 4.20). 
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Scheme 4.20: In(0)-mediated allylation of 4.26 
 
 In order to complete the total synthesis of (R)-convolutamydine A, a Wacker oxidation 
was to be performed.  Oxidation using standard catalytic PdCl2 and CuCl using molecular 
oxygen as a re-oxidant gave a white solid compound which appeared identical to the reported 
convolutamydine A, but underwent retro-Aldol to give 4.26 and acetone immediately upon 
entering any solution in preparation for analysis.  As such, HRMS and HPLC data could not be 
obtained, and the product could not be unambiguously confirmed for structure or optical activity 
(Scheme 4.21). 
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Scheme 4.21: Attempted Wacker oxidation of 4.41 to give 4.23 
 
4.6.  Synthesis of (R)-Convolutamydine E 
 Due to the extreme similarities between 4.23 and 4.24, the synthesis of 4.24 was initiated 
from the dibrominated allyl isatin 4.41.  Initial attempts to oxidatively cleave the allyl group of 
simple allyl isatin 4.20, used as a model system, were met with immediate decomposition of the 
formed aldehyde (Scheme 4.22 and Table 4.3).  The decomposition was so rapid that even the in 
situ addition of a reducing agent (i.e. without isolation of the aldehyde) did not yield the desired 
primary alcohol.  Even more active ozonolysis conditions using pyridine as an accelerant 
provided no product (Table 4.3, Entry 3)
30
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Scheme 4.22: Attempted oxidative cleavage of model system 4.20 
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Table 4.3: Attempts to oxidatively cleave 4.20 
Entry Reagent Rxn 
Solvent 
Trapping/Reducing 
agent 
% SM 
remaining
a 
% isolated 
yield
b 
1 O3 MeOH Me2S 0 0 
2 O3 MeOH NaBH3CN 0 0 
3 O3 EtOAc/Pyr
c 
NaBH3CN 0 0 
4 OsO4/NMO/NaIO4 tBuOH/H2O NaBH3CN
d 
0 0 
a
: As monitored by TLC.  
b
: After chromatography.  
c
: Pyridine was chosen as a co-solvent due to its ability to 
accelerate ozonolysis reactions.  
d
: NaBH3CN was used to trap the intermediate aldehyde as opposed to an ozonide. 
 
 Although none of the oxidative cleavage protocols yielded product, all of them very 
clearly converted 4.20 (as observed by TLC).  It was hypothesized that the 3° alcohol in 4.42 was 
somehow trapping either the ozonide or the aldehyde, and thus making a highly unstable ring 
system, which underwent the observed decomposition.  After carefully examining the literature 
for the previous syntheses, it was discovered that one had used oxidative cleavage, the report by 
Kobayashi, et al
22
.  In order to preserve the 3° alcohol center, they protected it as its TMS ether.  
It was not discussed as to why this was done, but presumably they observed the same 
interference in their ozonolysis and came to the same conclusion.  By adopting their final 
strategy, 4.41 was protected as its TMS-ether.  Isolation of this compound gave a 59% yield, but 
the material is relatively unstable and decomposes rapidly.  Direct input of the material isolated 
after rapid purification into the ozonolysis reaction provided the aldehyde (detectable by 
1
H-
NMR), which was also unstable in solution.  Direct input of the rapidly purified aldehyde into 
the reduction reaction gave the mono-protected diol after an extractive work-up.  While this diol 
is more stable, the TMS-ether does not allow for long-term storage and analyses, and so the 
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crude mono-protected diol was subjected directly to TBAF deprotection, which provided 4.24 is 
71% yield over the four steps (Scheme 4.23). 
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Scheme 4.23: Oxidative cleavage of 4.41 to yield 4.24 
 
4.7.  Conclusions 
 Although the synthesis of (R)-convolutamydine A was partially unsuccessful, it did 
demonstrate the utility of the In(0)-mediated allylation strategy developed by the Cook group.  
The group methodologies which have been focused on green chemistry-based approaches toward 
synthesis have provided a rapid means to these interesting structural motifs.  The total synthesis 
of (R)-convolutamydine E was much more successful, and provided a unique environment to 
attempt the oxidative cleavage.  While the exact structure is fairly unique, the presence of the 3° 
alcohol at both a benzylic position and a homoallylic position makes for an interesting argument 
for the widespread utility of this reaction.  It shows that it is possible to use the allylic group as a 
reactive handle for the synthesis of more complicated molecules, while still maintaining the 3° 
alcohol and that center’s stereochemistry.  The ozonolysis challenge also showcased the 
reactivity of these groups within the strain of the planar isatin core, which brings the alcohol and 
the resultant electrophilic carbon together. 
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4.8.  Experimental Section 
4.8.1.  General Reaction Considerations 
All reactions were conducted in oven-dried (100°C) glassware, and were run under an 
atmosphere of argon, unless otherwise stated.  EtOH is used as an absolute solution.  (S)-
PhPyBOX was prepared according to a previously reported procedure
31
.  Indium powder was 
purchased from Strem Chemicals.  Allyl bromide was purified by washing with sat. aq. NaHCO3 
followed by distilled H2O, drying over CaCl2, and distilling under reduced pressure.  MeOH was 
distilled from Mg(0).  TMSOTf was distilled under N2 immediately prior to use.  2,6-lutadine 
was dried over KOH for 24hrs prior to use.  DCM and THF were dried by passing the degassed 
solvent through a column of activated Cu/alumina under N2 immediately before use.  
Chromatography was performed on EMD silica gel (40-60 microns) using air pressure, unless 
otherwise specified.  Preparative TLC was performed on EMD 10 μm silica gel plates.  All other 
solvents and reagents were purchased at the highest level of purity and were used as received. 
NMR spectra were obtained on a Varian INOVA NMR instrument, at the indicated field 
strength in the indicated deuterated solvent.  NMR spectra are referenced to internal 
tetramethylsilane.  HRMS were collected on a Bruker BIOTOF III instrument with a positive 
ESI mode and are referenced to appropriate PEG or NaTFA standards.  FTIR spectra were 
collected on a Bruker Dalton FTIR instrument.  Melting points were collected on a Fisher-Johns 
apparatus and are uncorrected. 
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4.8.2.  Experimental Details 
2,6-Dibromo-4-nitroaniline (4.29) 
A 500-mL, 3-neck round bottom flask equipped with a magnetic stir bar, 
condenser, stopper, and addition funnel was charged with p-nitroaniline (15.00 g, 
0.11 mol) and glacial acetic acid (180 mL).  This slurry was set to stir at 65°C, and 
the addition funnel was charged with a solution of bromine (11.27 mL, 0.22 mol) 
in glacial acetic acid (140 mL).  This solution was added dropwise, with a heavy precipitate 
forming upon addition.  After approx. 10% of the bromine solution had been added, warm H2O 
(15 mL) was added to redissolve the precipitate.  The use of additional water did not aid in the 
dissolving of further precipitates.  After the bromine addition was complete, the reaction 
continued at 65°C for 1.5 hrs, then was cooled to RT.  The resultant slurry was poured into a 
stirring solution of ice (25 g) in water (250 mL), and the resultant yellow precipitate was filtered 
and air dried to give 4.29 as a fluffy yellow solid (30.64 g, 94%).  m.p. 193-195°C (lit. 204-
206°C
32
); 
1
H-NMR (400 MHz, DMSO-d6) δ 6.75 (bs, 2H, NH2), 8.25 (s, 2H, Ar-H, symm.); 
13
C-
NMR (100 MHz, DMSO-d6) δ 110.77, 133.43, 141.92, 154.63.  FTIR (thin film): ῡ (max): 3584, 
3372, 2293, 2853, 1605, 1457 (d), 1300, 1128 cm
-1
; HRMS (ESI), m/z: 318.8518 (M+Na
+
), calc. 
for C6H4N2O2Br2Na: 318.8511. 
 
3,5-Dibromo-1-nitrobenzene (4.30) 
A 50-mL, 2-neck round bottom flask equipped with a magnetic stir bar, condenser, 
and stopper was charged with 4.29 (1.92 g, 6.5 mmol), EtOH (22 mL), and 
concentrated H2SO4 (10% v/v, 2.2 mL).  This solution was set to stir at reflux, and 
powdered NaNO2 (1.44 g, 20.93 mmol) was added slowly through the open neck of the flask.  
NH2
NO2
Br Br
4.29
NO2
Br Br
4.30
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Vigorous frothing was observed upon addition, and the rate of addition was slowed accordingly 
to allow for this to subside.  After the addition was complete, the reaction ran at reflux for 24 hrs, 
upon which time TLC (60:40 EtOAc:hexanes) showed complete consumption of SM.  Reaction 
was cooled to RT, and poured onto crushed ice (25 g) in water (25 mL), and the resultant brown 
precipitate was filtered and air dried to give 4.30 (1.37 g, 75%), which was used without further 
purification.  m.p. 102-107°C (lit. 104°C)
33
; 
1
H-NMR (400 MHz, CDCl3) δ 8.00 (s, 1H, Ar-H), 
8.33 (s, 2H, Ar-H); 
13
C-NMR (100 MHz, CDCl3) δ 123.69, 125.80, 140.27.  FTIR (thin film): ῡ 
(max): 2293, 2853, 1462 (d) cm
-1
. 
 
3,5-Dibromoaniline hydrochloride (4.27) 
A 10-mL round bottom flask equipped with a magnetic stir bar was charged with 
4.30 (1.0 g, 3.56 mmol), SnCl2 (3.37 g, 17.80 mmol), and EtOH (absolute, 10mL).  
This mixture was brought to reflux, with the appearance changing from a brown 
slurry to a dark brown solution after approx. 1 min of heating.  The reaction continued at reflux 
for 4 hrs, when TLC (60:40 EtOAc:hexanes) determined complete consumption of the SM.  The 
reaction was cooled to RT, poured onto crushed ice (10 g), and diluted with H2O (10 mL).  The 
resultant solution was extracted with EtOAc (2 x 25 mL), with some hazy tin salts being 
observed in the organic phase.  The resultant organic slurry was filtered through Celite, and the 
filtrate was dried over MgSO4.  Filtration of the drying agent and concentration gave 4.27 as a 
tan/yellow solid (0.89g, 87%).  m.p.  >190°C (dec.); 
1
H-NMR (500 MHz, CDCl3) δ 7.03 (s, 1H, 
Ar-H), 6.84 (s, 2H, Ar-H), 3.75 (bs, 2H, NH2); 
13
C-NMR (125 MHz, CDCl3) δ 148.9, 123.9, 
123.6, 119.6, 119.0, 116.8; FTIR (thin film): ῡ (max): 3384 (broad), 2923 cm-1; HRMS (ESI), 
m/z: 251.8836 (M+H
+
), calc. for C6H6NBr2: 251.8841. 
NH3Cl
Br Br
4.27
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3,5-Dibromoisonitrosoanilide (4.31) 
A 50-mL round bottom flask equipped with a magnetic stir bar and a 
condenser was charged with 4.27 (1.44 g, 5.0 mmol), H2O (15 mL), EtOH (10 
mL), and concentrated HCl (0.15 mL).  To this solution was added 
hydroxylamine (50% in H2O, 0.5 mL, 7.5 mmol), and 1,1,1-trichloro-2-ethoxyethanol (1.16 g, 
6.0 mmol), in that order.  The resultant mixture was brought to reflux for 4 hrs, at which time 
TLC (60:40 EtOAc:hexanes) showed complete consumption of the SM.  The reaction mixture 
was allowed to boil without the condenser for 10 min., then was cooled to RT and filtered.  The 
filter cake was washed with H2O and dried in a dessicator over silica gel to yield 4.31 as a light 
yellow/off-white solid (1.13 g, 44%).  The product was taken forward to the next step without 
further purification. 
 
4,6-Dibromoisatin (4.26) 
A 2-dram vial equipped with a magnetic stir bar was charged with 80% 
H2SO4 (1 mL), and warmed to 55°C.  Solid 4.31 (0.2 g, 0.62 mmol) was 
added in portions over 15 min, then the now deep red solution was carefully 
heated to 80°C (anything higher than 80°C results in rapid decomposition) 
and then the reaction mixture was poured into 20 g crushed ice and allowed to sit for 30 min.  
The precipitate was filtered and washed with water to give 4.26 as a light brown solid (176 mg, 
87%).  Recrystallization from EtOAc gave fine brown needles.  mp 253°C (dec.); 
1
H-NMR (400 
MHz, DMSO-d6) δ  11.23 (s, 1H), 7.47 (dd, J=1.6 Hz, 3.6 Hz, 1H), 7.01 (dd, J=1.6 Hz, 3.6 Hz, 
1H); 
13
C-NMR (100 MHz, DMSO-d6) δ  216.6, 191.7, 159.3, 153.7, 132.0, 129.2, 120.9, 114.8; 
NH
NOH
O
Br
Br
4.31
N
H
OBr
Br
O
4.26
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FTIR (thin film): ῡ (max): 3682, 3019, 2400, 1711, 1523, 1423, 1221, 1214, 784, 735 cm-1; 
HRMS (ESI) m/z: 327.8407 (M+Na
+
)
+
, calc. for C8H3NO2Br2Na: 327.8403. 
 
(R)-3-Allyl-4,6-dibromo-3-hydroxy-2-oxindole (4.41) 
A 20-mL scintillation vial equipped with a magnetic stir bar was charged with 
4.26 (0.1 g, 0.33 mmol), (S)-PhPyBOX (20 mol%, 24 mg, 0.066 mmol), In 
powder (56 mg, 0.49 mmol), and MeOH (6 mL).  To this stirring slurry at RT 
was added allyl bromide (57 µL, 0.66 mmol) via syringe, and the reaction 
proceeded for 5 hrs, after which time TLC (60:40 EtOAc:hexanes) showed complete 
consumption of SM.  The volatiles were removed in vacuo and the residue was triturated with 
60:40 EtOAc:hexanes and passed as a slurry through a plug of silica gel, using 5 column 
volumes to wash the plug.  The resultant solution was concentrated to give 4.41 as a brown-
orange solid (64 mg, 99%), which was shown by chiral HPLC (AD-3 column, 10% iso-propanol 
in hexane, 1mL/min) to have an ee of 87%.  [α]D: 2.400 (c 0.5, MeOH); 1H-NMR (400 MHz, 
CDCl3) δ  8.81 (bs, 1H), 7.31 (d, J=1.6 Hz, 1H), 6.94 (d, J=1.2Hz), 5.34 (m, 1H), 5.07 (dd, J=1.6 
Hz, 17.2 Hz, 1H), 4.97 (dd, J=1.6Hz, 10Hz. 1H), 3.67 (bs, 1H), 2.95 (ddd, J=7.2 Hz, 10.8 Hz, 
162 Hz, 2H); 
13
C-NMR (100 MHz, CDCl3) δ  179.1, 143.5, 129.6, 129.5, 127.1, 124.0, 121.1, 
120.2, 113.3, 78.2, 40.0; FTIR (EtOH) ῡ (max): 3355, 2974, 2889, 1734, 1610, 1381, 1090, 
1050, 881, 735 cm
-1
; HRMS (ESI), m/z: 369.8873 [M+Na]
+
, calc. for C11H9O2NBr2Na: 
369.8872. 
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(R)-4,6-Dibromo-3-(2-hydroxyethyl)-3-hydroxy-2-oxindole (convolutamydine E, 4.24) 
A solution of 4.41 (87.5 mg, 0.252 mmol), in dry DCM (1.5 mL) was cooled 
to -30°C, under argon.  With stirring, 2,6-lutadine (0.18 mL, 1.54 mmol) was 
added, dropwise.  After addition, freshly distilled TMSOTf (0.15 mL, 0.635 
mmol) was added, dropwise.  After addition was complete, the reaction 
mixture was warmed to 0°C and allowed to stir for 3 hrs, when TLC (60:40 EtOAc:hexane) 
showed complete consumption of starting material.  The reaction was then quenched with sat. aq. 
NaHCO3 at that temperature, and allowed to warm to RT, then extracted with DCM (2 x 5 mL).  
The combined organic phases were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated.  The residue was purified by flash column chromatography using a short column of 
silica gel (N2 pressure, 60:40 EtOAc:hexane, Rf = 0.98) to give the TMS-protected compound as 
an off-white solid.  This was carried forward without further purification. 
 The TMS-protected material was dissolved in dry DCM (3.5 mL), and a stream of O3 was 
bubbled through the solution, with stirring, at -78°C.  After approx. 5 min, the solution had 
turned blue, and the O3 was continued for an additional 2 min, then argon was bubbled through 
the solution to remove any excess O3.  To the resultant pale solution was added Me2S (0.3 mL) 
and the reaction was warmed, with stirring, to 0°C, and kept there for 15 additional minutes.  The 
reaction was concentrated to give a light orange oil, which was dissolved in MeOH (1.5 mL), 
and powdered NaBH4 (7.7 mg, 0.204 mmol) was added to the stirring solution at 0°C, under a 
stream of N2.  The reaction ran for 2hrs, and then was quenched with sat. aq. NH4Cl, and 
extracted with EtOAc (3 x 5 mL).  The combined organic phases were washed with brine (10 
mL), dried (Na2SO4), filtered, and concentrated to give the desired monoprotected diol as a light 
yellow sticky solid, which was taken forward without further purification.   
N
H
O
Br
Br
OH
OH
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 The monoprotected diol was dissolved in dry THF (4 mL), and cooled to 0°C, under 
argon.  With stirring, a commercial solution of tetra-n-butylammonium fluoride (TBAF, 1.0 M in 
THF, 0.197 mL, 1.27 mmol) was added dropwise.  The solution turned to a lighter shade of 
yellow upon addition.  After 30 minutes at 0°C, the reaction was quenched with the addition of 
sat. aq. NH4Cl, and extracted with ether (2 x 5 mL).  The combined organic layers were washed 
with brine (10 mL), dried (Na2SO4), filtered, and concentrated.  Purification by preparative TLC 
using 2:1 EtOAc:hexane as eluent furnished the desired product, convolutamydine E (4.24), as a 
white solid (38.5 mg, 71% over 4 steps).  m.p. 132-134°C; 
1
H-NMR (400 MHz, acetone-d6) δ 
9.44 (bs, 1H), 7.19 (dd, J=0.8 Hz, 0.8 Hz, 1H), 6.94 (dd, J=0.8 Hz, 0.8 Hz, 1H), 5.12 (bs, 1H), 
5.05 (s, 1H), 3.37 (dt, J=6 Hz, 2.4 Hz, 2H), 2.32 (m, 2H, coupling of 0.8 Hz is observed); 
13
C-
NMR (100 MHz, acetone-d6) δ 185.6, 144.3, 143.2, 138.2, 135.5, 127.8, 127.7, 72.7, 52.9, 35.5; 
FTIR (thin film) ῡ (max) 3430, 2960, 2925, 2848, 1728, 1608 cm-1; HRMS (ESI), m/z: 371.8859, 
373.8811, 375.8810 [M+Na
+
], calc. for C10H9O3NBr2Na: 371.8841, 373.8821, 375.8802. 
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CHAPTER 5. FINAL CONCLUSIONS AND FUTURE WORK 
 
5.1.  Attempted Total Synthesis of Huperzine X 
 In the monumental effort to synthetsize this complex and complicated molecule, many 
reactions and potential pathways were explored.  Many of these did not yield and usable 
products, performed significant side reactions, or simply did not react under the literature 
reported conditions.  However, the use of these reactions as well as the reactions which produced 
the desired products has allowed for a broader view of the synthesis and the implications for the 
future of the project. 
 
 5.1.1.  The Main Synthesis 
 While the carbon backbone of the main Huperzine X was successfully synthesized, it has 
not been completed.  Initial screenings of conditions to eliminate the allylic alcohol and produce 
the desired 1,3-diene motif have been unsuccessful at both acquiring the desired structure in a 
reasonable yield as well as achieving high trans selectivity.  The issue is primarily the “loose” 
carbon chain, which cannot be held into a rigid structure in order to facilitate selectivity.  The 
solution to such a problem is unclear.  It does seem clear that direct elimination of the allylic 
alcohol is not going to result in the desired selectivity.  Another issue is the incorporation of the 
nitrogenous functionality.  As currently proposed, the nitrogen must me installed through a 
nucleophilic displacement of the parent alcohol with azide.  Reduction of this azide and 
protection with tosylate provides a long route to the desired structure.  It may be possible to 
utilize tosylamide as a starting material and couple the nitrogen directly using iridium catalysis
1
.  
In generalized studies, this was found to be possible to install the tosylamide directly onto 4-
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pentyn-1-ol, but the tosylamide 5.01 was found to be highly competitive to hydrozirconation 
under the established conditions.  While this is due in large part to the acidic hydrogen of the 
tosylamide, sulonylated amines are generally poor substrates for hydrozirconation (Scheme 5.1). 
 
OH
TsNH
2
[Cp*IrCl
2
]
2
 (2.5 mol %)
NaOAc (5 mol %)
130 °C, neat
45%
NHTs NHTsCp2Zr(Cl)
Cp
2
Zr(H)Cl
DCM
0 °C to RT
decomposition
5.01 5.02  
Scheme 5.1: Attempted use of Ir-catalyzed nitrogenous coupling to produce viable 
transmetalation partner 5.02 
 
If the alcohol problem can be solved and the nitrogen installed, the work already done on 
the Diels-Alder model system shows that the ynamide can be formed using the alkynyl iodonium 
triflate chemistry.  The cationic Rh(I) [4+2] cycloaddition will lead to thye formation of the B 
and D rings simultaneously.  If work can be completed on an enantioselective variant of the 
reaction (see Section 5.1.2), the major stereocenters of Huperzine X can be installed in one step 
(Scheme 5.2).  Quenching of the reactive vinyl silane with acryloyl chloride using a halogen 
source to facilitate reformation of the olefin should prove straightforward
2
.  Tosylamide 
deprotection is often problematic, and the recent surge in the use of SmI2 will almost certainly be 
hazardous to the other functionality in 5.07
3
, so the use of a more functional group tolerant 
approach will be necessary, as exemplified by Nayak with the use of low-valent Ti species
4
.  
Provided the deprotection does not alter the free olefins or the 1,4-cyclohexadiene structure, the 
liberated amine will undergo Michael addition, resulting in 5.08. 
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Scheme 5.2: Projected synthesis of the tricyclic core of Huperzine X 
 
With the A ring synthesized, efforts will be focused on transforming the OTBS group to 
the more reactive TMS group.  This can be accomplished through first a deprotection of the silyl 
ether, followed by acetylation of the allylic alcohol.  The acetylation should not affect the 
nitrogenous functionality, due to its conjugation as an enamine.  The allylic acetate should be 
able to be converted to the allylic TMS compound through now standard Pd-catalyzed 
chemistry
5
.  Our proposed intramolecular allylation can then be performed.  The final stages of 
the synthesis are more straightforward; the critical goal of creating the central lycopodine core 
will at this point have been successful. 
 
144 
 
5.1.2.  Diels-Alder Model System 
 There are two major areas of improvement for the Diels-Alder model system.  The most 
important is the optimization of the cationic Rh(I)-catalyzed intramolecular ynamide Diels-Alder 
chemistry.  Isolation of only 20% yield indicated that formation of the 6,6-fused ring system was 
problematic.  As the reaction is under kinetic control, and this does not favor 6,6-ring formations, 
it is possible that an increase in reaction temperature might facilitate this structure’s formation.  
As such, a screening of various temperatures may lead to optimization of the reaction.  It appears 
that the silver salt and solvents (DCE and toluene) are optimum for reactivity and solubility, and 
are thus not expected to change.  The use of Wilkenson’s catalyst is also optimum as it is 
relatively inexpensive and is able to survive prolong storage without purification. 
 If the yield can be improved, it is theoretically possible to add a chiral ligand to induce a 
chiral preference in the reaction.  The model system’s product possesses only one chiral center, 
making the added issues of syn/anti selectivity in the Diels-Alder reaction nonexistent.  Research 
has shown that Rh(I) catalyzed (both cationic and neutral metal centers) cycloadditions can be 
influenced to a large extent by simple chiral ligands such as BINAP
6
 and H8-BINAP
7
.  Most 
significant of these previous examples is the precedent set by Shibata and co-workers, using 
BINAP to effect [4+2] cycloadditions between 1,3-dienes and acetylenedicarboxylates, which 
share many similarities to our proposed ynamide Diels-Alder chemistry
8
.  In this light, we have 
confidence that a ligand of the BINAP family will be effective at controlling stereochemistry for 
our desired 1,4-cyclohexadiene product. 
 A side project that has been designed for examination as a model system is to synthesize 
5.09, a dimethylated analog of the previously shown 5.10 (2.67).  This molecule can be used to 
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test the theory that the low yield of the ynamide formation is due to 1,5-insertion of the transient 
vinylidene carbene created by the attack of the tosylamide nitrogen onto the iodonium alkyne 
and subsequent loss of iodobenzene (Scheme 5.3).  It is thought that blocking these positions will 
shut down the 1,5-insertion and increase the yield.  The two methyl groups should be far enough 
away from the reactive center that they shouldn’t directly interfere with the ynamide formation, 
but should only serve as insertion blocking groups. 
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Scheme 5.3: Alternative experiments to determine cause of low yield in ynamide formation 
 
While it is possible for both 5.11 and 5.12 to undergo [2+1] cycloaddition with the 
internal olefin of the 1,3-diene moiety, it is thought that this pathway is unfavorable due to the 
formation of a larger fused ring system (7,3).  The product of such a formation would also be 
difficult to detect, as it would be a vinyl cyclopropane, and thus likely to rearrange. 
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 With the creation of an optimized, enantioselective ynamide Diels-Alder reaction and 
better understanding of how to increase the yield of the initial ynamide formation, the Diels-
Alder model system will provide excellent support for the campaign to complete Huperzine X. 
 
5.1.3.  Allylation Model System 
 While we were unable to cause allyltrimethylsilane to react with 2,3-dihydro-4-pyridones 
protected with benzyl groups, it was thought that a more electron withdrawing group such as a 
tosyl might improve reactivity.  Tosylation of 4-piperidone (5.14) followed by IBX oxidation is 
reported
9
.  Although it is not reported, 2,3-dihydro-4-pyridone 5.16 should be able to be 
functionalized at the α position using reported iodination chemistry10.  Our studies have shown 
that metalation using iPrMgCl and subsequent CuI-mediated 1,4-addition of these types of α-
iodo-2,3-dihydro-4-pyridones onto methyl vinyl ketone is very effective (Scheme 5.4).  Standard 
triflation of the kinetic enolate and subsequent Kumada coupling is projected to produce the 
desired intramolecular allylaiton system.  The conditions for allylation promotion can be 
screened as an intermolecular variant using 5.16 and allyltrimethylsilane. 
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Scheme 5.4: Projected synthesis of a more reactive intramolecular allylation model system 
 
If the final allylation step can be optimized, the prospect of forming the C ring of the final 
natural product becomes illuminated.  All that remains is to complete the synthesis of the 
remaining rings to set up the intramolecular allylation and set the stage for the end-game of the 
total synthesis effort. 
 
5.1.4.  Final Conclusions 
 If the problems facing the Diels-Alder model system and the allylation model system can 
be ironed out, the remainder of the total synthesis will be set.  The primary problem facing the 
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main synthesis is the presence of the allylic alcohol after the vinyl addition to the intermediate 
aldehyde.  If this alcohol can be eliminated in a trans fashion, the installation of the nitrogen 
functionality should be trivial.  Formation of the ynamide has already been demonstrated, and 
has the possibility to be optimized further.  The cationic Rh(I)-catalyzed Diels-Alder is effective 
at creating the B and D rings simultaneously.  Ipso substitution of the produced vinyl silane with 
acryloyl chloride will cleanly produce the desired enone, and deprotection of the tosylamide will 
produce in situ Michael addition to form the A ring.  Finally, the C ring can be closed by 
transforming the OTBS group into a reactive allylic TMS group, which can undergo promoted 
quenching of the set-up iminium ion generated by polarization of the 2,3-dihydro-4-pyridone 
functionality.  With all of the rings set, differential oxidation of the olefins generates the 
penultimate structure, with a final methylation of the C-ring ketone completing the proposed 
total synthesis of Huperzine X. 
 
5.2.  Attempted Total Synthesis of (R)-Myricanol 
 The attempt made to synthesize the diarylheptanoid, (R)-myricanol, requires only two 
significant optimizations to reach a potential completion stage of the research.  Initially, the issue 
of how to install an allyl group to the ortho position of the northern arene ring is the most 
significant challenge.  Secondly, the optimization of the In(0)-mediated allylation onto the 
aliphatic aldehyde of the southern fragment to be enantioselective must be addressed. 
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5.2.1.  Synthesis of the Northern Fragment 
 While our efforts have been significant in the attempt to install the allyl group to the 
northern fragment, there are alternatives that were not explored for the lack of time.  These 
alternatives could hold the key to successfully completing this important scaffold.  One 
alternative to the Claisen rearrangement or metalation strategies is to add the allyl group as a 
nucleophile, rather than an electrophile.  Mal and co-workers have demonstrated the ability of 
allyl indium reagents to add to oxidized phenols
11
.  The products of this reaction quickly 
decompose to liberate MeOH and reform the aromatic ring, with transfer of the allyl group to the 
ortho position.  Not only will this chemistry allow us access to the elusive products we desire, it 
is also possible that the para position will be functionalized with a methoxy group, which can be 
selectively deprotected to give a more useful phenol that can be transformed into a boronate 
through Miyaura borylation. 
 
5.2.2.  Synthesis of the Southern Fragment 
 The southern fragment was synthesized quite effectively with our initial attempts.  The 
most significant drawback of the synthesis (detailed in Chapter 3) is that it is difficult to achieve 
complete selectivity in the bromination of ethyl 4-hydroxy-dihydrocinnamate.  Through 
serendipitous experimentation, it was discovered that careful extraction with diethyl ether 
allowed for the selective removal of the dibrominated material by solvating the monobrominated 
compound in the mixture.  Extraction with EtOAc did not produce this effect.  While the low 
yield of this reaction can be attributed to the formation of dibrominated products as well as the 
desired monobrominated species, the extractive work-up allows for isolation of the 
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monobrominated compound selectively.  The yield does not seem to be improved by changing 
the bromine source.  While Br2 gave the best results, NBS and benzyltrimethylammonium 
tribromide (BnN(CH3)3Br3) gave similar results, with no observed selectivity for 
monobromination.  Direct installation of the boron for cross-coupling also was unsuccessful.  
Regardless of these observations, the final MOM-protected bromophenol was obtained in 
acceptable yields.  
 
5.2.3.  Biaryl Formation and Completion Steps 
 Upon completion of the northen fragment, it is thought that previously reported 
asymmetric Sukuzi coupling can produce the desired atropisomeric biaryl moiety
12
.  Asymmetric 
Suzuki coupling can occur with high stereoselectivity with either enantiomer of the BINAP 
ligand
13
, or with more electron rich binapthylamino-phosphines
14
.  The binapthylamino-
phosphines can be synthesized racemically
14
, then resolved to isolate either enantiomer
15
, thus 
enabling access to either potential atropisomer of the natural product.  This is desireable because 
it is unclear which ligand will produce which enantiomer of the biaryl system.  The MOM group 
of the southern fragement and the methoxy group of the northern fragment should be sufficiently 
bulky enough to force restricted rotation about the biaryl bond, thus preventing degradation of 
any achieved enantiomeric excess.  After the asymmetric Sukuki coupling, DIBAL-H reduction 
of the ester group followed by reoxidation (as described in Section 5.1.1) to the aldehyde will set 
up an asymmetric allylation.  The Cook group’s In(0)-mediated allylation is quite functional for 
aliphatic aldehydes, and can be performed without exclusion of moisture or air, and represents an 
attractive alternative to more sensitive asymmetric allylation methodologies.  However, currently 
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there is no ligand which provides enantioselectivity for this transformation.  While it is desired to 
find an appropriate ligand for the in situ generated indium Lewis acid, it may not be possible to 
achieve strong coordination to the aliphatic aldehyde.  There is partial support of this by the 
Cook groups’ unpublished work on aliphatic α-ketoamides, where the enantioselectivity is 
partially eroded by the lack of an aromatic ring near the reaction center, suggesting a π-stacking 
interaction as partially responsible for initial ligand association with the substrate.  Studies with 
hydrocinnamaldehyde have shown that the aromatic ring is too far away from the aldehyde for 
any π-stacking associative mechanism to be effective.  Previous research in the group on achiral 
aliphatic hydrazones has shown that chiral triflone BINOL-type ligands are effective at 
transferring chirality, and these ligands may provide the enantioselectivity desired for aliphatic 
aldehydes.  An alternative option is the use of chiral phosphoric acids, using a BINOL-style 
platform.  These species possess chiral discriminating groups on the naphthyl rings ortho to the 
phosphoric acid group, which can be used to shield one face of the aldehyde after initial 
protonation of said aldehyde.  The ion pair’s proximity to the reactive center would allow for 
stereochemical information to be transferred.  One drawback is that these phosphoric acid 
catalysts have not been screened against the In(0)-mediated allylation, and may create problems 
associated with the initial formation of the In(III)-Lewis acid generated during the allyl indium 
reagent formation. 
 The final stages of the synthesis are quite straightforward.  Ring-closing metathesis 
(RCM) of the two terminal olefins will produce the macrocyclic structure, while standard 
hydrogenation methods will reduce the new internal olefin to the saturated analog.  Subsequent 
deprotection of the two arene rings will unmask the natural product.  The southern half’s now 
exposed hydroxyl group may not be sterically large enough to prevent rotation around the biaryl 
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bond, but the locking of the structure with the formation of the saturated macrocyclic ring will 
prevent any biaryl bond rotation at this stage. 
 
5.3.  Final Conclusions on the Synthesis of Convolutamydine E  
 The synthesis of convolutamydine E was undertaken in support of the Cook group’s 
primary research area of environmentally benign allylation methodologies.  Using indium metal 
and a simple, amino-acid derived chiral ligand, the allylation of 4,6-dibromoisatin was successful 
with a high enantioselectivity and nearly quantitiative yield.  Final transformations towards 
convolutamydines A and E were also successful, with convolutamydine A being unstable to 
isolation.  Convolutamydine E was isolated and fully characterized with excellent comparisons 
to the literature.  This chemistry has shown that simple, effective methods for forming new C-C 
bonds can be achieved in high yields and enantioselectivities using environmentally friendly 
indium, with wide functional group tolerance.  The prerequisite synthesis of 4,6-dibromoisatin 
was also achieved in yields far exceeding previously reported routes, making the complete 
synthesis very attractive.  The chemistry has been expanded to linear α-ketoamides, and the 
nucleophilic diversity has been increased to include crotylations and cyclohexenylations.  
Identificaiton of new total synthesis targets with substitution patterns on the allyl chain will open 
up new possibilities for showcasing this important chemistry. 
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